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1.  THE RETINA
Inherited retinal diseases, as a group, are the major cause of registered visual handicap in 
the developed world. Mutations in over 260 genes have been implicated in inherited 
retinal diseases, making it one of the most genetically diverse among the hereditary 
diseases.2 The retina’s anatomical complexity and multitude of functions is further 
reflected by the large variety of vision problems that can be caused by retinal disease: 
impaired vision in the dark or in light, impaired color vision, distortion of vision (e.g., 
straight lines that appear curved or wavy), extra visual sensations like flickering or flashes, 
complete loss of central vision or peripheral vision, to total loss of vision.  
Top right: Ignacio Icke (Wikimedia Commons), “Eye diagram”, modified by Esmee Runhart.
Figure 1. Anatomy of the human eye and retina. The top left panel shows a color fundus 
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Gross anatomy of the eye
The retina is the light sensitive tissue that lines the inside of the back of the eye. There, light that 
enters the eye via the cornea, the pupil and the lens is converted into electrical signals (Figure 1). 
These signals are then transmitted through the optic nerve, along the visual pathways, and 
eventually processed in the occipital cortex of the brain for visual recognition. On examination of 
the retina using ophthalmoscopy or imaging techniques, an important landmark is the optic 
nerve. This cranial nerve II is visible as a circular white-yellow area from which the major blood 
vessels of the retina radiate. It also contains the ganglion cell axons that transmit the electrical 
signal created through the phototransduction cascade (see ‘The phototransduction cascade’) to 
the visual cortex. Approximately 4.5-5 mm next to the optic nerve, a blood vessel-free reddish 
spot called the fovea can be discerned. The clivus in the center of the fovea is known as the 
foveola. The peripheral retina extends from the vascular arcades to the ora serrata, where the 
retina is connected to the corpus ciliare.
The healthy retina is only 100 to 250 micrometers thin and can be subdivided into ten 
organized layers. It is separated from the posterior vitreous by the internal limiting 
membrane, formed by the endfeet of Müller (glia) cells. The nerve fiber layer is formed by 
the axons of the ganglion cells (Figure 1 [a]) and their cell bodies are located in the 
ganglion cell layer [b]. The inner nuclear layer contains the cell bodies of the amacrine, 
bipolar, horizontal, and Müller cells [d]; the outer nuclear layer contains the cell bodies of 
the photoreceptor cells [f]. The inner [c] and outer plexiform layer [e] are formed by the 
synapses between these three layers of cell bodies. Supportive junctions between 
photoreceptors and Müller cells compose the external limiting membrane [g]. The transition 
between the inner segment and the cell body of the photoreceptors is known as the 
ellipsoid zone [h]. Finally, the retinal pigment epithelium (RPE) [i] lies outermost in the 
retina against the choroid [j].3
The photoreceptors and the RPE are most relevant to this thesis. The vast majority of the 
126 million photoreceptors in the human retina are rods (95%).4 Rods dominate the 
peripheral retina, and are highly sensitive to light, which allows vision in dim lighting 
conditions and detection of motion (Figure 2).5 Cones on the other hand are concentrated 
in the macula, quickly respond to variations in light intensity and are responsible for high 
visual acuity and color vision. Color perception is possible due to three types of cones 
that respond to short (blue)-, medium (green)- and long (red)-wavelength light, also called 
S-cones, M-cones, and L-cones, respectively. The five principal regions of the rods and 
cones are the outer segment, the connecting cilium, the inner segment, the nuclear 
region and the synaptic region. The outer segments of photoreceptor cells are tightly 
packed with membrane disks full of visual pigment. In cones, the outer segments contain 
many invaginations of the surface membrane; in rods, the disks membranes are entirely 
discontinuous of the surface membrane. Outer segments are rapidly renewed at a rate of 
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10% per 24h. Disk synthesis occurs at the base, and older disks, damaged as a consequence 
of light, oxygen and free radicals, are displaced distally and eventually shed and 
phagocytosed by the RPE.6-8 
The RPE is vital to the survival of photoreceptors, not only due to its function in the 
phagocytosis of damaged outer segments, but also for its role in the renewal of photo -
pigments (see ‘The retinoid cycles’). The RPE further functions as the outer blood-retina 
barrier that prevents the uncontrolled transport of molecules and ions from the choroid to 
the subretinal space (external limiting membrane until the apical surface of the RPE). 
Moreover, it is involved in the exchange of nutrients, ions, water, metabolic end products 
between the subretinal space and the permeable choriocapillaris, and the secretion of growth 
factors and immunosuppressive factors. Finally, the pigment melanin in melanosomes 
absorbs scattered light which improves vision and reduces oxidative stress.9 
Cmglee (Wikimedia Commons), “Human photoreceptor distribution”, modified by Esmee Runhart based on 
Curcio 1990.4 Top left inserted panels reprinted with permission from J Comp Neurol. 1990, Curcio, Sloan, Kalina, 
& Hendrickson.
Figure 2. The distribution of rods and cones in the human retina. En face optical sections 
through photoreceptors show how small rods outnumber the large cones throughout almost the 
entire retina, except for the central approximately 0.8-1.0mm. The absolute center of the fovea, the 
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The phototransduction cascade 
The sequence of reactions that converts the energy of a photon into an electric signal, 
known as the phototransduction cascade, takes place in the outer segments of 
photoreceptor cells (Figure 3). Here, in the lipid bilayer of outer segment disk membranes, 
phototransduction starts when the visual pigment rhodopsin or cone-opsin absorbs a 
photon. The visual pigment consists of the transmembrane apoprotein opsin and the 
photoreactive chromophore 11-cis-retinal. Upon capture of a photon, 11-cis-retinal undergoes 
photoisomerization to all-trans-retinal, which changes the structure of the pigment.10,11 
Visual pigments are G protein-coupled receptors (GPCR) signaling through so-called G 
proteins. The photoisomerized pigment (Figure 3: Rh*) activates the G-protein transducin 
(Gt) by exchange of GDP for GTP on the α-subunit of the G-protein (Gtα), which then 
stimulates a phosphodiesterase (PDE) that hydrolyzes cyclic GMP (cGMP) to GMP. 
The decrease in free cGMP closes the cyclic-nucleotide-gated (CNG) cation channels 
in the plasma membrane that are open in darkness. The stop of Na+ and Ca2+ influx 
hyperpolarizes the photoreceptor cell, which leads to inhibition of glutamate release at 
the photoreceptor’s synapse.12
The complex deactivation of the phototransduction cascade involves the action of: 
1. the G-protein-coupled-receptor-kinase 1 (GRK1) and the protein arrestin, that phosphorylate 
the photoisomerized opsin and block its activity12; 2. the GTPase-activating-protein (GAP) 
complex, that deactivates the active G-protein (Gtα*); 3. guanylate cyclase-activating 
protein that activates guanylate cyclase (GC) to return the cGMP concentration to normal. 
Moreover, Ca2+ mediates multiple negative feedback mechanisms: in darkness, a steady 
Ca2+ influx via the non-selective CNG cation channels is balanced by an equal Ca2+ efflux 
via a Na/Ca,K exchanger (NCKX) in the plasma membrane. In light, the closure of the CNG 
channels results in a decreasing intracellular Ca2+ concentration. The Ca2+ decrease leads 
to 1. increased GC activity, because Ca2+ has an inhibitory effect on guanylate activating 
proteins (GCAP); 2. negative modulation of GRK1 via Ca2+-binding protein recoverin, 
enhancing phosphorylation and arrestin binding of activated opsin (Rh*); 3. increased 
affinity of cGMP for the CNG channel which reopen after initially being closed as reaction 
to light.12
Cone phototransduction is largely similar to that in rods.13 In addition to a difference in 
visual pigments, the other primary phototransduction proteins like transducin, PDE and 
the cGMP-gated channel have different isoforms in rods and cones.14 Large quantitative 
difference exist in terms of sensitivity and kinetics: the response to one photon is 100x 
smaller in cones than in rods, whereas the cone response is several times faster and is 
nearly unsaturable.12,15 
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The retinoid cycles
To sustain normal visual sensitivity, all-trans-retinal must be converted back to 11-cis-retinal. 
This occurs through a series of biochemical reactions known as the visual or retinoid cycle 
(Figure 4). When light isomerizes all-cis-retinal to all-trans-retinal, the latter is released from 
opsin into the cytoplasm. It can then traverse one of two pathways: direct entry in the 
retinoid cycle or a detour in which the flippase ATP Binding Cassette Subfamily A Member 4 
(ABCA4) is involved. 
In the classic (rod and cone) retinoid cycle, all-trans-retinal is reduced to all-trans-retinol 
(a.k.a. vitamin A) by all-trans retinol dehydrogenase (all-trans RDH; RDH8) in the outer 
segment cytoplasm and transported to the RPE by the interphotoreceptor retinoid- 
binding protein (IRBP). There, all-trans-retinol is esterified by lecithin-retinol acyltransferase 
(LRAT), isomerized to 11-cis-retinol by the isomerohydrolase RPE65, and oxidized to 
11-cis-retinal by RDH5 and other RDHs, before being transported into the interphotoreceptor 
With permission adapted from Cell; Yau and Hardie, 2009.12 
Figure 4. The retinoid cycles. IRBP, interphotoreceptor retinoid-binding protein; CRBP, cellular 
retinol- binding protein; CRALBP, cellular retinaldehyde-binding protein; RDH, retinol dehydrogenase; 
REH, retinyl ester hydrolase; LRAT, lecithin:retinol acyl transferase; MFAT, multifunction O-acyltransferase. 
LRAT and RPE65 are absent in Müller cells. The isomerase and MFAT in Müller cells likely are kinetically 
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matrix by cellular retinaldehyde-binding protein (CRALBP) and back to the photoreceptor 
outer segments by IRBP to combine with opsin. 
In the intraretinal (cone) retinoid cycle, all-trans-retinol is transported from the cone outer 
segments into Müller cells by IRBP where it is isomerized to 11-cis-retinol, 9-cis-retinol and 
18-cis-retinol.16-18 The proteins responsible for the 11-cis-retinol synthesis in Müller cells 
have not been unequivocally established. A few studies suggested that 11-cis-retinol can 
either be esterified by multifunction O-acyltransferase (MFAT) to form 11-cis-retinyl ester 
or captured by the cellular retinaldehyde-binding protein (CRALBP).19,20 A more recent 
study suggested an important role for retinal G protein-coupled receptor (RGR) opsin and 
retinol dehydrogenase-10 (Rdh10) instead of the previously suggested isomerosynthase 
MFAT.22 Upon hydrolysis by a currently undefined 11-cis-retinol-ester hydrolase, 11-cis-retinol 
bound to CRALBP is returned to the interphotoreceptor matrix, where it binds IRBP to 
be returned to the cone outer segment.21 There, it is oxidized to 11-cis-retinal – again by 
an unknown retinol dehydrogenase – to conjugate with cone opsins, forming a new 
pigment molecule. 
However, a substantial fraction of all-trans-retinal, released into the disk, reversibly reacts 
with phosphatidylethanolamine (PE) located in the disk membrane to form N-retinylidene-PE 
(N‐trans-R‐PE) and is trapped in the disk lumen.22,23 In parallel, excess 11-cis-retinal not 
required for the regeneration of the visual pigment and PE form N-11-cis-retinylidene-PE 
(N-cis‐R‐PE).24 The transmembrane protein known as adenosine triphosphate-binding 
cassette transporter, subfamily A, member 4 (ABCA4) flips N‐trans-R‐PE and N-cis‐R‐PE 
from the luminal side of the disk to the cytoplasm (Chapter 1.3, Figure 8). N-cis-R-PE is 
isomerized to its all-trans isomer, which can also be transported by ABCA4. All-trans-retinal 
produced through the reversible dissociation of N‐trans-R‐PE is accessible for RDH8 and 
it is reduced to  all-trans- retinol as part of the retinoid cycle described above.24 In this way, 
ABCA4 prevents the accumulation of 11-cis- and all-trans-retinal in disks. The next chapters 
describe the consequences of dysfunction of ABCA4.
2.  THE PHENOTYPIC SPECTRUM OF STARGARDT DISEASE
Stargardt disease (STGD) is named after Dr. Karl Stargardt, who in 1909 described a familial 
progressive macular degeneration characterized by the symmetric presence of 
yellow-white flecks in the macula of both eyes.1 His patients experienced progressive 
central vision loss over the course of years with an onset in childhood or adolescence. In 
the earliest stage, only subtle, hardly discernable features might be present: macular 
pigmentary changes and/or a lack of the foveal reflex. In later disease stages, pigmentary 
clumps could appear in the macula and flecks could coalesce and extend to the 
midperiphery. In the latest stage, a yellow-grey pigmented lesion was observed, through 
which an atrophic choriocapillaris was visible, and the temporal quadrant of the optic 
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nerve could “fade” a little (Figure 5). The retinal vasculature and the peripheral retina 
remained unchanged throughout the disease stages. Largely similar observations were 
made by Franceschetti in the 60’s, who introduced the term ‘fundus flavimaculatus’, after 
the characteristic yellow-white pisciform flecks in STGD. For many years, there was 
discussion whether STGD and fundus flavimaculatus were in fact the same disease entity. 
Back in 1909, dr. Stargardt already made two observations that challenge the diagnosis 
and management of the disease to date. First, STGD shares some phenotypic characteristics 
with other retinal diseases – dr. Stargardt mentioned retinitis punctata albescens and 
 chorioretinitis – which can cause misdiagnosis. Second, patients can have visual complaints 
before macular abnormalities can be distinguished on ophthalmoscopy, and vice versa: 
the disease can be diagnosed in asymptomatic patients.
Although the original description of STGD is still applicable for many cases and dominate 
textbooks and scientific literature on STGD to date, diagnostic developments have 
broadened the scope of STGD. Currently, the major diagnostic techniques are optical 
coherence tomography, fundus autofluorescence (Figure 6) and genetic testing (chapter 
1.4). Short-wavelength fundus autofluorescence imaging allows visualization of the 
distribution of lipofuscin in the RPE. The characteristic flecks in STGD are hyperautofluo-
rescent, indicating accumulation of lipofuscin fluorophores (Figure 6).22,25 Areas of 
decreased autofluorescence indicate photoreceptor loss and absent autofluorescence 
indicates complete RPE loss.26 This technique is of great use in the diagnostic work up 
because abnormal autofluorescence patterns are often easier and earlier discriminated 
than changes on ophthalmoscopy or fundus photography. However, the earliest signs of 
STGD might best be discriminated using optical coherence tomography. Prior to functional 
Figure 5. 1909: Drawing of Stargardt disease in a 18-year old man who had experienced progressive 
loss of vision for 5 years. Visual acuity had decreased to counting fingers. He had a central scotoma. 
Color perception was normal. Two siblings had the similar affection, two others did not.1
Latin: English
fundus: bottom, lowest part
flavus: yellow
maculatus: polluted, spotted, marked with spots
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or other structural abnormalities, the external limiting membrane can thicken, which 
might reflect a gliotic response to cellular stress at photoreceptor level.27,28 Also, the 
ellipsoid zone – a photoreceptor-attributable band – may recede earlier than the RPE.29,30 
After the advent of these imaging techniques in the 90’s and the identification of the 
underlying gene, ABCA4, in 1997,31 several phenotypes could convincingly be subsumed 
under the umbrella of ABCA4-associated STGD: STGD type 1 (STGD1). Part of its broad 
phenotypic spectrum today are cone-rod dystrophy, cone dystrophy, fundus flavimaculatus 
and bull’s eye maculopathy (Figure 7). STGD1 invariably primarily affects the macula. 
As the disease progresses, both flecks and atrophy centrifugally expand beyond the 
vascular arcades, until – in severe cases – eventually a retina-wide degeneration is found.32 
Flecks and peripapillary sparing are common and quite specific characteristics but are not 
always present.
Although originally considered a juvenile macular degeneration, patients may experience 
initial visual complaints between the first and the eighth decade of life.33-37 Classifications 
Figure 6. 2020: Retinal imaging in a patient with classical STGD. The yellow-white flecks in 
STGD are hyperautofluorescent on an short-wave fundus autofluorescence image (top-right). One 
intensely hyperautofluorescent fleck is present in the foveal cross-section of the spectral-domain 
optical coherence tomography scan, where it corresponds to a subretinal deposit. Central macular 
atrophy is visible as an area of hypoautofluorescence, which is visible as thinning and loss of the 
outer retinal layers on spectral-domain optical coherence tomography (bottom). The peripapillary 
area is spared.
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based on the extent of funduscopic retinal abnormalities or  electrophysiologic findings 
have been suggested by others.38,39 These classifications can be used to indicate stages in 
disease, but not all patients pass each stage, and these  classifications have not been shown 
useful in assessment of etiology or prognosis. Instead, we would rather group patients 
based on their natural history. This has led to a division based on age at onset, which has 
been associated with visual prognosis.40 Early-onset STGD1 is often considered disease 
with an onset ≤10 years, and late-onset disease ≥45 years. In spite of the ambiguous nature 
of these boundaries and uncertainty in the self-reported age at onset as a reflection of the 
actual disease onset, the generalization helps in diagnostics, monitoring and counseling. 
Early-onset STGD1 is characterized by minor structural abnormalities in the earliest disease 
stage, which badly correspond to the often pronounced functional abnormalities, and fast 
progression toward chorioretinal degeneration.34,37 Late-onset STGD1 has characteristic 
features of a sharply demarcated area of RPE loss that initially spares the fovea, and a 
relatively mild disease progression.33,41 With the expansion of the phenotypic spectrum, 
also the number of phenotypically overlapping diseases has increased, which – like dr. 
Stargardt already remarked – can easily cause misdiagnosis (Figure 7). 
3.  THE PATHOPHYSIOLOGY OF STARGARDT DISEASE
The ABCA4 protein, that has a vital role in the retinoid cycle described earlier, stands at the 
basis of the pathophysiology of STGD1. The protein is localized in the outer segments of 
rod and cone photoreceptors and in RPE cells,31,42,43 and limited expression of this gene 
has been found in keratinocytes, fibroblasts and hair follicles.44-46 Being involved in the 
clearance of 11-cis- and all-trans-retinal from the photoreceptor disks (Figure 8), lack of 
functional ABCA4 protein induces the accumulation of N‐trans-R‐PE: the conjugate of 
all-trans-retinal and phosphatidylethanolamine (PE). Consequently, di‐retinoid‐pyridinium‐
phosphatidylethanolamine (A2PE) is formed in the disk, and N‐retinylidene‐N‐retinyl-
ethano lamine (A2E) and other bisretinoids are formed in RPE cell lysosomes upon diurnal 
phagocytosis of the 10% of outer segments.22,47,48 
These bisretinoids collectively called lipofuscin are not exclusively present in the RPE of 
patients with STGD1.49 They are to a lesser extent also found in the RPE of healthy 
individuals, where the amount steadily accumulates with age because undigested outer 
segment parts eventually form lipofuscin granules in lysosomes.22,50 Mice with loss of 
ABCA4 function (Abca4-/- mice) show excessive accumulation of lipofuscin in the RPE and 
loss of RPE induced by blue light.51,52 The best characterized bisretinoid of lipofuscin is its 
major constituent, the fluorophore A2E. This photoreactive A2E was shown to mediate 
light-induced apoptosis of RPE cells, likely via the generation of reactive oxygen species 
and mitochondrial dysfunction upon exposure to especially blue light.53-56 Photo-oxida-
tion of A2E in the RPE activates the complement system and alters the transcription of 
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Figure 7. The phenotypic heterogeneity of STGD1 and phenotypically overlapping maculo-
pathies. The disease-causing gene is printed in italics. mtDNA, mitochondrial DNA; variant m.03243A>G 
is associated with maternally inherited diabetes and deafness (MIDD), and mitochondrial myopathy, 
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genes involved in the stress response, apoptosis and immune response.57-59 Furthermore, 
lipofuscin was shown to disrupt lysosomal and antioxidant systems in RPE cells.60 These 
histological findings are consistent with the following sequence of events observed in 
imaging studies: hyperautofluorescence, indicating accumulation of lipofuscin in the RPE, 
occurs early in the disease process prior to functional loss; and RPE loss most likely 
precedes photoreceptor loss.51,61-63 
However, the mechanisms by which lipofuscin accumulates in STGD1 are not straightfor-
ward. All-trans-retinal, the generation of which required light activation of the visual 
pigment, was long considered the necessary precursor of A2E and lipofuscin. However, 
Abca4-/- mice reared in darkness do not accumulate lipofuscin or A2E faster than those 
reared in light.64 Thus, light activation of the visual pigment apparently is not required for 
the formation of A2E and lipofuscin. Another possible source of formation of A2E formation 
in the RPE is 11-cis-retinal in the visual pigments of phagocytosed outer segment disks. 
Recently, it was shown that ABCA4 to a lesser degree is expressed in the RPE as well, where 
it might perform the same function as in photoreceptors: the translocation of N‐trans-R‐
PE, formed after degradation of the visual pigment, from the luminal to the cytoplasmic 
side of endolysosome membranes.43 Absence of ABCA4 in the RPE internal membranes 
led to enhanced deposition of bisretinoids.
Reprinted with permission from PNAS; Faraz Quazi, Robert S Molday; 2014 Apr 1;111(13):5024-9.
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Also, the histopathological substrate of flecks, the hallmark of STGD1, is still under debate. 
Flecks that are hyperautofluorescent both in short-wavelength autofluorescence and 
near-infrared autofluorescence correspond to hyperreflective material in optical coherence 
tomography. These flecks have long been assumed to be lipofuscin-laded RPE cells.65 
More recently they were suggested to reflect bisretinoids residing in photoreceptors, or 
the accumulation of subretinal macrophages packed with pigment granules (lipofuscin, 
melanin and melanolipofuscin) from degenerated RPE cells.51,66 Increased short-wave-
length autofluorescence has also been attributed to vertically multi-layered RPE cells at 
the borders of geographic atrophy,67 but a different study showed that these exhibited 
much weaker short-wavelength autofluorescence and near infrared autofluorescence 
intensities than subretinal macrophages.51 
The own immune system of the retina, i.e. microglia and the complement system, plays a 
role in neurodegeneration. For one, the aging retina shows features of a low-grade 
inflammation: activation of microglial and complement deposition.68 The retina’s macro - 
phages are the tissue-resident microglia in the inner retina and peripheral microphages 
that migrate from the local blood vessels.69 Both are involved in the phagocytosis of dead 
photoreceptors and cellular debris like outer segments, and accumulate lipofuscin-like 
material.69-71 Additionally, compared to wildtype mice, Abca4-/- mice showed higher levels 
of complement activation in RPE cells and downregulation of complement regulatory 
proteins, which protect cells from attack by the complement system.72
Although this magnificent histopathological research made it clear that the lipofuscin 
accumulation in STGD1 can exert its deteriorating effect on the retina via several 
mechanisms, the exact mechanisms and the contribution of each to the great variation in 
phenotypes are still incompletely understood. Hopes are that with the near-to-elucida-
tion of this complex interplay of mechanisms, a therapy will be just around the corner.
4.  THE GENOTYPE OF STARGARDT DISEASE 
In 1997, biallelic variants in the ABCA4 gene were found to cause STGD1.31 Since then, 
a large number of disease-causing ABCA4 variants has been identified: over 1200 and 
counting (www.lovd.nl/ABCA4). Missense variants are most common (67% of patients; 
6% of which are complex alleles, i.e. multiple variants on one allele), followed by protein 
truncating variants (nonsense, frameshift and canonical splice site variants; 23%), 
noncanonical splice site variants (5%), deep-intronic variants (4%) and structural variants 
(1%).35 Most of the structural, deep-intronic and noncanonical splice site variants also 
result in protein truncation. Variants can further be classified according to severity: severe, 
moderate, mild and hypomorphic. The term ‘hypomorphic’ is used to refer to mild variants 
that only result in disease if present in combination with a severe variant on the other 
allele (i.e. the second gene copy). However, assessment of a variant’s severity is not 
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straightforward, due to lack of the high-resolution structure of the ABCA4 protein and 
thereby functional studies. Therefore, severity is assessed based on genotype-phenotype 
analysis and, occasionally, functional studies involving in vitro assays of ATP binding, 
ATPase activity and messenger RNA splicing. Figure 9 shows the ABCA4 genotype-pheno-
type correlation model proposed by Cremers et al. in 1998 that has since been updated 
according to new knowledge on genotype-phenotype correlation.73-75 The model shows 
the inverse relation between the disease severity and the residual ABCA4 function due to 
different combinations of ABCA4 variants. 
The ABCA4 genotype-phenotype correlation model represents, ike any model, an over-
simplification of the broad spectrum of ABCA4-associated disease. This model does not 
take into account the huge variation of ABCA4 genotypes that is created by combinations 
of more than 1200 disease-associated variants. Importantly, it immediately shows that it 
has its limitations in predicting disease severity: a combination of severe and mild can 
result in intermediate or “classical” STGD1 as well as late-onset STGD1. Moreover, the 
clinical variability among patients with STGD1 cannot fully be explained by the ABCA4 
genotype, as will be highlighted in this thesis. 
The large clinical variability of STGD1 in combination with the existence of many pheno-
typically overlapping macular diseases impede diagnostics. Comprehensive genetic 
testing can overcome these diagnostic challenges. However, ABCA4 sequencing merely 
is a confirmative test, being specific rather than sensitive: if positive, the clinical diagnosis 
is generally considered confirmed, but if negative, the test is often just considered 
uninformative. Despite the great yield of ABCA4 mutations to date, still 30% of cases were 
genetically unexplained in 2017, at the start of the studies presented in this thesis. 
Late-onset STGD1 remained particularly unexplained: in about half of the patients with 
late-onset STGD1 (onset >44 years of age) only one disease-causing allele was identified, 
despite the sequence analysis of all coding variants.33 This further complicated the 
diagnosis of late-onset STGD1, which is already challenged by the common and 
overlapping phenotype of age-related macular degeneration. The overlap has led to 
misdiagnosis of patients with late-onset STGD1, through the misconception that late-onset 
STGD1 was in fact a variation of age-related macular degeneration.76 Needless to say, 
accurate management depends on a correct and timely diagnosis. Diagnosis is essential 
to the process of learning how to cope with this blinding disease, in making career choices and 
in family planning. Furthermore, each undiagnosed case or series of cases and unidentified 
phenotype, represent an opportunity to elucidate the disease’s pathophysiology, which 
may result in an effective treatment. 
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5.  THE MANAGEMENT OF STARGARDT DISEASE
The management of STGD1 is currently limited to counseling, visual aids and measures 
that may prevent acceleration of disease progression. Patients are advised to limit exposure 
to light by for instance wearing glasses that filter out short-wavelength light, on the 
ground that the described knowledge of the pathophysiology includes phototoxicity to 
especially blue light. Also, excessive vitamin A intake is discouraged on the basis of the 
described pathophysiological knowledge and animal studies showing accelerated 
accumulation of lipofuscin with vitamin A supplementation.77 
Although there is no cure yet, many treatment strategies have been or are currently being 
tested in preclinical studies or clinical trials. The approaches include gene augmentation, 
genome editing, splice modulation, pharmacological compounds, optogenetics, cell 
replacement and retinal prostheses.78 A phase I/II clinical trial employing a lentivirus to 
deliver a functional copy of the ABCA4 gene (SAR422459) via subretinal injection has been 
ongoing for a few years. Although allegedly safe, no peer-reviewed data on safety or 
efficacy have been published yet.79 Alternative strategies to deliver the ABCA4 gene copy 
to retinal cells are developed in preclinical studies.78 In addition to gene augmentation, 
gene and RNA editing and modulation therapies are under study. First, mutation-specific 
RNA molecules called antisense oligonucleotides are used to redirect miss-splicing caused 
by mainly deep-intronic mutations. In the past few years, several known and novel ABCA4 
variants were shown to be amenable targets for antisense oligonucleotides in vitro.80-83 
Second, genome editing techniques, which substitute mutant nucleotides with the 
wildtype, are under study. Gene and RNA therapies are expected to be most promising in 
the earliest disease stages, whereas cell replacement and prostheses might proof to be of 
use especially in late disease stages. An important pro to stem cell replacement would be 
its broad applicability in retinal degenerations, irrespective of the precise mutation. The 
results of several small (safety) studies on cell replacements in STGD1 using stem cells, RPE 
cells derived from human embryonic stem cells or adipose tissue-derived mesenchymal 
stem cells have been published. These reported no safety concerns.84-88 Efficacy on the 
short and the long term remains to be determined, along with the optimal origin, differ-
entiation and administration of the stem cells. Furthermore, the results of two clinical trials 
involving pharmacological agents have been published: the omega-3-fatty acid docosa-
hexaenoic acid (DHA), which is found in photoreceptors and may protect against AMD, 
and the neuroprotectant saffron, which may protect photoreceptors from oxidative 
stress.89-92 Like several of the strategies above, these compounds were well tolerated but 
their efficacy has not been proven. Finally, we await the results of clinical trials involving 
pharmacological agents that target the retinoid cycle (C20-D3-vitamin A/ALK-001 and 
Emixustat hydrochloride), lipofuscin (remofuscin/Soraprazan) or the complement system 
(avacincaptad pegol/Zimura).93-96
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Proving efficacy of an intervention in STGD1 is challenging due to the fact that the disease 
is rare and it has a wide range of phenotypes and progression rates, both still incompletely 
characterized. As a consequence, a generally suitable endpoint, one that is clinically 
meaningful, non-invasive, reliable and sensitive, has been hard to define. Thus, detailed 
evaluation of the phenotypic variation and natural history are still of great importance to 
assess the effect of experimental therapies. 
6.  AIMS OF THIS THESIS
This thesis provides novel insights into the clinical variability of STGD1 and its association 
with the ABCA4 genotype by
- studying the role of frequent ABCA4 variants in STGD1;
- evaluating the natural history of STGD1.
We revisit the ABCA4 genotype-phenotype model that describes the phenotypic 
expression of ABCA4 variants. This knowledge aids in reaching a correct and timely 
diagnosis and in evaluation of the natural history of STGD1, both essential to disease 
management.
Chapter 2 and 3 describe novel, frequent ABCA4 variants. Genotype-phenotype analyses 
and functional studies on RNA level are performed to evaluate their pathogenicity. We 
study the variable phenotypes and natural history associated with these variants and 
introduce the first evidence for their reduced penetrance. 
Chapter 4 and 5 evaluate the natural history of STGD1 in more detail. The disease course 
in siblings with STGD1 is compared, to assess the extent of clinical variability in STGD1 
beyond the ABCA4 genotype. In a cohort of unrelated patients, the natural course of 
disease over three to five years is prospectively studied using microperimetry and fundus 
autofluorescence. The value of fundus autofluorescence patterns as a biomarker for 
disease progression is explored. Understanding of these patterns will impact the use of 
these images to assess therapeutic outcomes.  
Chapter 6 and 7 evaluate the occurrence of STGD1 and its basic disease demographics in 
two uniquely large patients populations, which helps to place the findings of genetic, 
clinical and basic studies into perspective. The prevalence of disease is studied to assess 
the market for therapies and to corroborate earlier evidence for reduced penetrance. We 
perform further studies on penetrance and evaluate preliminary hints for disease 
modifiers: factors beyond the ABCA4 gene that may modify the STGD1 phenotype and/or 
progression. A revised ABCA4 genotype-phenotype model is proposed.
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Chapter 8 integrates the findings from this thesis into a genotype-based family counseling 
approach. The presented genotype-directed framework can help inform patients and 
their families about personalized inheritance risks more reliably than generalized 
autosomal recessive risk counseling.
Chapter 9 further discusses the studies described in this thesis and places the combined 
knowledge and novel hypotheses into a wider context. 
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ABSTRACT
Purpose: To assess the occurrence and the disease expression of the common p.
Asn1868Ile variant in patients with Stargardt disease (STGD1) harboring known, monoallelic 
causal ABCA4 variants.
Methods: The coding and non-coding regions of ABCA4 were sequenced in 67 and 63 
STGD1 probands respectively, harboring monoallelic ABCA4 variants. In case p.Asn1868Ile 
was detected, segregation analysis was performed whenever possible. Probands and 
affected siblings harboring p.Asn1868Ile without additional variants in cis were clinically 
evaluated retrospectively. Two asymptomatic siblings carrying the same ABCA4 variants as 
their probands were clinically examined. The penetrance of p.Asn1868Ile was calculated 
employing allele frequency data of ABCA4 variants in non-Finnish European individuals.
Results: The p.Asn1868Ile variant was found in cis with known variants in 14/67 probands. 
In 27/67 probands, we identified p.Asn1868Ile without additional variants in cis, in combination 
with known, mainly severe ABCA4 variants. In 23/27 probands, the trans configuration was 
established. Among 27 probands and 6/7 STGD1 siblings carrying p.Asn1868Ile, 42% 
manifested late-onset disease (>44yrs). We additionally identified four asymptomatic 
relatives carrying a combination of a severe variant and p.Asn1868Ile; ophthalmologic 
examination in two persons did not reveal STGD1. Based on ABCA4 allele frequency data, 
we conservatively estimated the penetrance of p.Asn1868Ile, when present in trans with a 
severe variant, to be below 5%.  
Conclusions: A significant fraction of genetically unexplained STGD1 cases carries p.
Asn1868Ile as a second variant. Our findings suggest exceptional differences in disease 
expression or even nonpenetrance of this ABCA4 variant, pointing towards an important 
role for genetic or environmental modifiers in STGD1. 
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INTRODUCTION
Autosomal recessive Stargardt disease (STGD1, MIM 248200) represents the most common 
hereditary macular dystrophy (estimated prevalence 1:10,000)1 and is funduscopically 
characterized by lipofuscin deposits in the retinal pigment epithelium (RPE) presenting as 
yellow-white flecks, and progressive atrophy of the macular retinal pigment epithelium.2,3 
STGD1 is caused by sequence variants in the transmembrane ATP-binding cassette 
transporter type A4 (ABCA4, MIM 601691).4 Different combinations of ABCA4 variants give 
rise to several phenotypes, which can partly be attributed to differences in the residual 
activity of the ABCA4 protein.5-10 A combination of disease-causing ABCA4 alleles may 
therefore result in a severe, early-onset STGD1 phenotype (i.e. onset ≤10 years of age),11,12 
which is often observed as rapidly progressive cone-rod dystrophy,5,13 in classical STGD1,10 
or in late-onset STGD1.14-16 In about half of the patients with late-onset STGD1 (onset >44 
years of age) only one disease-causing allele was identified, despite the sequence analysis 
of all coding variants.16
In carriers of monoallelic ABCA4 variants, the second variant can reside in introns, outside 
of splice sites, not detected by standard sequencing methods.17-20 A very small fraction of 
these unidentified defects comprise copy number variants which elude detection by 
PCR-based sequencing techniques.18,21-23 Identification of disease-causing alleles and 
insight into their associations with differences in disease presentation and severity is 
essential for the counseling of patients, and becomes increasingly important as research 
on therapeutic approaches is rapidly evolving.  
Recently, a frequent ABCA4 coding variant, c.5603A>T (p.Asn1868Ile), which thus far was 
considered benign due to its high minor allele frequency (AF) of 6,6% in the non-Finnish 
European population,24 was associated with STGD1.25,26 This variant was found to be 
phenotypically expressed only when in trans with a deleterious mutation (i.e. presence of 
the variants on different alleles), and explained >50% of all monoallelic cases and ~80% of 
late-onset cases in a US cohort.26 In addition, the c.2588G>C (p.[Gly863Ala,Gly863del]) 
variant was proposed to act as a mild pathogenic variant only when in cis with p.Asn1868Ile 
(i.e. presence of the variants on the same allele).
In this study, we investigated STGD1 probands with a single disease-causing ABCA4 allele 
for the presence of the p.Asn1868Ile variant, performed segregation analysis through the 
inclusion of unaffected family members to assess the configuration of the identified 
ABCA4 variants (i.e. in cis or in trans), and performed ophthalmologic studies to evaluate 
the full spectrum of phenotypes associated with the single-variant allele p.Asn1868Ile (i.e. 
no ABCA4 variants identified in cis). In addition, we calculated the penetrance for the 
p.Asn1868Ile variant by employing allele frequencies of severe ABCA4 variants.
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METHODS
Study population and genetic analysis
We ascertained 67 clinically suspected STGD1 patients in whom only one disease- 
causing variant in the ABCA4 gene had been identified, from eight ophthalmic centers 
in The Netherlands (n=64) and one center in Germany (n=3). Between 1998 and 2017 
these subjects were screened for disease-causing variants in the coding regions and 
flanking splice sites of ABCA4 and recently, for 63 subjects, ~95% of the entire ABCA4 gene 
(exons and introns) was further sequenced by using a custom Haloplex Target Enrichment 
kit (Agilent, Santa Clara, CA, USA) as described previously.27 All variants identified 
by Haloplex-based ABCA4 sequencing were confirmed using Sanger sequencing. We 
investigated probands harboring monoallelic variants for the presence of the p.Asn1868Ile 
variant and rare (minor AF <0.005) deep-intronic variants. Four DNA samples were 
analyzed using non-haloplex-based alternative techniques (Supplemental Methods S1). 
Segregation of the sequence variants identified in the probands was studied by sequencing 
the corresponding genomic DNA fragments in relatives (Supplemental Table S1). Participants 
gave informed consent after an explanation of the nature of the study. The study 
procedures were performed according to approval of the medical ethics committee of 
the Radboud university medical center and the tenets of the Declaration of Helsinki.
Clinical evaluation
Probands and affected siblings carrying the single-variant allele p.Asn1868Ile were 
clinically evaluated. Medical records were reviewed and available clinical data were 
collected, comprising age at onset and initial symptoms, age at diagnosis, best-corrected 
visual acuity (BCVA) and findings on ophthalmoscopy. Age of onset was defined as the 
age at which the initial symptoms were noted by the patient. In asymptomatic subjects 
and in cases where age at onset was not noted in the patient file, we used the age at 
which macular abnormalities were first diagnosed by an ophthalmologist.
Furthermore, we examined available data acquired by fundus photography, fundus auto-
fluorescence (FAF) imaging using a confocal scanning laser ophthalmoscope (cSLO; 
Spectralis; Heidelberg Engineering, Heidelberg, Germany), spectral domain-optical 
coherence tomography (OCT) (Spectralis) or time-domain OCT (Stratus, Carl Zeiss Meditec, 
Dublin, CA), fluorescein angiography (FA) and full-field electroretinography (ffERG) 
according to the International Society for Clinical Electrophysiology of Vision standards. 
We assessed presence of foveal sparing, which we defined as RPE atrophy encircling a 
structurally and functionally (BCVA≥20/200) preserved fovea by ≥180⁰,15 by evaluation of 
FAF and/or OCT. 
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Two asymptomatic siblings who carried the same combination of ABCA4 variants as the 
respective probands, were clinically examined by measurement of BCVA and performance 
of fundus photography, FAF and OCT. 
ABCA4 allele frequency calculations and p.Asn1868Ile penetrance estimates
To assess the penetrance of the common variant p.Asn1868Ile when present in trans with 
a severe ABCA4 variant, we employed AF data in ~33,000 non-Finnish European control 
subjects in Exome Aggregation Consortium24 (ExAC) (available at: http://exac.broadinstitute.
org; accessed September 01, 2017), as at least 24/27 patients belong to this population. 
First, since we did not know all ABCA4 variants that are in linkage disequilibrium with 
p.Asn1868Ile, we estimated the frequency of the single-variant allele p.Asn1868Ile. Zernant 
et al. (2017) indicated that 10% of c.2588G>C alleles carry c.5603A>T (p.Asn1868Ile) in cis 
and that this allele, containing both variants, probably acts as a fully penetrant mild allele 
if present in a compound heterozygous state with a severe ABCA4 variant.26 In the same 
study, consistent with our data, the frequent non-canonical splice site variant c.5461-10T>C 
was always found in cis with c.5603A>T (p.Asn1868Ile). Therefore, the AF of the single-variant 
allele p.Asn1868Ile was calculated based on its total AF minus the AF of c.5461-10T>C and 
10% of the AF of c.2588G>C. Other variants have been found in cis with p.Asn1868Ile, 
but their cumulative non-Finnish European AF likely is negligible and were not taken into 
account. 
Second, we calculated a cumulative AF of severe ABCA4 variants. We determined the sum 
AF of all protein-truncating variants (i.e. stop mutations, frameshift mutations) and 
canonical splice site variants that in the majority of cases result in exon skipping and likely 
in absence of ABCA4 activity, and added the AF of non-canonical splice site variants (i.e. 
RNA splice variants outside the conserved intronic dinucleotides at the ends of introns) 
that resulted in less than 25% of normally spliced ABCA4.28   
Finally, given an estimated prevalence of STGD1 of 1 in 10,000 individuals1 and a population 
in The Netherlands of 17,150,000 people, the expected and observed number of STGD1 
patients due to the combination of the single-variant allele p.Asn1868Ile and a severe 
variant in The Netherlands were compared. 
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RESULTS
Genetic analysis
In 14/67 probands, we found p.Asn1868Ile to be in cis with causal protein-coding or splice 
site variants, i.e. c.5461-10T>C (n=9), c.2588G>C (n=3), c.4469G>A (n=1) and c.818G>A 
(n=1). We excluded these patients from clinical evaluation. 
In 27/67 probands we detected the single-variant allele p.Asn1868Ile; in 23 patients we 
could establish the trans configuration of the identified variants (Figure 1A-B, and 
Supplemental Figures S1 and S2), either due to segregation analysis (n=21) or because the 
p.Asn1868Ile variant was found in a homozygous state (Y-II:1 and AA-II:1). In the remaining 
four probands (K-II:1, N-II:1, R-II:1, Z-II:1), segregation analysis could not be completed due to 
the absence of DNA of relatives (Table 1-footnote II, Supplemental Figure S2). Additionally, 
in probands I-II:3, J-II:2, Y-II:1 and AA-II:1, we could not exclude the presence of intronic 
variants in cis with p.Asn1868Ile as the non-coding regions of ABCA4 in these individuals 
were not sequenced.
Among the 27 probands harboring the single-variant allele p.Asn1868Ile, 19 carried p.
Asn1868Ile together with a protein truncating mutation due to a stop (n=4), a frameshift 
(n=4), a canonical splice site variant (n=1), or because of non-canonical splice site variants 
elsewhere shown to result in protein truncations (n=10) (Table 1).27,28 The remaining eight 
probands harbored seven unique variants: six missense variants, and one non-canonical 
splice site variant (c.5714+5G>A) that has a moderately severe effect on splicing.28 Among 
these missense variants, p.Gly1961Glu in the vast majority of STGD1 cases acts as a mild 
variant26,29,30 while p.Phe608Ile is considered a severe variant.31 For the remaining 
missense variants (p.Glu1087Lys, p.Cys1488Arg, p.Gly1972Arg, p.Met2143Arg), the effect on 
protein function is unclear.
Segregation-analysis in ten siblings affected by STGD1 identified seven individuals who 
harbored the same causal variants as the respective probands (Figure 1A). In two families, 
we found affected siblings carrying different combinations of disease-causing ABCA4 
alleles (Supplemental Figure S1). 
Clinical evaluation
Thirty-four STGD1 patients (27 probands and 7 siblings) that harbor p.Asn1868Ile in 
combination with a known causal variant were identified, 12 of whom were male and 
22 female. Detailed clinical characteristics of 32/34 subjects carrying p.Asn1868Ile are 
depicted in Table 1. For two individuals detailed clinical data were not available (A-II:2 and, 
besides age at onset, A-II:1, Figure 1A).
None of the subjects manifested early-onset STGD1 (age at onset ≤10 years). Fourteen 
patients showed late-onset STGD1 (age at onset >44 years), and nineteen subjects 
manifested classical STGD1 (age at onset 11-44 years). The mean age of onset was 42 years 
(SD, 16 years), with the majority of patients presenting with decreased visual acuity. Other 
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initial symptoms included scotoma and metamorphopsia. Patients D-II:3, R-II:1 and U-II:1 
did not experience visual symptoms at the time of diagnosis at the age of 52, 30 and 37 
years, respectively: all three manifested few flecks, largely confined to the macular region, 
and a perifoveal ring of RPE atrophy with a relatively spared fovea. 
Figure 1. ABCA4 variant c.5603A>T (V1) is associated with variable age at onset and putative 
nonpenetrance of Stargardt disease. A. Segregation analysis of ABCA4 variants in STGD1 families 
A-D and G with multiple affected individuals showed that V1 in combination with a severe variant 
segregated with the disease: As expected for an autosomal recessive inherited Mendelian trait, all 
affected and genetically tested individuals in families A-D and G carry two ABCA4 variants in trans, 
whereas unaffected individuals carry one or no variant. B. In families E, F and H, reduced penetrance 
or even nonpenetrance occurs. Family H is part of a previously described multi-generation 
pedigree.13,20 Proband H-II:3 and the unaffected sibling H-II:1 carry V1 and c.2919-?_3328+?del, while 
unaffected individual H-II:2, the spouse of H-II:1, is compound heterozygous for V1 and c.[5461-
10T>C;5603A>T]. For H-I:1, the variants where deduced by haplotype analysis.
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Classical STGD1, in the majority (14/19), was characterized by early involvement of the 
macula featuring flecks, beaten bronze atrophy and/or mottled decreased FAF, all largely 
confined to the macular and perimacular region. In the minority (5/19), flecks throughout 
the posterior pole were observed, accompanied by pronounced atrophy in the posterior 
pole and midperiphery in 4/5 patients. The latter combination of fundus characteristics 
might represent a later disease stage, since available data of the first decade(s) after disease 
onset for the four patients manifesting atrophy (B-II:3, I-II:3, G-II:4, and T-II:1) were insufficient 
to assess fundus characteristics early in the disease. However, in 1 of the 5 patients (C-II:1 
with an age at onset of 41 years) flecks throughout the posterior pole and midperiphery 
with parafoveal atrophy were observed in the year after he first experienced symptoms, 
suggesting either slowly progressive disease that the patient himself had long been 
unaware of, or a different subphenotype. Foveal sparing in the classical STGD1 group was 
observed in 5/19 patients (age at onset 27-41 years) (Table 1). 
Late-onset STGD1, in the majority (8/13 clinically evaluated patients), was characterized 
by flecks throughout the posterior pole and midperiphery, often followed by sharply 
demarcated atrophy. Yet, three patients (E-II:3, J-II:2, Y-II:1, with an age at onset of 56, 56 and 
47, respectively) showed early exclusive involvement of the macula with perimacular 
flecks and macular beaten bronze atrophy and/or macular mottled decreased FAF, 
which characteristics were observed in the majority of the classical STGD1 patients. 
The remaining two patients showed both flecks throughout the posterior pole and 
midperiphery as well as mottled decreased FAF in the macula at first presentation. RPE 
atrophy in a foveal sparing pattern was observed in 9/13 subjects, whereas 2/13 patients 
did not show macular atrophy yet. 
In two late-onset STGD1 patients (G-II:1 and G-II:2), who were initially diagnosed with 
age-related macular degeneration (AMD) at the age of 72 and 69 respectively, flecks 
appeared absent, as assessed by ophthalmoscopy and fundus photography. Yet, they did 
exhibit widespread hypo- and hyperautofluorescent flecks on FAF (Figure 2), highlighting 
the clinical value of FAF in the differentiation between AMD and late-onset STGD1.
Variable age at onset and incomplete penetrance
When comparing affected siblings who harbor p.Asn1868Ile (Figure 1A), we observed 
fairly constant ages at onset in families A, C and D, whereas in family B the age at onset 
between affected siblings varied tremendously (19 and 54 years of age). In addition to 
STGD1, B-II:3 sufferred from Coats-like exudative vasculopathy, but this was first observed 
at the age of 57 and affected only the right eye. 
Surprisingly, we found three asymptomatic male siblings (E-II:1, F-II:1 and H-II:1) in three 
STGD1 families that carried the same compound heterozygous variants as their probands 
(Figure 1B). Also unaffected person H-II:2 carried an ABCA4 allele with a severe variant 
(c.[5461-10T>C;5603A>T]) and c.5603A>T (p.Asn1868Ile) on the other allele. For asymptomatic 
siblings E-II:1 and H-II:1, in view of the large gap between their current age and the age at 
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onset of the proband, it is plausible that they remain unaffected and can be considered 
nonpenetrant. Moreover, current manifestation of STGD1 in E-II:1 was excluded during 
ophthalmologic examination: fundus photography, FAF and OCT of E-II:1 showed no 
STGD1 phenotype at the age of 70, when his BCVA was 20/25 in the right eye and 20/20 in 
the left eye (Figure 3A-C). His sibling E-II:3 reported initial symptoms at the age of 56 and 
was diagnosed with STGD1 at the age of 59 (Figure 3D-F). Although the third asymptomatic 
sibling F-II:1 may develop STGD1 later in life considering his current age and the age of 
onset of the proband, also he underwent ophthalmologic examination which excluded 
current manifestation of STGD1. His fundus photography, FAF and OCT showed no 
abnormalities at the age of 47, and BCVA was 20/20 in both eyes (Figure 3G-I). His sibling 
F-II:2 reported initial symptoms at the age of 32 and was diagnosed with STGD1 at the age 
of 38 (Figure 3J-L). The asymptomatic cases in family H were not clinically examined so 
current manifestation of mild STGD1 phenotypes could not be excluded.    
Individuals harboring an ABCA4 variant that had been designated as severe, did not show 
STGD1 phenotypes more often or more severe, compared to individuals who harbored 
a variant with mild, moderately severe or unknown effect, with regard to age at onset or 
occurrence of foveal sparing. 
p.Asn1868Ile shows a very low penetrance in the Caucasian population
Based on previous findings26 and the results of this study, we can conclude that 
p.Asn1868Ile represents a mild ABCA4 variant that in the majority of cases only results in 
STGD1 when present in trans with a severe ABCA4 variant. First, the maximum AF of the 
single-variant allele p.Asn1868Ile among ~66,000 non-Finnish European control alleles, 
based on its total AF minus the AF of c.5461-10T>C and 10% of the AF of c.2588G>C, was 
0.0645 (Table 2A). Second, the total AF of severe ABCA4 variants (protein-truncating 
variants and non-canonical splice site variants determined to have a severe effect)28 was 
0.00271 (Table 2B), which yielded an estimated prevalence of individuals with one severe 
ABCA4 variant and p.Asn1868Ile of 0.000349 (Table 2C). Given a total population in 
The Netherlands of 17,150,000 persons, the theoretical number of STGD1 cases with a 
severe variant and p.Asn1868Ile thereby is 5991. Third, the prevalence of STGD1 is estimated at 
1 in 10,000 individuals1, and in the Nijmegen STGD1 cohort, STGD1 due to a severe ABCA4 
variant and p.Asn1868Ile was observed in 25/300 (8.3%) probands (Table 2D). Given a total 
population in The Netherlands of 17,150,000 people, STGD1 due to this combination of 
variants was expected in ~143 persons. If the non-Finnish European AF are comparable 
to those in The Netherlands, we concluded that the penetrance of the single-variant 
allele p.Asn1868Ile, when present in combination with a severe ABCA4 variant, was 2.4% 
Table 2E). 
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Table 1  Clinical and genetic characteristics of STGD1 patients carrying c.5603A>T (p.Asn1868Ile)




Latest Visual Acuity Fundus and Imaging Features Dark Choroid 
on Fluorescein 
Angiography
Full-field ERG† Genotype: ABCA4 Variant(s) in Trans








A-II:4 / ♀ / 75a,b 71 20/25 20/20 Yellow-white pisciform flecks throughout the posterior 
pole, no atrophy 
Yes N N c.768G>T p.(Leu257Valfs*17)∆ S
B-II:1 / ♂ / 63a,b,c 54 20/200 20/200 Yellow-white pisciform flecks throughout the posterior pole 
and mid-periphery with chorioretinal atrophy in macula 
Yes SR SR c.768G>T p.(Leu257Valfs*17)∆ S
B-II:3 / ♀ / 60 19 CF 20/400 Extensive chorioretinal atrophy and pigmentary changes 
in macula with yellow-grey pisciform flecks throughout 
posterior pole and midperiphery. Additionally, temporal 
and inferior peripheral in RE chorioretinal scars of Coats-like 
lesions and laser therapy.  
Yes NP NP c.768G>T p.(Leu257Valfs*17)∆ S
C-II:1 / ♂ / 49 41 20/20 20/20 Yellow-white pisciform flecks throughout the posterior pole 
and mid-periphery with parafoveal chorioretinal atrophy in 
the left eye with foveal sparing
NP N (45y) N (45y) c.768G>T p.(Leu257Valfs*17)∆ S
C-II:2 / ♀ / 55 45‡ 20/50 20/20 Yellow-white pisciform flecks throughout the posterior pole 
and extensive chorioretinal atrophy with foveal sparing
NP NP NP c.768G>T p.(Leu257Valfs*17)∆ S
D-II:1 / ♂ / 68 61 CF 20/130 62yrs: yellow-white pisciform flecks throughout the 
posterior pole and parafoveal chorioretinal atrophy with 
foveal sparing 
68yrs: chorioretinal atrophy in macula with a few 
surrounding pisciform yellow-white flecks  
Yes N (63y) NP (63y) c.768G>T p.(Leu257Valfs*17)∆ S
D-II:3 / ♂ / 58 52‡ 20/20 20/22 Predominantly perimacular pisciform yellow-white flecks 
and mottled decreased FAF in macula with foveal sparing 
NP NP NP c.768G>T p.(Leu257Valfs*17)∆ S
E-II:3 / ♀ / 64a,b,c 56 20/400 20/400 Foveal changes with perimacular and peripapillary irregular 
yellow-white flecks and mottled decreased FAF in macula 
(Fig 3D-F)
Yes N N c.4462T>C p.(Cys1488Arg) NA
F-II:2 / ♂ / 41 32 20/66 20/66 Foveal changes with perimacular and peripapillary irregular 
yellow-white flecks and mottled decreased FAF in macula 
(Fig 3J-L)
Yes N N c.1822T>A p.(Phe608Ile) S
G-II:1 / ♀ / 76 72 20/25 20/32 Parafoveal pigmentary changes RE, and chorioretinal 
atrophy with foveal sparing and hyper- and 
hypoautofluorescent flecks throughout posterior pole on 
FAF
NP NP NP c.5762_5763dup p.(Ala1922Trpfs*18) S
G-II:2 / ♂ / 73c 69 20/25 20/40 Chorioretinal atrophy with foveal sparing and hyper- and 
hypoautofluorescent flecks throughout posterior pole and 
midperiphery on FAF (Fig 2A-C)
NP N N/MR c.5762_5763dup p.(Ala1922Trpfs*18) S
G-II:4 / ♀ / 70 37 CF CF Extensive chorioretinal atrophy and pigmentary changes in 
posterior pole and hyper- and hypoautofluorescent flecks 
throughout posterior pole and midperiphery on FAF
NP NP NP c.5762_5763dup p.(Ala1922Trpfs*18) S
H-II:3 / ♂ / 38d 30 20/125 HM§ Perimacular irregular yellow-white flecks and beaten 
bronze atrophy in macula (no OCT/FAF)
Yes N N c.2919-?_3328+?del p.(Ser974Glnfs*64) S
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Table 1  Clinical and genetic characteristics of STGD1 patients carrying c.5603A>T (p.Asn1868Ile)
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Yes N N c.768G>T p.(Leu257Valfs*17)∆ S
B-II:1 / ♂ / 63a,b,c 54 20/200 20/200 Yellow-white pisciform flecks throughout the posterior pole 
and mid-periphery with chorioretinal atrophy in macula 
Yes SR SR c.768G>T p.(Leu257Valfs*17)∆ S
B-II:3 / ♀ / 60 19 CF 20/400 Extensive chorioretinal atrophy and pigmentary changes 
in macula with yellow-grey pisciform flecks throughout 
posterior pole and midperiphery. Additionally, temporal 
and inferior peripheral in RE chorioretinal scars of Coats-like 
lesions and laser therapy.  
Yes NP NP c.768G>T p.(Leu257Valfs*17)∆ S
C-II:1 / ♂ / 49 41 20/20 20/20 Yellow-white pisciform flecks throughout the posterior pole 
and mid-periphery with parafoveal chorioretinal atrophy in 
the left eye with foveal sparing
NP N (45y) N (45y) c.768G>T p.(Leu257Valfs*17)∆ S
C-II:2 / ♀ / 55 45‡ 20/50 20/20 Yellow-white pisciform flecks throughout the posterior pole 
and extensive chorioretinal atrophy with foveal sparing
NP NP NP c.768G>T p.(Leu257Valfs*17)∆ S
D-II:1 / ♂ / 68 61 CF 20/130 62yrs: yellow-white pisciform flecks throughout the 
posterior pole and parafoveal chorioretinal atrophy with 
foveal sparing 
68yrs: chorioretinal atrophy in macula with a few 
surrounding pisciform yellow-white flecks  
Yes N (63y) NP (63y) c.768G>T p.(Leu257Valfs*17)∆ S
D-II:3 / ♂ / 58 52‡ 20/20 20/22 Predominantly perimacular pisciform yellow-white flecks 
and mottled decreased FAF in macula with foveal sparing 
NP NP NP c.768G>T p.(Leu257Valfs*17)∆ S
E-II:3 / ♀ / 64a,b,c 56 20/400 20/400 Foveal changes with perimacular and peripapillary irregular 
yellow-white flecks and mottled decreased FAF in macula 
(Fig 3D-F)
Yes N N c.4462T>C p.(Cys1488Arg) NA
F-II:2 / ♂ / 41 32 20/66 20/66 Foveal changes with perimacular and peripapillary irregular 
yellow-white flecks and mottled decreased FAF in macula 
(Fig 3J-L)
Yes N N c.1822T>A p.(Phe608Ile) S
G-II:1 / ♀ / 76 72 20/25 20/32 Parafoveal pigmentary changes RE, and chorioretinal 
atrophy with foveal sparing and hyper- and 
hypoautofluorescent flecks throughout posterior pole on 
FAF
NP NP NP c.5762_5763dup p.(Ala1922Trpfs*18) S
G-II:2 / ♂ / 73c 69 20/25 20/40 Chorioretinal atrophy with foveal sparing and hyper- and 
hypoautofluorescent flecks throughout posterior pole and 
midperiphery on FAF (Fig 2A-C)
NP N N/MR c.5762_5763dup p.(Ala1922Trpfs*18) S
G-II:4 / ♀ / 70 37 CF CF Extensive chorioretinal atrophy and pigmentary changes in 
posterior pole and hyper- and hypoautofluorescent flecks 
throughout posterior pole and midperiphery on FAF
NP NP NP c.5762_5763dup p.(Ala1922Trpfs*18) S
H-II:3 / ♂ / 38d 30 20/125 HM§ Perimacular irregular yellow-white flecks and beaten 
bronze atrophy in macula (no OCT/FAF)
Yes N N c.2919-?_3328+?del p.(Ser974Glnfs*64) S
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Latest Visual Acuity Fundus and Imaging Features Dark Choroid 
on Fluorescein 
Angiography
Full-field ERG† Genotype: ABCA4 Variant(s) in Trans








I-II:3 / ♀ / 29e 18 20/50 20/33 Parafoveal pigmentary changes with yellow-white 
pisciform flecks throughout the posterior pole and mild 
atrophy in macula (no OCT/FAF)
No N N c.768G>T p.(Leu257Valfs*17)∆ S
J-II:2 / ♂ / 57 56 20/32 20/330 Pigmentary changes in macula, perimacular yellow-white 
flecks and chorioretinal atrophy with in RE foveal sparing, 
in both eyes surrounded by an area of increased 
background FAF






K-II:1 / ♀ / 29 23 20/200 20/125 Foveal changes and perimacular yellow-white flecks (no 
OCT/FAF)
Yes NP NP c.5914G>A||,# p.(Gly1972Arg) NA
L-II:1 / ♀ / 46 31‡ 20/200 20/200 Foveal changes with perimacular yellow-white irregular 
flecks and mottled decreased FAF in macula
Yes N (31y) N (31y) c.768G>T p.(Leu257Valfs*17)∆ S
M-II:1 / ♀ / 69 53 20/50 20/100 Foveal changes with yellow-white pisciform flecks 
throughout the posterior pole and mid-periphery and 
chorioretinal atrophy with foveal sparing; Attenuated 
arterioles
Yes MR (53y) N (53y) c.6155del p.(Asn2052Thrfs*9) S
N-II:1 / ♀ / 71a,b,c,f 45‡ CF 20/20 45yrs: yellow-white pisciform flecks throughout the 
posterior pole
71yrs: extensive chorioretinal atrophy in macula of RE after 
years of foveal sparing, chorioretinal atrophy with foveal 
sparing in LE
Yes SR SR c.3874C>T|| p.(Gln1292*) S
O-II:1 / ♀ / 39 32 20/22 20/20 Foveal changes with perimacular yellow-white irregular 
flecks, and mottled FAF in macula with foveal sparing
NP NP NP c.768G>T p.(Leu257Valfs*17)∆ S
P-II:1 / ♀ / 35c 32 20/50 20/100 Foveal changes with perimacular yellow-white irregular 
flecks and mottled decreased FAF in macula surrounded by 
a zone of increased background FAF
NP N N c.6428T>G p.(Met2143Arg) NA
Q-II:1 / ♀ / 46 42‡ 20/30 20/32 Foveal changes with perimacular yellow-white irregular 
flecks and mottled decreased FAF in macula
Yes NP NP c.5714+5G>A p.[=, Glu1863Leufs*33)∆ Mo
R-II:1 / ♂ / 30 30‡ 20/28 20/22 Perimacular ring of increased FAF around a zone of mottled 
decreased FAF with foveal sparing and normal fovea reflex; 
A few mild hyperfluorescent flecks in posterior pole
NP N N c.5917delG|| p.(Val1973*) S
S-II:1 / ♀ / 30 26 20/200 20/50 Foveal changes with perimacular yellow-white irregular 
flecks and mottled decreased FAF in macula
Yes N N c.1822T>A p.(Phe608Ile) S
T-II:1 / ♂ / 45c 36 20/66 CF Foveal pigmentary changes and yellow-white pisciform 
flecks throughout the posterior pole and mid-periphery 
with chorioretinal atrophy in macula
NP NP NP c.3259G>A p.(Glu1087Lys) NA
U-II:1 / ♀ / 40 37‡ 20/40 20/66 Perimacular yellow-white pisciform flecks and mottled 
decreased FAF in macula with foveal sparing
NP N (37y) NP (37y) c.1938-1G>A p.(?) S
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Latest Visual Acuity Fundus and Imaging Features Dark Choroid 
on Fluorescein 
Angiography
Full-field ERG† Genotype: ABCA4 Variant(s) in Trans








I-II:3 / ♀ / 29e 18 20/50 20/33 Parafoveal pigmentary changes with yellow-white 
pisciform flecks throughout the posterior pole and mild 
atrophy in macula (no OCT/FAF)
No N N c.768G>T p.(Leu257Valfs*17)∆ S
J-II:2 / ♂ / 57 56 20/32 20/330 Pigmentary changes in macula, perimacular yellow-white 
flecks and chorioretinal atrophy with in RE foveal sparing, 
in both eyes surrounded by an area of increased 
background FAF






K-II:1 / ♀ / 29 23 20/200 20/125 Foveal changes and perimacular yellow-white flecks (no 
OCT/FAF)
Yes NP NP c.5914G>A||,# p.(Gly1972Arg) NA
L-II:1 / ♀ / 46 31‡ 20/200 20/200 Foveal changes with perimacular yellow-white irregular 
flecks and mottled decreased FAF in macula
Yes N (31y) N (31y) c.768G>T p.(Leu257Valfs*17)∆ S
M-II:1 / ♀ / 69 53 20/50 20/100 Foveal changes with yellow-white pisciform flecks 
throughout the posterior pole and mid-periphery and 
chorioretinal atrophy with foveal sparing; Attenuated 
arterioles
Yes MR (53y) N (53y) c.6155del p.(Asn2052Thrfs*9) S
N-II:1 / ♀ / 71a,b,c,f 45‡ CF 20/20 45yrs: yellow-white pisciform flecks throughout the 
posterior pole
71yrs: extensive chorioretinal atrophy in macula of RE after 
years of foveal sparing, chorioretinal atrophy with foveal 
sparing in LE
Yes SR SR c.3874C>T|| p.(Gln1292*) S
O-II:1 / ♀ / 39 32 20/22 20/20 Foveal changes with perimacular yellow-white irregular 
flecks, and mottled FAF in macula with foveal sparing
NP NP NP c.768G>T p.(Leu257Valfs*17)∆ S
P-II:1 / ♀ / 35c 32 20/50 20/100 Foveal changes with perimacular yellow-white irregular 
flecks and mottled decreased FAF in macula surrounded by 
a zone of increased background FAF
NP N N c.6428T>G p.(Met2143Arg) NA
Q-II:1 / ♀ / 46 42‡ 20/30 20/32 Foveal changes with perimacular yellow-white irregular 
flecks and mottled decreased FAF in macula
Yes NP NP c.5714+5G>A p.[=, Glu1863Leufs*33)∆ Mo
R-II:1 / ♂ / 30 30‡ 20/28 20/22 Perimacular ring of increased FAF around a zone of mottled 
decreased FAF with foveal sparing and normal fovea reflex; 
A few mild hyperfluorescent flecks in posterior pole
NP N N c.5917delG|| p.(Val1973*) S
S-II:1 / ♀ / 30 26 20/200 20/50 Foveal changes with perimacular yellow-white irregular 
flecks and mottled decreased FAF in macula
Yes N N c.1822T>A p.(Phe608Ile) S
T-II:1 / ♂ / 45c 36 20/66 CF Foveal pigmentary changes and yellow-white pisciform 
flecks throughout the posterior pole and mid-periphery 
with chorioretinal atrophy in macula
NP NP NP c.3259G>A p.(Glu1087Lys) NA
U-II:1 / ♀ / 40 37‡ 20/40 20/66 Perimacular yellow-white pisciform flecks and mottled 
decreased FAF in macula with foveal sparing
NP N (37y) NP (37y) c.1938-1G>A p.(?) S
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Latest Visual Acuity Fundus and Imaging Features Dark Choroid 
on Fluorescein 
Angiography
Full-field ERG† Genotype: ABCA4 Variant(s) in Trans








V-II:1 / ♀ / 31 27‡ CF 20/100 Perimacular yellow-white pisciform flecks and mottled 
decreased FAF in macula, surrounded by a zone of 
increased background FAF, initially with foveal sparing
NP SR (27y) N (27y) c.5882G>A p.(Gly1961Glu) M
W-II:1 / ♀ / 55 42 20/130 20/200 Perimacular yellow-white irregular flecks and a zone of 
increased background FAF in macula with foveal mottled 
decreased FAF
NP N (42y) N (42y) c.768G>T p.(Leu257Valfs*17)∆ S
X-II:1 / ♀ / 32c 20 20/200 20/125 Perimacular yellow-white irregular flecks with chorioretinal 
atrophy in macula
No N N c.4506C>A p.(Cys1502*) S
Y-II:1 / ♀ / 53 47‡ 20/25 20/20 Perimacular yellow-white irregular flecks; Parafoveal 
chorioretinal atrophy with foveal sparing in RE, and mottled 
decreased FAF with foveal sparing in LE






Z-II:1 / ♀ / 44 21 CF CF 22yrs: Abnormal foveal reflex with macular pigmentary 
changes
44yrs: Perimacular yellow-white irregular flecks and 
chorioretinal atrophy in macula
NP N/NP (20y) N/NP (20y) c.4234C>T|| p.(Gln1412*) S
AA-II:1 / ♂ / 58 57 20/20 20/20 Yellow-white pisciform flecks throughout the posterior 
pole, no atrophy





CF, counting fingers; ERG, electroretinography; FAF, fundus autofluorescence; fs, frameshift; HM, hand motion, LE, 
left eye; M, mild effect; Mo, moderately severe effect; NA, not applicable; NP, not performed; RE, right eye; 
S, severe effect; yrs, years; ♀, female; ♂, male; †ERG results at latest visit, unless stated otherwise; N, normal 
amplitude (equal to or above the lower 5% of the range for a normal population); MR, moderately reduced 
amplitude (1%–5% of normal range); SR, severely reduced amplitude (<1% of normal range); ‡age at diagnosis; 
§amblyopic eye; ||trans configuration could not be established by segregation analysis or homozygosity; #also 
CNGB3 c.1148delC heterozygous; ∆based on in vitro splice assays27,28. Previously mentioned cases: a) Westeneng 
et al., 2012;16 b) Lambertus, Lindner, Bax et al., 2016;32 c) Lambertus, Bax, Groenewoud et al., 2016;33 d) Klevering 
et al., 200413 and Bax et al., 201520; e) Hoyng et al., 1996;34 and f) van Huet et al., 201415.
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Latest Visual Acuity Fundus and Imaging Features Dark Choroid 
on Fluorescein 
Angiography
Full-field ERG† Genotype: ABCA4 Variant(s) in Trans








V-II:1 / ♀ / 31 27‡ CF 20/100 Perimacular yellow-white pisciform flecks and mottled 
decreased FAF in macula, surrounded by a zone of 
increased background FAF, initially with foveal sparing
NP SR (27y) N (27y) c.5882G>A p.(Gly1961Glu) M
W-II:1 / ♀ / 55 42 20/130 20/200 Perimacular yellow-white irregular flecks and a zone of 
increased background FAF in macula with foveal mottled 
decreased FAF
NP N (42y) N (42y) c.768G>T p.(Leu257Valfs*17)∆ S
X-II:1 / ♀ / 32c 20 20/200 20/125 Perimacular yellow-white irregular flecks with chorioretinal 
atrophy in macula
No N N c.4506C>A p.(Cys1502*) S
Y-II:1 / ♀ / 53 47‡ 20/25 20/20 Perimacular yellow-white irregular flecks; Parafoveal 
chorioretinal atrophy with foveal sparing in RE, and mottled 
decreased FAF with foveal sparing in LE






Z-II:1 / ♀ / 44 21 CF CF 22yrs: Abnormal foveal reflex with macular pigmentary 
changes
44yrs: Perimacular yellow-white irregular flecks and 
chorioretinal atrophy in macula
NP N/NP (20y) N/NP (20y) c.4234C>T|| p.(Gln1412*) S
AA-II:1 / ♂ / 58 57 20/20 20/20 Yellow-white pisciform flecks throughout the posterior 
pole, no atrophy
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Table 2  Penetrance calculation for c.5603A>T when in trans with severe ABCA4 variants.




Single-variant allele c.5603A>T (p) 0.06453
B Sum allele frequency of severe ABCA4 variants
ABCA4 protein-truncating and canonical splice site variants 0.00198
ABCA4 severe non-canonical splice site variants*** 0.00083
Severe ABCA4 variants (q) 0.00271
C. Theoretical number of STGD1 cases with severe variant and c.5603A>T
Frequency of STGD1 cases with severe variant and c.5603A>T (2pq) 0.000349
Number of STGD1 cases in The Netherlands with severe variant and c.5603A>T 5,991
D. Observed number of STGD1 cases with severe variant and c.5603A>T
Total STGD1 prevalence 0.0001
Proportion STGD1 cases in Nijmegen carrying severe variant and c.5603A>T 0.0833
Prevalence STGD1 cases in The Netherlands with severe variant and c.5603A>T 0.00000833
Number of STGD1 cases in The Netherlands with severe variant and c.5603A>T 143
E. Penetrance of c.5603A>T in combination with a severe variant 
(observed/theoretical numer of STGD1 cases 0.0239
*Assuming complete linkage disequilibrium between c.5603A>T and c.5641-10T>C based on this study and a 
previously published report.26 **Based on the observation that in an AMD cohort, 10% of individuals with 
c.2588G>C also carry c.5603A>T.26 ***Based on in vitro splice assays of non-canonical splice site variants.28
Figure 2. Retinal imaging of a patient with a very late onset of STGD1. A. Fundus photography 
showed no signs of flecks in patient G-II:2 at the age of 72, 3 years after disease onset. B-C. FAF 
performed in the same patient, at the same time, showed widespread hypo- and hyper-autofluores-
cent lesions. FAF and OCT showed perifoveal chorioretinal atrophy with foveal sparing.  
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Figure 3. Retinal imaging of two sibling pairs in which an affected and an unaffected sibling 
harbor the same combination of ABCA4 variants. A-C. Asymptomatic sibling E-II:1 does not 
manifest STGD1 as assessed by fundus photography, FAF and OCT at the age of 70 years. Fundus 
photography shows one small yellow-white, round lesion, which appears hyperautofluorescent on 
FAF, and is visible as a single subretinal deposit on OCT. D-F. Patient E-II:3 shows perimacular and 
peripapillary irregular yellow-white flecks on fundus photography at the age of 64. FAF reveals hy-
per-autofluorescent lesions corresponding with the flecks, and mottled decreased autofluores-
cence in the macula. OCT shows macular RPE atrophy. G-I. Asymptomatic sibling F-II:1 shows no 
abnormalities on fundus photography, FAF and OCT at the age of 47 years. J-L. Patient F-II:2 shows 
foveal changes with perimacular and peripapillary irregular yellow-white flecks, mottled decreased 
FAF in the macula and central RPE atrophy at the age of 41 years, 9 years after disease onset.
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As these calculations were based on a few assumptions, we also calculated the penetrance 
based on alternative assumptions regarding the prevalence of STGD1 and the frequency 
of severe ABCA4 variants (Supplemental Results S2). When uncertainties in these factors of 
the calculation were taken into account, and in the unlikely situation that the alternative 
assumptions would act in concert, the penetrance of p.Asn1868Ile ranged between 0.24% 
and 9.54%.
DISCUSSION
By combining ABCA4 sequence analysis and segregation analysis of the identified variants, 
we detected the common variant p.Asn1868Ile as the second allele in 40% of cases 
carrying monoallelic variants in our genetically unexplained STGD1 cohort. In the vast 
majority of the cases, p.Asn1868Ile was found in trans with severe ABCA4 variants, thus 
pointing towards the mild nature of this exonic variant in STGD1. In agreement with a 
previous study,26 we found that a high proportion of these p.Asn1868Ile carriers manifest 
the late-onset STGD1 phenotype. However, among our cases, age at onset was highly 
variable. Strikingly, we identified one asymptomatic sibling and two unaffected siblings, 
all of whom carried the same combination of ABCA4 variants as the respective probands. 
The very low calculated penetrance of p.Asn1868Ile of 2.4% in addition to the observed 
variability in age at onset and phenotypes among individuals carrying the same 
combinations of ABCA4 variants, leads us to hypothesize that cis or trans acting genetic 
modifiers or environmental factors greatly influence ABCA4 gene expression and thereby 
the clinical presentation of STGD1.
As yet, very little is known about the potential nature, role and mechanisms of modifiers 
in STGD1. One group studied gene expression variation in the human retina and found 
that ABCA4 showed 1.5-fold higher expression in males compared to females.35 Males 
carrying a high-expressed mild ABCA4 allele thereby may be less prone to develop STGD1. 
In our study, we also observed an overrepresentation of females (22/34, 65%) among 
patients carrying p.Asn1868Ile (one-sample one-sided binomial test p=0.0615). 
Furthermore, all three putative nonpenetrant siblings are male. Further research is needed 
to identify possible modifiers, explain the mechanisms whereby they modify gene 
expression and, most interestingly, explore their potential as therapeutic targets.  
Clinical overlap with other macular diseases along with inconclusive results of genetic 
analyses can make the diagnosis of late-onset STGD1 particularly challenging, as illustrated 
by case G-II:1 and G-II:2 who first experienced symptoms at the age of 72 and 69, 
respectively. FAF and genetic analysis in these cases were valuable in distinguishing 
late-onset STGD1 from AMD. The identification of the second disease-causing allele, 
whereby a significant fraction of late-onset STGD1 cases is now genetically explained, 
strengthens the assumption that late-onset STGD1 represents a distinct disease entity that 
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should not be confused with AMD.26 An accurate diagnosis is essential for appropriate 
counseling of patients regarding prognosis and heritability, and is relevant for putative 
therapies, e.g., either recommendation or dissuading of vitamin A supplement use in AMD 
and STGD1, respectively. Moreover, several therapeutic trials in STGD1 patients are ongoing 
(http://www.clinicaltrials.gov, last accessed 21-03-2018), requiring identification of both 
disease-causing ABCA4 alleles. 
Assessment of nonpenetrance has a few limitations. First, this study showed that age at 
onset, which constitutes a rather subjective measure, can vary tremendously even among 
siblings carrying the same ABCA4 variants. Therefore, nonpenetrance cannot easily be 
confirmed by clinical examination of unaffected persons carrying bi-allelic disease-caus-
ing ABCA4 variants. Regardless of whether the currently unaffected subjects develop 
STGD1 later in life, a highly variable disease expression was observed that raises new 
questions about the disease mechanisms. Second, although we have experimentally 
proven the veracity of a nonpenetrance phenomenon, we are conscious of the fact that 
nonpenetrance estimates cannot be considered as definitive. Most importantly, late-onset 
STGD1 currently may be underdiagnosed or misdiagnosed due to the clinical overlap with 
AMD. In an AMD cohort (n=698) from the Radboudumc, we however did not observe 
persons with a combination of a severe ABCA4 variant and p.Asn1868Ile, suggesting that 
misdiagnosis cannot be a major factor in centers of clinical expertise on STGD1. Moreover, 
since several non-truncating ABCA4 variants might also behave like ‘severe’ variants, our 
estimate of the cumulative AF of severe variants in the population may in fact be higher 
which would make the resultant penetrance estimate (2.4%) even lower.
Conclusions
Identification of genetic variants underlying STGD1 is essential to provide accurate 
counseling to patients and relatives and to drive therapeutic approaches. A significant 
proportion of STGD1 patients carries p.Asn1868Ile, which is associated with late-onset 
STGD1 and a variable disease expression. In line with these findings, we calculated an 
exceptionally low penetrance of the p.Asn1868Ile variant, which may be explained by the 
action of cis or trans acting genetic modifiers or non-genetic factors in STGD1.
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SUPPLEMENTAL MATERIAL
Supplemental Methods S1. Alternative genetic analyses
Four DNA samples were not analyzed using Haloplex sequencing. Patient I-II:3 was 
previously analyzed by linkage analysis34, allele-specific primer extension analysis by 
Asper Biotech in 2002, followed by Sanger sequencing of the identified variants. Patients 
Y-II:1 and AA-II:1 were analyzed for ABCA4 variants using Sanger sequencing of the 50 
coding exons and flanking intronic sequences. Patient Y-II:1 was also analyzed using 
multiplex ligation-dependent probe amplification analysis according to the manufacturer’s 
instructions (SALSA MLPA kit P151-P152 ABCA4; MRC-Holland, Amsterdam, The Netherlands). 
The DNA of patient J-II:2 was analyzed by whole exome sequencing (WES). Exome 
enrichment was performed using the Agilent SureSelectXT Human All Exon 50Mb kit 
(Agilent Technologies, Santa Clara, CA) and WES was performed on the Illumina HiSeq2000 
platform by BGI (Copenhagen, Denmark) as previously described.36
Supplemental Results S2. Penetrance calculations using other assumptions
a) Prevalence of STGD1 among individuals carrying p.Asn1868Ile and a severe variant is 
twice as high (Figure 4D)
 As some participants showed disease onset in their sixties, and as foveal sparing may 
cause a prolonged asymptomatic course, late onset STGD1 may be underdiagnosed. 
Also, patients with late-onset STGD1 may be misdiagnosed due to clinical overlap 
with other macular diseases. If the prevalence of STGD1 due to the combination of 
p.Asn1868Ile with a severe ABCA4 variant would be twice as high, the penetrance of 
this combination of variants would be 4.78% [2*2.39%].
b) Prevalence of STGD1 is higher; proportion of STGD1 cases carrying p.Asn1868Ile and 
a severe variant stays the same (Figure 4D)
 To date, only one STGD1 prevalence has been published.1 If its prevalence is two 
times higher, the penetrance of p.Asn1868Ile, when found in combination with a 
severe ABCA4 variant, would be 4.78%.
c) Prevalence of STGD1 is lower (Figure 4D)
 If the STGD1 prevalence is two times lower, the penetrance of p.Asn1868Ile, when 
found in combination with a severe ABCA4 variant, would be 1.2% [0.5*2.39%].
d) Sum frequency of severe ABCA4 variants is higher (Figure 4B)
 First, we calculated a higher cumulative AF of severe ABCA4 variants by adding the AF 
of the following two variant groups, employing AF data in ~66,000 non-Finnish 
European control alleles. 
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 As published elsewhere31, we identified non-truncating variants that were at least 
100 times more frequent in STGD1 patients than in controls, and occurred with one of 
the two frequent known ‘mild’ variants c.2588G>C and c.5882G>A, or occurred in at 
least one patient with disease onset before 10 years of age: total AF 0.0003. Also 
based on the premise that mild variants always are present in trans with a severe 
ABCA4 variant in STGD1 cases, we selected variants that were found in trans with one 
of five statistically determined ‘mild’ ABCA4 variants in STGD1 cases (i.e. c.[2588G>C; 
5603A>T], c.5882G>A, c.3113C>T, c.5714+5G>A and c.6089G>A): non-redundant total 
AF 0.0037. 
 Thereby, the cumulative AF of these presumed severe ABCA4 variants was 0.0067, 
which suggests a prevalence of individuals carrying both a severe and p.Asn1868Ile 
of 0.000865 in the non-Finnish European population. This results in a theoretical 
number of STGD1 cases in the NL with a severe variant and c.5603A>T of 14,829, and 
thereby a penetrance of 0.0096%.This sum frequency of severe variants may still 
represent an underestimate as we cannot rule out the possibility that a combination 
of a moderately severe variant with p.Asn1868Ile can also result in STGD1. If the above 
described estimate of the sum frequency of severe and moderately severe variants is 
twice as high (0.0134), the penetrance of p.Asn1868Ile, when found in combination 
with a severe ABCA4 variant, would be 0.48% [0.5*0.96%].
In conclusion, the minimal penetrance estimation based on all the minimizing factors – 
lower STGD1 prevalence and a higher severe ABCA4 variant frequency – would come 
down to 0.96%*0.5*0.5 = 0.24%. If we assume that all the maximizing factors apply, i.e. 
underestimation of the late-onset STGD1 prevalence due to p.Asn1868Ile in combination 
with a severe variant and underestimation of the total STGD1 prevalence, the maximum 
penetrance would be 2.39%*2*2 = 9.54%. Therefore, taking into account the cumulative 
effect of all variables in the calculation, the penetrance of the p.Asn1868Ile lies between 
0.24% and 9.54%.
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Supplemental Figure S1. Stargardt siblings presenting with different ABCA4 genotypes
Based on haplotype analysis in family I with three siblings affected by STGD1 two decades ago34, 
and ABCA4 sequence analysis, we were able to identify the causal variants in two of three siblings, i.e. 
the variants c.768G>T (p.Leu257Valfs*17) and c.2588G>C (p.[Gly863Ala,Gly863del]), that previously 
were designated as severe and mild ABCA4 variants, respectively.8,10 As expected, the c.2588G>C 
variant was found to be in cis with c.5603A>T (p.Asn1868Ile) thereby forming the allele c.
[2588G>C;5603A>T]. The affected person I-II:3 only carried the c.768G>T variant and was genetically 
unexplained. With the possibility that the p.Asn1868Ile variant may have been overlooked as a 
causal variant, we tested its presence in all family members and found it to be present in a 
homozygous state in the unaffected mother I-I:2 and in a compound heterozygous manner in I-II:3. 
In the mother, one of these variants is present in cis with c.2588G>C, which thereby constitutes a 
penetrant mild ABCA4 allele. In I-II:3, it is present in a compound heterozygous configuration 
together with the severe variant c.768G>T. All siblings experienced initial symptoms at the age of 18 
to 19 years. However, at the age of 29 years BCVA of I-II:3 had declined to 20/50 in the right eye and 
20/33 in the left eye, whereas BCVA at the same age in I-II:2 was 20/80 in the right eye and 20/125 in 
the left eye and in I-II:1 below 20/100 in both eyes.  
In Family J, J-II:1 carries c.[5461-10T>C;5603A>T] and p.(Val643Gly). The non-canonical splice site variant 
c.5461-10T>C is known to result in exon 39 or exon 39/40 skipping and protein truncation27; 
p.Val643Gly is a variant with unknown significance. Her brother (J-II:2), showing late-onset STGD1, 
carries the same allele c.[5461-10T>C;5603A>T] in combination with p.Asn1868Ile. The initial 
symptom of vision loss occurred at the age of 56 and 51 years in J-II:1 and J-II:2, respectively. They 
manifested similar phenotypes with central chorioretinal atrophy surrounded by a ring of increased 
FAF and a few hyperfluorescent flecks, although J-II:1 at the age of 57 exhibited foveal sparing, whereas 
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Supplemental Figure S2. Pedigrees of family K to family AA
The ABCA4 variant c.5603A>T (p.Asn1868Ile), in addition to a known causal ABCA4 variant, was 
identified exclusively in the proband in 17 single-case families. Segregation analysis in 11 of these 
families, and p.Asn1868Ile homozygosity in probands Y-II:1 and AA-II:1, established the trans 
configuration of the identified variants. In the remaining probands K-II:1, N-II:1, R-II:1, Z-II:1, segregation 
analysis could not be completed due to the absence of DNA of relatives. Three probands are male, 
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Supplemental Table S1  Primers for ABCA4 variant segregation analysis
Forward (5’-> 3’) Reverse (5’-> 3’) Product size (bp)
Ex6F_6R ACACAAGGTATTCCCAGGTTC AAGGATTGTCCAGAACACCA 396
Ex13F_13R CAGAGTCACATTGTGGCTAATATT TCTAAAGACATGGAAGCCTTG 467
Ex14F_14R CCTCTACCAGGTACAGAGC AGATGTCACGCTCTCCTTG 389
Ex19F_23R CACCACCTTGTGAGTCTTCC GTGAGTGGACATGATGATGG 5551
Ex22F_22R CACCCTCCACAGCCCCTTAAC AAATGGCAGGTGAGAGAGTG 264
Ex27F_27R GCTACCAGCCTGGTATTTCATTG GTTATAACCCATGCCTGAAG 493
Ex28F_28R ACCCTGCTTATTATGTTCCCC CAGTGAAGTGGGAAGGTCAG 378
Ex30F_30R CACACCTAGTCAGTCACAAAAC ACTCAGGAGATACCAGGGAC 451
Ex39F_39R CTGCAAGGACTCTCTGTCTG CAACAAGGTCCCCTCCTAG 367
Ex40F_40R CCAGGTCTGTGGGGTGAG CTCCTGAGGAAAGAAATGACC 279
Ex41F_41R GGACACTGTACAGCCAGC TGTTCTATAGAAGGAAAATGGC 247
Ex42F_42R CGAGATGTCTCAGTACTCACCAC CATATGTGACTTGCATTATGGC 349
Ex43F_43R CTTACCCTGGGGCCTGAC CTCAGAGCCACCCTACTATAG 277
Ex45F_45R GTTTGGGGTGTTTGCTTGTC ACCTATTTCCCCAACCCAAGAG 257
Ex46F_47R CTTCTGTCAGCTCATCCTCCA CTCTTCCAAGTGTCAATGGAG 455
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ABSTRACT
Purpose: To investigate the role of two deep-intronic ABCA4 variants, that showed a mild 
splice defect in vitro and can occur on the same allele as the low penetrant c.5603A>T, in 
Stargardt disease (STGD1).
Methods: Ophthalmic data were assessed of 18 STGD1 patients who harbored 
c.769-784C>T or c.4253+43G>A in combination with a severe ABCA4 variant. Subjects 
carrying c.[769-784C>T;5603A>T] were clinically compared to a STGD1 cohort previously 
published carrying c.5603A>T noncomplex. We calculated the penetrances of the intronic 
variants using ABCA4 allele frequency data of the general population and investigated the 
effect of c.769-784C>T on splicing in photoreceptor progenitor cells (PPCs).
Results: Mostly, late-onset, foveal-sparing STGD1 was observed among subjects harboring 
c.769-784C>T or c.4253+43G>A (median age of onset, 54.5 and 52.0 years, respectively). 
However, ages of onset, phenotypes in fundo, and visual acuity courses varied widely. No 
significant clinical differences were observed between the c.[769-784C>T;5603A>T] cohort 
and the c.4253+43G>A or the c.5603A>T cohort. The penetrances of c.769-784C>T 
(20.5-39.6%) and c.4253+43G>A (35.8-43.1%) were reduced, when not considering the 
effect of yet unidentified or known factors in cis, such as c.5603A>T (identified in 7/7 
probands with c.769-784C>T; 1/8 probands with c.4253+43G>A). Variant c.769-784C>T 
resulted in a pseudo-exon insertion in 15% of the total mRNA (i.e. ~30% of the c.769-784C>T 
allele alone).
Conclusions: Two mild intronic ABCA4 variants could further explain missing heritability 
in late-onset STGD1, distinguishing it from age-related macular degeneration. The 
observed clinical variability and calculated reduced penetrance urge research into 
modifiers within and outside of the ABCA4 gene.
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INTRODUCTION
Stargardt disease (STGD1 [Mendelian Inheritance in Man: 248200]) is typically characterized 
by rapid visual acuity decline in childhood or early adulthood, and by yellow-white 
pisciform flecks throughout the posterior pole and macular atrophy on fundoscopy.1,2 
We previously described a cohort of patients with late-onset STGD1 which was 
characterized by slowly progressive sharply demarcated retinal pigment epithelium (RPE) 
atrophy in a foveal-sparing pattern.3-5 However, the diagnosis of late-onset STGD1 
remained questionable due to unidentified disease-causing ABCA4 alleles, and phenotypic 
overlap with other macular diseases, the most frequent of which is age-related macular 
degeneration (AMD).6 
Recently, a large part of the missing heritability of late-onset STGD1 was elucidated by the 
frequent ABCA4 coding variant c.5603A>T (p.Asn1868Ile), which was found to cause STGD1 
only when present in combination with a deleterious mutation.7 Interestingly, this mild 
variant was associated with an exceptional clinical variability.8 Moreover, this variant clearly 
showed reduced penetrance in the Dutch population (~5%), that is, the vast majority of 
individuals carrying c.5603A>T in trans with (i.e. positioned on the other allele as) a severe 
variant do not manifest STGD1.8-10 Reduced penetrance has rarely been reported in auto-
somal-recessive retinal diseases.11-13 Occurrence of this phenomenon has major implications 
for genetic counseling and future directions for research into modifying factors, which 
could result in targets for therapeutics. 
Very recently, we identified eight deep-intronic variants among 67% of genetically 
unsolved STGD1 patients.14 The two most frequently identified variants, c.769-784C>T and 
c.4253+43G>A, only showed a partial splice defect in vitro. Variant c.769-784C>T strengthened 
a cryptic splice site at a noncanonical nucleotide position resulting in pseudo-exon 
inclusion. As this c.769-784C>T variant was consistently found in cis with (i.e. positioned on 
the same allele as) the mild c.5603A>T variant, its causal role could not be fully established 
yet. Variant c.4253+43G>A disrupted predicted splice silencers and created an exonic 
splicing enhancer leading to partial skipping of exon 28. Like c.5603A>T, variant 
c.4253+43G>A was associated with late-onset STGD1 and found to be phenotypically 
expressed only when in trans with a severe variant.15 
In this study, we investigate the phenotypic characteristics associated with deep-intronic 
ABCA4 variants c.769-784C>T and c.4253+43G>A, and clinically compared these patients 
to our previously described patient cohort carrying c.5603A>T without variants in cis. 
Furthermore, we aim to strengthen the observation that c.769-784C>T has an effect on 
splicing, and to assess the penetrance of both intronic variants. This information is 
paramount for the differential diagnostics of late-onset STGD1 and to discern this disease 
from AMD.
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METHODS
Subjects
Participants originated from the population of STGD1 patients in ophthalmic centers 
in The Netherlands participating in the RD5000 study group.16 Fifteen genetically 
unexplained probands and three affected siblings in whom the c.768-784C>T variant or 
the c.4253+43G>A variant was found as the second allele, after HaloPlex-based (Agilent, 
Santa Clara, CA, USA) sequencing and segregation analysis by Sangermano et al.,14 were 
identified. All records were reviewed retrospectively. Additionally, skin biopsies were 
collected from a STGD1 patient harboring c.769-784C>T and a control individual, and 
splice assays were performed in photoreceptor progenitor cells (PPCs). Ultimately, we 
performed penetrance calculations employing ABCA4 allele frequency data of one 
European and two Dutch population databases. 
All procedures were approved by the Medical Ethics Committee of Erasmus Medical 
Center (MEC-2010-359). Informed consent was obtained after explanation of the study, 
and the study adhered to the tenets of the Declaration of Helsinki.  
Clinical evaluation
Clinical data collected from medical records included age of onset and initial symptoms, 
age at diagnosis, best-corrected visual acuity (VA), findings on ophthalmoscopy, retinal 
imaging, and full-field electroretinography (ffERG). We examined available fundus 
photography, fundus autofluorescence (FAF) imaging (using a confocal scanning laser 
ophthalmoscope; Spectralis; Heidelberg Engineering, Heidelberg, Germany), spectral 
domain-optical coherence tomography (OCT; Spectralis or Cirrus, Carl Zeiss Meditec Inc., 
Dublin, CA, USA), and ffERG acquired according to the International Society for Clinical 
Electrophysiology of Vision standards.17 We assessed the presence of foveal sparing, which 
we defined as RPE atrophy encircling a structurally and functionally (VA ≥20/200 Snellen) 
preserved fovea by 180⁰ or more, by evaluation of FAF and/or OCT.4 The previously 
described definition ‘definitely decreased autofluorescence’ was used in the assessment 
of FAF.18 
Age of onset was defined as the age at which the patient first experienced visual 
complaints. In asymptomatic subjects or in case age at onset was not reported, we used 
the age at which decrease in VA was first documented or the age at which macular 
abnormalities were first diagnosed. Age of onset was compared across patient groups 
with different ABCA4 genotypes, using Mann-Whitney U Tests for independent samples. 
A p-value of <0.05 was considered statistically significant.
We performed Kaplan-Meier survival analysis to determine the median survival time to 
develop severe visual impairment, defined as a VA of less than 20/200 Snellen (decimal, 
0.10) in accordance with the International Classification of Diseases, 11th revision.19 Patients 
were censored if the time interval between the first measurement of severe visual 
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impairment and the prior visit was more than 5 years, and patients were excluded if VA 
was available at only one time point and already was less than 20/200 Snellen. Additionally, 
we investigated whether c.769-784C>T has an additive effect on disease severity compared 
with the c.5603A>T variant alone by including age at onset and VA data of a previously 
described cohort of STGD1 patients carrying the noncomplex c.5603A>T variant.8 
Assessment of RNA splice defects in photoreceptor progenitor cells
To determine whether deep-intronic variant c.769-784C>T results in aberrant splicing of 
ABCA4 pre-mRNA, fibroblasts of a patient and a control were reprogrammed into induced 
pluripotent stem cells and differentiated into PPCs as previously described.20 All differen-
tiations were performed in duplicate. Reverse-transcription-polymerase chain reaction 
(RT-PCR) was performed using ABCA4 exonic primers located in ABCA4 exon 6 and 8. Gel 
resolution, excision, and purification of the bands of RT-PCR products, and Sanger 
sequencing were performed as described elsewhere.20 Details of RT-PCR primers are 
given in Supplementary Table S1. 
To determine the fraction of correctly spliced product, densitometric analysis was performed 
using Image J software (http://imagej.nih.gov/ij/; provided in the public domain by 
the National Institutes of Health, Bethesda, MD, USA).21 The analysis was performed in 
duplicate, and values were normalized for the size of the different fragments present in 
each RT-PCR product mixture.
Penetrance calculations
We assessed the penetrance of c.769-784C>T and c.4253+43G>A, when present in trans 
with a severe ABCA4 variant, by comparing the observed number of patients carrying this 
combination of variants with the expected number of patients. 
The expected number of patients was calculated based on ABCA4 allele frequency data of 
the general population, as previously described.8,10 The cumulative frequency of severe 
ABCA4 alleles was 0.00195, determined in our in-house whole exome sequencing dataset, 
containing data of 21,559 individuals.10 We investigated the minor allele frequency (MAF) 
of the intronic variants of interest in the non-Finnish European (nFE) population in the 
Genome Aggregation Database (gnomAD),22,23 and the Dutch population in the Genome 
of The Netherlands database (GoNL).24,25 The median age at diagnosis in the study cohort 
of interest (i.e. c.769-784C>T or c.4253+43G>A carriers) served as a cut-off value to 
determine the number of individuals in The Netherlands at risk for disease due to both 
genotype and age.26
The observed number of patients carrying the intronic variant of interest in The Netherlands 
could be extrapolated given the proportion of patients harboring the intronic variant of 
interest at Radboud University Medical Center, the estimated STGD1 prevalence of 1 in 
10,000 individuals,27 and the total Dutch population.26 
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RESULTS
Genetic characteristics
A total of 15 probands was included in this study, and in 13 probands, the trans configuration 
of the identified ABCA4 variants was confirmed (i.e. variants positioned on different alleles; 
Figure 1). In families S and R, DNA of relatives was not available. Seven probands and one 
affected sibling harbored c.[769-784C>T;5603A>T] in trans with a severe ABCA4 variant. 
Eight probands and two affected siblings harbored c.4253+43G>A in trans with a severe 
ABCA4 variant. One proband (M-II:1) also carried c.5603A>T on the same allele as 
c.4253+43G>A.
Clinical characteristics 
Detailed clinical characteristics of all subjects are displayed in Supplementary Table S2. 
Patients presented with decreased VA, central scotoma, and/or distorted vision, and one 
patient was asymptomatic. Patients harboring c.[769-784C>T;5603A>T] reported a median 
age at onset of 54.5 (range, 20-69) years. This did not significantly differ from the age of 
onset among 33 patients carrying the noncomplex c.5603A>T variant previously reported, of 
whom the median was 41 (range, 18-72) years8 (Mann-Whitney U: p=0.146, Supplementary 
Figure S1). Patients harboring c.4253+43G>A had a median age at onset of 52.0 (range, 
20-68) years, while the single patient who carried c.[4253+43G>A;5603A>T] had the 
youngest age at onset of 18 years. 
Patients harboring c.[769-784C>T;5603A>T] mainly manifested late-onset STGD1 characterized 
by pisciform yellow-white flecks throughout the posterior pole and midperiphery on 
fundoscopy, appearing hyperautofluorescent on FAF, and sharply demarcated RPE atrophy 
in the macula on FAF, corresponding to loss of the outer retinal layers from the outer 
plexiform layer to the RPE on OCT, in a foveal-sparing pattern (Figure 2A). 
One patient, sibling Q-II:2, had a discordant onset: Q-II:2 already reported initial symptoms 
at the age of 20 years. Fundoscopy showed an abnormal foveal reflex with surrounding 
hypopigmentated lesions and yellow flecks at the age of 23, with a VA of 20/63 in the right 
eye and 20/100 in the left eye (Supplementary Figure S2). Over the years, macular lesions 
of RPE atrophy extended, surrounded by yellow-white flecks throughout the posterior 
pole and midperiphery. During triennial follow-up, VA gradually declined and reached 
20/200 in the left eye at the age of 26 years but not in the right eye until the age of 39 
years. In striking contrast, the brother, Q-II:1, had an age at onset of 69 years and fundus 
features in accordance with the characteristic findings of the group. The VA first reached 
20/200 in the right eye at the age of 75, while VA in the left eye still was 20/100 at the last 
visit, at age 78 years (Supplementary Figure S2). 
Patients harboring c.4253+43G>A also mainly manifested the characteristic late-onset 
STGD1 features. Six patients (H-I:2, J-II:1, J-II:2, J-II:3, N-II:3, R-II:3; age of onset 53, 68, 56, 61, 
31, and 52 years, respectively) showed foveal sparing up to the latest visit at age 63, 71, 75, 
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Figure 1. Genetic data and age of onset. Pedigrees, genotype, and age at onset of all patients for 
whom segregation analysis has been performed. Patient identifiers correspond with our previous 
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71, 42, and 68 years, respectively (Figure 2B). Yet, three patients (D-I:1, F-II:2, G-I:2) showed 
fewer and smaller flecks, mostly confined to the macula, and did not exhibit the typical 
foveal sparing atrophy. Instead, FAF of patient D-I:1 and G-I:2 showed mottled decreased 
autofluorescence in the macula accompanied by one parafoveal, over the years expanding, 
sharply demarcated atrophic lesion. Interestingly, patient D-I:1 showed distinct intereye 
discordance in fundoscopic features and the VA course (Supplementary Figures S2 and 
S3). At the age of 56, the right eye showed progressed disease with a large macular lesion 
of definitely decreased autofluorescence and RPE atrophy, whereas no RPE atrophy was 
observed in the left eye during annual follow-up until the age of 61. 
Patient F-II:2 had a much younger age at onset of 20 years and a rapid VA decline already 
at the age of 24 years. This patient initially manifested central RPE alterations and perifoveal 
small yellow flecks. Over the years, flecks enlarged and spread across the posterior pole, 
and beaten bronze macular atrophy corresponding to mottled decreased autofluores-
cence appeared (Supplementary Figure S3).
Patient M-II:1, the single patient who harbored c.4253+43G>A in cis with c.5603A>T 
showed flecks mostly confined to the macula, macular mottled decreased autofluores-
cence, and macular loss of the outer nuclear layer and ellipsoid zone at the age of 21, 3 
years after the initial symptom of VA loss (Figure 2C). At the age of 24, VA in the right and 
left eye had already declined to 20/66 and 20/100, respectively.
Results of ffERG were abnormal in only two out of nine patients in whom ffERG had been 
performed. Patients A-I:2 and H-I:2 had severely reduced responses under light-adapted 
conditions and moderately reduced responses under dark-adapted conditions at the age 
of 56 and 60 years, respectively. 
Two patients had ocular comorbidity. Patient S-II:1 had mild nonproliferative diabetic 
retinopathy and an amblyopic right eye. Over a decade after onset of STGD1, patient D-I:1 
suffered from a central retinal vein occlusion in the right eye and a hemi-retinal vein 
occlusion in the left eye. 
The VA courses of all eyes are depicted in Supplementary Figure S2. Patients carrying c.
[769-784C>T;5603A>T] had a median VA at the latest visit, at a median disease duration of 
14 (range, 8-28) years, of 20/180 (decimal, 0.11; range, 0.05-1.0) in the right eye and 20/125 
(0.16; range, 0.05-0.63) in the left eye. Patients carrying c.4253+43G>A had a median VA at 
the latest visit, at a median disease duration of 11 (range 3-25) years, of 20/125 (0.16; range, 
0.03-1.0) in the right and 20/25 (0.8; range, 0.05-1.0) in the left eye. 
Survival analysis of the time to severe visual impairment of patients in this study and 
patients carrying the noncomplex c.5603A>T in our STGD1 cohort showed comparable 
survival times across groups, as depicted in Figure 3. Mean VA survival times for patients 
carrying c.[769-784C>T;5603A>T] versus patients carrying the noncomplex c.5603A>T allele 
were 71 versus 69 years in the right eye, and 74 versus 71 years in the left eye, respectively. 
Mean survival time for right eyes of c.4253+43G>A carriers was 66 years. All left eyes were 
censored before reaching VA<20/200, at a median age of 63 (range, 25-71) years.
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Figure 3. Visual acuity survival. Kaplan-Meier survival plots for the time to reach severe visual 
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Splice defect due to c.769-784C>T in patient-derived photoreceptor 
progenitor cells 
RT-PCR was performed in PPCs derived from subject A-I:2. In the patient’s PPCs treated 
with cycloheximide, which blocks nonsense-mediated decay of mRNA, gel analysis and 
Sanger sequencing revealed a band of 327 nucleotides, corresponding to the correct 
transcript, and another band of 489 nucleotides, corresponding to a 162-nucleotides 
pseudo- exon insertion (Supplementary Figure S4 and Figure S5). The pseudo-exon fragment 
accounted for 15% of the total mRNA (Supplementary Table S3). 
Reduced penetrance of c.769-784C>T and c.4253+43G>A when not taking 
into account variants in cis
The ‘observed’ number of STGD1 cases who harbor either c.769-784C>T or c.4253+43G>A 
in combination with a severe ABCA4 variant in The Netherlands was extrapolated to be 
29 and 46, respectively (Table). 
The ‘expected’ number of patients carrying c.769-784C>T in combination with a severe 
variant was 72, based on the nFE MAF of c.769-784C>T of 0.00415. Based on the 2-fold 
higher Dutch MAF of c.769-784C>T (0.00802), 139 individuals were expected to be at risk 
for disease due to the ABCA4 variants they harbor and their age (higher than median age 
at diagnosis in patient cohort). For c.4253+43G>A, the ‘expected’ number of patients was 
128, based on a nFE MAF of c.4253+43G>A of 0.00603. Based on a slightly different Dutch 
MAF of c.4253+43G>A of 0.00501, 106 individuals were expected to be at risk. 
For c.769-784C>T and c.4253+43G>A in trans with a severe ABCA4 variant, comparison of the 
expected numbers of patients with the observed number of patients in The Netherlands 
resulted in an estimated penetrance of 20.5% (Dutch MAF) to 39.6% (nFE MAF) and 35.8% 
(nFE MAF) to 43.1% (Dutch MAF), respectively.
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Table   Penetrance calculations for ABCA4 variants c.769-784C>T and c.4253+43G>A 
when in trans with a severe ABCA4 variant, not taking cis variants into account
c.769-784C>T c.4253+43G>A
Observed number of patients
Proportion of STGD1 cases carrying severe variant and 
intronic variant of interest 000.0167 000.0267
Number of STGD1 cases with severe variant and 
intronic variant of interest in The NL* 029 046
Expected number of patients
Cumulative allele frequency of ABCA4 protein-
truncating, canonical splice site variants, and severe 
noncanonical splice site variants in The NL† (p) 000.001953 000.001953







Frequencies of individuals with severe variant and 
intronic variant of interest (2pq)
Based on q nFE gnomAD





Number of STGD1 cases with severe variant and the 
intronic variant of interest in The NL older than the 
median age at diagnosis‡
Based on q nFE gnomAD






Penetrance of a severe variant with the intronic variant 
(observed/expected number of patients)
Based on q nFE gnomAD





GoNL, population database ‘Genome of The Netherlands’; nFE gnomAD, non-Finnish European population in the 
Genome Aggregation Database; NL, population of The Netherlands. 
* Conservatively assuming STGD1 prevalence in The Netherlands to be 1:10,000. Total Dutch population: 17,150,000.
† Based on in vitro splice assays of noncanonical splice site variants.28
‡ Median age at diagnosis in the c.769-784C>T cohort and the c.4253+43G>A cohort was 59 and 55 years, 
respectively.
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DISCUSSION
Following the common c.5603A>T coding variant,7,8 two recently discovered frequent 
deep-intronic ABCA4 variants could further explain the missing heritability in late-onset 
STGD1.14,15 The majority of the subjects in this study manifested late-onset STGD1 (72%) 
characterized by pisciform flecks throughout the posterior pole and midperiphery, and 
macular sharply demarcated RPE atrophy – if present at all – in a foveal-sparing pattern. No 
significant differences with respect to phenotypic features and VA course were observed 
between the c.769-784C>T and the c.4253+43G>A cohort. 
The identification of the second disease-causing ABCA4 allele in an increasing number of 
patients with late-onset STGD1 undeniably anchors the described phenotype in the 
spectrum of ABCA4 disease. Still, patients are initially misdiagnosed with AMD on a regular 
basis. Important phenotypic differential diagnostic findings in late-onset STGD1 are the 
flecks, which, compared to drusen, are more irregularly shaped, often more intensely hy-
perautofluorescent on FAF images, often but not always more diffusely spread across the 
posterior pole and midperiphery29 and correspond to hyperreflective depositions 
traversing photoreceptor-attributable bands on OCT.30 Also, in contrast to AMD, STGD1 is 
only very rarely complicated by a neovascularization.31,32 The correct clinical diagnosis 
and the identification of underlying genetic variants have become paramount with 
emerging therapies for both STGD1 and geographic atrophy in AMD, not only for proper 
patient selection for trials, but also for the identification of therapeutic targets. In fact, 
both c.769-784C>T and c.4253+43G>A ABCA4 variants were already shown to be targets 
for partial splice correction by antisense oligonucleotides.14 
Although most subjects exhibited characteristic late-onset STGD1 features, we observed 
notable clinical variability among subjects carrying the same combination of an intronic 
and a severe ABCA4 variant, even among siblings (family Q) and within subjects (D-I:1). 
Both the c.[769-784C>T;5603A>T] and c.4253+43G>A cohort had a large range in age of 
onset, and VA courses varied widely. No comorbidities nor other factors were perceived 
that might explain the clinical variability. These results suggest that factors outside ABCA4 
may modify the disease course. A few studies indicated that the activation of the 
complement cascade could play a role in the pathogenesis of STGD1.33,34 Parallel to the 
complement cascade, other overlapping disease-modifying factors might act in late-onset 
STGD1 and AMD.
RNA analysis in patient-derived PPCs showed that c.769-784C>T results in a pseudo-exon 
insertion in 15% of total mRNA, compared to 8.6% in HEK293T cells assessed previously.14 
As the other allele of this patient harbored a missense variant (p.Phe608Ile), which is not 
expected to affect mRNA stability, the 15% defective total mRNA is considered to result 
from a 30% defective mRNA transcript from the c.769-784C>T allele alone, assuming that 
the missense allele in trans is equally expressed. The RNA analysis in PPCs corroborated a 
mild effect of c.769-784C>T on splicing. A similar observation was made for variant 
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c.4539+2028C>T, which led to a 345-nt pseudo-exon insertion in patient-derived PPCs in 
15% of total mRNA and approximately 30% of mRNA derived from the allele carrying 
c.4539+2028C>T.20 In contrast, no pseudo-exon insertion was found in fibroblasts of the 
same patient. These results strongly suggest that retina-specific splice factors play a role 
in the defects observed for both c.769-784C>T and c.4539+2028C>T.
Despite the enrichment of the complex c.[769-784C>T;5603A>T] allele among patients 
versus controls14 and our splice assays that indicate that variant c.769-784C>T has an 
additive pathogenic effect, significant clinical differences between patients who harbor 
c.[769-784C>T;5603A>T] versus patients only harboring c.5603A>T were not observed. In 
the genetic study, the age of onset among patients carrying c.[769-784C>T;5603A>T] was 
higher than the age of onset of patients carrying the single c.5603A>T variant, but the 
other cohort was smaller and included patients from abroad.14 Variant c.4253+43G>A was 
found in cis with c.5603A>T in only one patient. Interestingly, this patient had a strikingly 
early age of onset (18 years), discordant phenotype in fundo and a relatively fast VA decline. 
These results suggest that variant c.5603A>T and other, yet unidentified, cis variants might 
influence the expression, and possibly the penetrance, of the ABCA4 allele.
We calculated the penetrance of c.769-784C>T and c.4253+43G>A, when present in trans 
with a severe variant, and found that, respectively, 20.5 to 39.6% and 35.8 to 43.1% of the 
individuals carrying these ABCA4 variants actually manifest STGD1. Other ABCA4 variants 
on the same allele might well influence the penetrance. In fact, in this study cohort, variant 
c.769-784C>T was consistently found in cis with c.5603A>T, the mild variant for which we 
previously calculated an extremely low penetrance (~5%), and for which we consequently 
argued that yet unidentified factors explain its penetrance in patients.8,10 It is possible that 
c.5603A>T acts as a modifier that results in full penetrance of the complex c.[769-
784C>T;5603A>T] allele. As expected, we recently identified variant c.769-784C>T without 
c.5603A>T in two late-onset STGD1 cases in a large follow-up study (Khan M, Cremers FPM, 
unpublished observations, 2019). Further studies are needed to corroborate current findings 
and provide undeniable evidence of the pathogenicity of the c.769-784C>T variant.
This study has a few limitations, mainly due to the complexity of penetrance calculations 
discussed previously.8,10 Population differences in the prevalence of the variants of interest 
and severe variants influence the calculated penetrance. To minimize the risk of this 
sampling bias, we used and compared allele frequencies of the European and the Dutch 
population. Missense variants that might have a severe effect on ABCA4 protein function 
were not included in the calculation of severe ABCA4 variant frequency, which has most 
likely resulted in overestimation of the calculated penetrance.35 Second, age of onset was 
defined as the age at which the patient first experienced visual complaints. Alternatively, 
if complaints were absent or not reported (in only 2 subjects), we used age at which 
decrease in VA was first documented or the age at which macular abnormalities were first 
diagnosed. To a larger degree, age of onset might be influenced by recall bias and other 
patient-specific factors, such as daily activities, comorbidities, and location of lesions.
 Intronic ABCA4 alleles in late-onset Stargardt disease | 77
3
In conclusion, this study showed that intronic ABCA4 variants resulting in a mild splice 
defect, in addition to the coding c.5603A>T variant, could genetically explain a large 
proportion of the late-onset STGD1 cases, which aids in the differential diagnosis of 
late-onset STGD1 and AMD. At the same time, these mild variants were associated with a 
notable clinical variability, which needs to be considered in the design of upcoming 
clinical trials. The results of the present study and our previous studies on c.5603A>T,8,10 
indicating that cis variants, like c.5603A>T, as well as factors outside ABCA4 could modify 
the disease course, should be considered in family counseling and warrant further studies 
on STGD1 modifiers. 
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SUPPLEMENTARY MATERIAL
Supplemental Figure S1. Age of onset for mild ABCA4 variants
Box-and-whisker plot detailing the spread of the age of onset in the patient cohort. Boxes represent 
the interquartile range, and the error bars represent maxima and minima. 
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Supplemental Figure S2. Visual acuity courses of all subjects
Graphs in the upper panel represent the visual acuity courses of the right eyes, and graphs in the 
lower panel represent the visual acuity (VA) courses of the left eyes, of patients harboring (A, D) 
c.[769-784C>T;5603A>T], (B, E) c.4253+43G>A or (C, F) c.[4253+43G>A;5603A>T]. Disease duration is 
defined as the time between the onset of complaints and the measurement. Patient S-II:1 has an 
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Supplemental Figure S3. Variable disease expression in the cohort  
CF, counting fingers; LE, left eye; RE, right eye; RPE, retinal pigment epithelium; VA, visual acuity; y, year
A. Subject J-II:3, who carried c.4253+43G>A and p.Leu257Valfs*17, presented with intact retinal 
layers on OCT apart from a few large RPE deposits throughout the posterior pole, at the age of 62 
years. By the age of 67, flecks had spread across the posterior pole and midperiphery, enlarged and 
coalesced, while the fovea remained spared. Perifoveal focal thinning of the outer retinal layers 
could be observed on the OCT.
B. Subject F-II:2, who carried c.4253+43G>A and p.Phe608Ile, had a relatively young age at onset (20 
years) and flecks were mostly confined to the macula. Retinal imaging initially showed macular RPE 
alterations and perifoveal small yellow flecks. By the age of 41, flecks had enlarged and spread a little 
further across the posterior pole. Beaten bronze macular atrophy corresponding to mottled 
decreased autofluorescence and loss of outer retinal layers on OCT could be observed.
C. Subject D-I:1, carrying c.4253+43G>A and p.Cys1455Arg, showed distinct inter-eye discordance 
over time. At the age of 56, 11 years after the disease manifested, the right eye (C1) showed 
progressed disease with a large macular lesion of definitely decreased autofluorescence and RPE 
atrophy, whereas no RPE atrophy was observed in the left eye (C2) yet. The left eye did start to show 
macular mottled decreased autofluorescence corresponding to thinning of the outer retinal layers 
on OCT. Neither of the eyes exhibited the characteristic foveal sparing atrophy.
A B
J-II:3 – 67y – RE – VA 20/16 F-II:2 – 41y – LE – VA CF
D-I:1 – 56y – RE – VA 20/125
C1 C2
D-I:1 – 56y – LE – VA 20/60
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Supplemental Figure S4. Identification of the splice defect caused by variant c.769-784C>T 
in patient-derived photoreceptor progenitor cells
Reverse-transcription polymerase chain reaction (RT-PCR) on mRNA in photoreceptor progenitor 
cells (PPCs) from a control (CON) and patient A-I:2. The patient carries c.[769-784C>T;5603A>T] and 
the missense variant p.Phe608Ile. All tests were performed in duplicate (Rep 1 and 2), with 
cycloheximide treatment (CHX+) and without (CHX-). In the patient’s PPCs treated with CHX, gel 
analysis revealed a band corresponding to the correct transcript and another band corresponding 
to a pseudo-exon insertion. The latter band was not present in control PPCs. An additional band is 
shown in the CHX treated patient-derived PPCs, corresponding to hybrid molecules consisting of 
correct fragments and those carrying the insertion, the so-called heteroduplexes. Glyceralde-















-CHX +CHX +CHX -CHX +CHX -CHX +CHX-CHX
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Supplemental Figure S5. Sequence analysis of reverse-transcription polymerase chain reaction 
products of patient-derived photoreceptor progenitor cells
Sanger sequenced electropherograms for a control and for patient A-I:2, who harbors c.[769-784C>T; 
5603A>T] and p.Phe608Ile.
C C G T G T G C T T C C C A
Control: correct mRNA
Patient A-I:2: pseudoexon
e6 e7 e4e3e7 8
T C A  A G A  G  T T T A  T C C C
162 nt
PEe6 e7
C C G T G T G  G A T C A G  T A G C A  G T G C T T C C C A
Control: correct mRNA
Supplemental Table S1  Primers for reverse-transcription polymerase chain reaction 
analysis
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Supplemental Table S3  Densitometric analysis of the splice defect due to c.769-784C>T
Band Control PPCs Patient PPCs
-CHX +CHX -CHX +CHX -CHX +CHX -CHX +CHX 
% % % % % % % %
Wildtype 100.0 100.0 100.0 100.0 100.0 84.6 100.0 85.0
Pseudo-exon 0.0 0.0 0.0 0.0 0.0 15.4 0.0 15.0
Densitometric analysis of the splice defect due to c.769-784C>T in patient-derived photoreceptor cells (PPCs) and 
control PPCs in the presence (+) and the absence (-) of cycloheximide (CHX) treatment. For each fragment, 
intensity measurement was performed in duplicate. Fragments intensity in the patient’s CHX-treated cells was 
corrected for the heteroduplexes.
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ABSTRACT
Purpose: To investigate intersibling phenotypic concordance in Stargardt disease (STGD1).
Design: Retrospective cohort study.
Participants: Siblings with genetically confirmed STGD1 and at least 1 available fundus 
autofluorescence (FAF) image of both eyes.
Methods: We compared age of onset within families. Disease duration was matched to 
investigate differences in best corrected visual acuity (BCVA), and compared the survival 
time for reaching severe visual impairment (<20/200 Snellen or >1.0 logarithm of the 
minimal angle of resolution (logMAR)). Central retinal atrophy area was quantified 
independently by 2 experienced graders using semiautomated software and compared 
between siblings. Both graders performed qualitative assessment of FAF and spectral- 
domain optical coherence tomography (SD OCT) images to identify phenotypic differences.
Main outcome measures: Differences in age at onset, disease duration-matched BCVA, 
time to develop severe visual impairment, FAF atrophy area, FAF patterns, and genotypes.
Results: Substantial differences in age at onset were present in 5 of 17 families, ranging 
from 13 to 39 years. Median BCVA at baseline was 0.60 logMAR (range, -0.20 to 2.30 
logMAR; Snellen equivalent, 20/80 (range, 20/12-hand movements)) in the right eye and 
0.50 logMAR (range, -0.20 to 2.30 LogMAR; Snellen equivalent, 20/63 (range, 20/12-hand 
movements)) in the left eye. Disease duration-matched BCVA was investigated in 12 of 17 
families, and the median difference was 0.41 logMAR (range, 0.00–1.10 logMAR) for the 
right eye and 0.41 logMAR (range, 0.00–1.08 logMAR) for the left eye. We observed notable 
differences in time to severe visual impairment development in 7 families, ranging from 1 
to 29 years. Median central retinal atrophy area was 11.38 mm2 in the right eye (range, 
1.98–44.78 mm2) and 10.59 mm2 in the left eye (range, 1.61–40.59 mm2) and highly 
comparable between siblings. Similarly, qualitative FAF and SD OCT phenotypes were 
highly comparable between siblings.
Conclusion: Phenotypic discordance between siblings with STGD1 carrying the same 
ABCA4 variants is a prevalent phenomenon. Although the FAF phenotypes are highly 
comparable between siblings, functional outcomes differ substantially. This complicates 
both sibling-based prognosis and genotype-phenotype correlations and has important 
implications for patient care and management.
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INTRODUCTION
Stargardt disease (STGD1), which is caused by variants in the ABCA4 gene, is an autosomal 
recessive retinal dystrophy characterized by central retinal degeneration, yellow-white flecks 
in the posterior pole, and a beaten-bronze aspect of the retina as seen during fundoscopy.1 
Patients usually develop visual complaints in childhood or early adolescence;2,3 however 
the disease may present itself up to the seventh decade of life.4,5 The disease has an 
estimated prevalence of 1:10,000.6
The clinical phenotype of STGD1 may vary widely, ranging from mild visual complaints 
and few fundus abnormalities even after the fifth decade of life4,5 to severe visual 
impairment by young adolescence accompanied by advanced retinal degeneration.3,7 
Variant severity has been proposed as a predictor of the STGD1 phenotype, with a 
combination of null variants resulting in a severe phenotype8 and a combination of null 
and milder variants leading to varying degrees of a somewhat milder phenotype.9-11 
However, genotype-phenotype correlations have not yet been established for most 
ABCA4 variants, not only because of the recessive nature and phenotypic variability of the 
disease but also because of the enormous number of genetic variants. To date, more than 
900 unique variants have been reported in ABCA4-related retinopathies, of which 50% are 
missense variants.12 
In light of this vast heterogeneity, phenotypic discordance in the presence of genetic 
homogeneity within STGD1 families has been described previously. However, these 
studies did not account for differences in age at onset that may explain why the phenotype 
seems to be discordant and often were limited by lack of genetic analysis.13-15 Information 
regarding intersibling discordance is limited further because of the relatively small number 
of reported observations. 
Sibling studies are a valuable tool both in evaluating genotype-phenotype correlations 
and in patient counseling and prognosis, yet few such studies have been performed in 
STGD1.13,15-19 In this study, we investigated the intersibling phenotypic variability in a large 
cohort of siblings with genetically confirmed STGD1. This information is important to 
determine whether the phenotype of siblings can be used as a prognostic marker within 




We selected siblings with a phenotype consistent with STGD1 seen at the outpatient clinic 
of the Department of Ophthalmology, Radboud university medical center, Nijmegen, The 
Netherlands. Patients were included based on (1) the availability of adequate clinical data, 
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(2) at least 1 fundus autofluorescence (FAF) image of both eyes, and (3) the presence of at 
least 2 likely disease-causing variants in the ABCA4 gene. Patients who did not meet these 
criteria were excluded. Written informed consent was obtained from participants before 
performing additional ophthalmologic examinations. This study adhered to the tenets of 
the Declaration of Helsinki, and institutional review board approval was acquired (Erasmus 
Medical Center, Rotterdam, The Netherlands) before the start of the study. 
Genetic analysis
Screening for variants in the ABCA4 gene was conducted at the Department of Human 
Genetics, Radboud university medical center, as part of routine patient care or previous 
studies. Sanger sequencing was performed to confirm all identified mutations. Four 
patients (P24, P25, P34, and P35) were screened recently as part of a study aimed at 
identifying the second disease-causing variant in a large cohort of monoallelic STGD1 
patients using a previously described custom Haloplex Target Enrichment kit (Agilent, 
Santa Clara, CA).20 Genotypes were classified based on their pathogenicity rating in 
accordance with the American College of Medical Genetics classification.21
Clinical evaluation
We reviewed medical records and extracted relevant clinical data, including patient 
demographics, age at disease onset, and best-corrected visual acuity (BCVA). Imaging 
databases were consulted and checked for central color fundus photographs (Topcon 
TRC-50IX (Topcon Corporation, Tokyo, Japan) or Visucam 500 (Carl Zeiss Meditec, Jena, 
Germany)), FAF images, and spectral-domain optical coherence tomography (SD OCT) 
images (Spectralis; Heidelberg Engineering, Heidelberg, Germany). Age at onset was 
defined as the age at which the patient first experienced symptoms that could be related 
to the disease (visual acuity decline, loss of color vision, central and paracentral visual field 
defects), and disease duration was calculated by subtracting the date at onset from the 
examination date. We considered 10 years to be a clinically significant difference in age at 
onset between siblings. BCVA was measured using either Snellen or Early Treatment 
Diabetic Retinopathy Study (ETDRS) charts and was transformed to the logarithm of the 
minimal angle of resolution (logMAR). A clinically significant difference in BCVA was 
defined as a difference of 0.3 logMAR or more, which is equivalent to 3 ETDRS lines or 15 
letters.22 Visual acuity values for counting fingers and hand movements were defined as 
2.0 logMAR and 2.3 logMAR, respectively.23,24
Fundus autofluorescence imaging and SD-OCT
FAF images were captured using a short-wavelength confocal scanning laser ophthalmoscope 
(488-nm excitation) and were graded quantitatively based on the presence and size of 
definitely decreased autofluorescence (DDAF).25 DDAF was defined as a well-delineated 
area of hypoautofluorescence with a signal intensity identical to that of the optic nerve 
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head. DDAF areas in the periphery were not taken into account because of low autofluo-
rescence scan coverage of the peripheral retina. Subsequently, we measured DDAF area 
only within the vascular arcades. Atrophy measurements were performed using previously 
validated EyeNED (non-commercial software, developed in-house) semiautomated 
grading software.26,27
Qualitative comparison of FAF images was performed by analyzing the following 3 traits: 
(1) type of retinal atrophy, (2) absence or presence of flecks, and (3) fleck distribution. 
We encountered 2 types of retinal atrophy: patchy or geographic atrophy similar to the 
previously defined DDAF and mottled, irregular atrophy analogous to what has been 
termed “poorly demarcated, questionably decreased autofluorescence”, and we qualitatively 
compared patients based on these 2 atrophy types.25 We used SD OCT to confirm that 
DDAF area corresponded to deterioration of the photoreceptor and retinal pigment 
epithelium (RPE) layers using the foveal OCT scan line, guided by the infrared OCT 
reference image. Additionally, we qualitatively investigated the overall central retinal layer 
state and structure and checked for the presence of a foveal-sparing atrophy pattern. 
Foveal sparing was defined as outer retinal degeneration visible on FAF, SD OCT, or both, 
surrounding the fovea by at least 180⁰ and a visual acuity of at least 20/200 Snellen.28
Two experienced graders (D.V., E.H.R.) independently graded the FAF and SD OCT images 
and determined whether the qualitative phenotype was similar within families based on 
consensus grading. If no consensus could be reached, the phenotype was considered 
dissimilar. For quantitative analysis, we used the mean of both grader measurements as 
the definitive DDAF area. 
Statistical and comparative analysis
IBM SPSS Statistics software version 2 (IBM Corp, Armonk, NY) was used to conduct all 
statistical analyses. Kaplan-Meyer survival analysis was performed to determine the time 
until visual acuity reached the severe visual impairment (SVI) threshold value of worse 
than 20/200 Snellen (>1.0 logMAR).29 This analysis was also performed using disease 
duration instead of age as the time-dependent variable to estimate disease progression 
rate. Agreement in atrophy area measurements was assessed using the absolute intraclass 
correlation coefficient and a Bland-Altman plot. For optimal comparison of disease 
phenotypes between siblings within families, we selected only the BCVA measurements, 
survival, and imaging data that were acquired at a disease duration within 2 years of the 
reference patient. Siblings within families in which a match in disease duration ± 2 years 
could not be made were excluded from analysis. 
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RESULTS
Patients
We screened a total of 463 patients with a clinical diagnosis of STGD1, 83 of whom also 
had an affected sibling. Thirty-seven patients were excluded because of lack of adequate 
clinical and genetic data, and 7 patients were excluded because of lack of FAF images. We 
therefore included 39 patients from 17 families in this study.
Clinical data
The median study cohort age at onset was 14 years (range, 4.7–64.3 years). Median BCVA 
at baseline was 0.60 logMAR (range, -0.20 to 2.30 logMAR; Snellen equivalent, 20/80 
(range, 20/12–hand movements)) in the right eye and 0.50 logMAR (range, -0.20 to 2.30 
logMAR; Snellen equivalent, 20/63 (range, 20/12–hand movements)) in the left eye. Disease 
duration at baseline varied from -8 to 49 years (median, 1 year), the median follow-up time 
was 11 years (range, 0–50 years), and the median number of visits was 5.5 (range, 1–24). 
More details on baseline clinical characteristics can be found in Table 1.
The median difference in age at onset between siblings among all families was 4.5 years 
(range, 0–39 years). Of the 17 families included in this study, 5 families (1, 10, 13, 15, and 16) 
showed clinically significant intersibling differences in age at onset of 13, 16, 39, 18, and 13 
years, respectively. We were able to match disease duration ±2 years in 12 of 17 families 
and found notable differences in matched BCVA in all 12 of these families of up to 1.1 
logMAR (median, 0.41 logMAR; minimum, 0 logMAR; interquartile range (IQR), 0.18-0.61 
logMAR) in the right eye and 1.08 logMAR (median, 0.41 logMAR; minimum 0 logMAR; IQR, 
0.24-0.57 logMAR) in the left eye. 
Survival times for the predetermined visual acuity threshold for SVI varied substantially 
between patients. Twenty-nine of 39 patients (55 of 78 eyes) enrolled in this study 
developed SVI in at least 1 eye. Overall, the median time to SVI development was 38 years 
in the right eye (95% confidence interval, 30.02–47.98 years) and 39 years in the left eye 
(95% confidence interval, 28.79–49.21 years). A comparison in survival time between 
siblings was possible in 12 families. The median difference in time to reach a BCVA of more 
than 1.0 logMAR (Snellen equivalent, <20/200) was 6.5 years (range, 2–26 years) in the right 
eye and 6.5 years (range, 0–29 years) in the left eye. To assess disease progression rate, we 
also analyzed the survival time until SVI based on disease duration. We were able to 
perform this analysis in 27 of 39 patients, and these patients demonstrated SVI in a median 
time of 18 years (95% confidence interval, 11.31–24.69 years) after disease onset. The 
median intersibling differences were 9 years (range, 1-26 years) and 6 years (range, 1-29 
years) for the right and left eyes, respectively. 
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Fundus autofluorescence and spectral-domain optical coherence 
tomography
SD-OCT images were available for all but 1 patient. Although FAF images were available 
for all included patients, we were able to measure the areas of DDAF of only 16 patients 
from 9 families. The median DDAF area was 11.38 mm2 in the right eye (range, 1.98–44.78 
mm2) and 10.59 mm2 in the left eye (range, 1.61–40.59 mm2) at a median disease duration 
of 25 years (range, 1–49 years). Differences between siblings were difficult to ascertain 
because of high variability in disease duration at FAF examination dates. Subsequently, we 
were able to compare DDAF area in only 4 families (families 1, 6, 9, and 11) and found highly 
comparable intersibling atrophy areas (Table 2), with the exception of family 1 (16.90 and 
16.33 mm2 difference in the right and left eyes, respectively in P1 and P3) and family 13 
(11.36 and 9.01 mm2 difference in the right and left eyes, respectively). The intraclass 
correlation coefficient for both graders (D.V. and E.H.R.) was 0.996 for the right eye and 
0.982 for the left eye. Combined with the Bland-Altman plot (Supplemental Figure 1), we 
conclude there was a strong correlation and good agreement between graders. 
Qualitative analysis of FAF and SD OCT images revealed comparable disease phenotypes 
in terms of absence or presence of flecks, fleck distribution, retinal atrophy type, and OCT 
characteristics in all families. We found a foveal-sparing atrophy pattern in 3 patients 
(patients 29, 32, and 33), 2 of whom were siblings (family 14).
Discordance in phenotype
We found a substantial intersibling difference in age at onset (families 1, 10, 13, 15, and 16), 
disease duration-matched BCVA (families 1-3 and 6-13), and disease duration-based 
survival time until SVI development (families 1, 2, 4, 5, 8, 10, and 13) in 15 families. 
Quantitative FAF atrophy area was comparable in most families; however, we found large 
differences in DDAF area between siblings from family 1 and within family 13. Subsequent 
to these results, families 1 and 13 showed particularly interesting and notable intersibling 
differences in all outcome measures. All findings on intersibling comparisons are 
summarized in Table 2.
Family 1, consisting of 3 siblings (2 female and 1 male; patients P1, P2, and P3) all carrying 
the variants c.2409_2410del (p.Phe804fs) and c.2588G>C (p.[Gly863Ala,Gly863del]), 
showed a significant difference in age at onset of 12 and 13 years between the male 
sibling and the oldest and youngest sisters, respectively. Although the male patient also 
showed the worst BCVA at matched disease duration, the oldest sister was the first by far 
to demonstrate SVI (6 years for the right and 2 years for the left eye compared with 13 and 
4 years, respectively, in the brother and 18 years in the youngest sister). The FAF images 
revealed a similar phenotype between all siblings, marked by widespread hypofluores-
cent flecks and RPE atrophy in the sisters. However, the brother exhibited more hyperflu-
orescent pisciform flecks and less peripheral involvement compared with both sisters. 
This likely reflects the fact that the brother, who has a much later age at onset, was earlier 
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Figure 1. Fundus photographs, fundus autofluorescence (FAF) images, and foveal spectral- 
domain optical coherence tomography (SD OCT) images from family 1. Very similar phenotype 
among siblings – (A) patient P1, (B) patient P2, and (C) patient P3 – shown on (A1, B1, and C1) fundus 
photographs and (A2, A3, B2, B3, C2, and C3) FAF images characterized by yellow-white flecks and 
hyperpigmentations in the posterior pole on color fundus photography. Fundus autofluorescence 
images reveal hypofluorescent and hyperfluorescent flecks with central definitely decreased auto-
fluorescence that slowly spreads toward the midperiphery. A4, A5, B4, B5, C4, C5, Foveal OCT scan 
lines corresponding to the FAF images revealing extensive retinal atrophy corresponding with hypo-
autofluorescence on FAF. Disease duration (in years) at time of image capture is displayed in the 
bottom right corners. 
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in the disease process at the time of examination, before hyperfluorescent flecks spread to 
the entire posterior pole and resorbed to become hypofluorscent. Seven years later, the 
hyperfluorescent flecks were resorbed partially and had formed hypofluorescent flecks 
and RPE atrophy similar to the sisters’ phenotype (Figure 1). 
Family 13 consists of 4 siblings (3 females and 1 male; patients P28, P29, P30, and P31) 
carrying the c.5537T>C (p.Ile1846Thr) and c.5882G>A (p.Gly1961Glu) ABCA4 variants. Age at 
onset was highly dissimilar in the male patient (patient P29), which differed 39 years from 
the younger twin sisters (P28 and P31). Interestingly, patient P30 reached SVI 10 years 
earlier than her twin sister and 9 years earlier than her other sister (patient P29). Atrophy 
area was also largest in this patient relative to disease duration. The phenotype on 
funduscopy was very similar between siblings in this family (Figure 2).
Genotype-phenotype correlation
Among the 17 families included in this study, a total of 20 unique ABCA4 variants were 
identified, of which 8 variants were pathogenic and 6 variants were likely pathogenic 
(Table 3). Two deep-intronic variants and 2 deletions were designated as pathogenic 
based on functional assessments in recent studies. One additional unreported splice site 
variant (c.4128+1G>A) likely results in the skipping of exon 27 and a subsequent frame 
shift. Nonsense-mediated decay of the mRNA would then be predicted to result in the 
absence of ABCA4 protein. Finally, variant c.5603A>T, which until recently was considered 
benign, has been shown to cause (late-onset) STGD1 when in trans with a severe variant 
in some individuals,30 whereas others (>95%) remain unaffected.31 All patients from the 
same family harbored identical ABCA4 variants. The most common variant in our study 
cohort was c.2588G>C (13 compound heterozygous patients), followed by c.768G>T (12 
compound heterozygous patients) and c.5882G>A (8 compound heterozygous patients). 
The 2 families manifesting the largest discordance (families 1 and 13) carried variants 
c.5882G>A and c.2588G>C compound heterozygously with a likely pathogenic variant. 
Variant c.5882G>A was consistently present in siblings who manifested a bull’s eye 
maculopathy and showed a discordant age at onset. No other genotype was associated 
with intersibling discordance. 
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DISCUSSION
In this study, we compared the STGD1 phenotypes between siblings carrying the same 
genetic variants in ABCA4 and found a discordant phenotype between siblings in 11 of 17 
families in our study cohort, suggesting that familial discordance is a prevalent 
phenomenon in STGD1. This finding is important in patient counseling and should be 
considered when basing patient prognosis on clinical findings in siblings with STGD1. Only 
a few studies among STGD1 siblings have been performed,13,15-19 often lacking in patient 
numbers and genetic analysis, and the current study sheds new light on earlier findings 
and hypotheses through the retrospective clinical analysis of a large cohort of genetically 
confirmed STGD1 siblings. 
We observed a difference in age at onset of 10 years or more between siblings in 5 families, 
ranging from 13 to 39 years. Interestingly, in each of these families, the highest age at 
onset was reported by male patients. Although there was no overall difference in age at 
onset between male and female patients, it is interesting to note and could suggest a role 
for gender-related disease modifiers. We found no other reports that match this 
observation, and to the best of our knowledge, there are no other studies that found an 
overall later age at onset among male STGD1 patients. Recently, although also limited by 
small patient numbers, a study among STGD1 patients carrying c.5603A>T reported more 
affected females than males. Moreover, likely nonpenetrant biallelic siblings in 3 of 3 
families were males. Other factors besides the ABCA4 genotype, either genetic or 
environmental, were hypothesized to be responsible for the variable disease expression 
and reduced penetrance observed in that study.31
We were able to match 28 patients of 12 families on disease duration ±2 years and 
compared the BCVA within these families. Strikingly, substantial differences in BCVA of up 
to 11 ETDRS-lines (median, 4 lines) were present, suggesting that disease progression rate 
can vary greatly between siblings. This was further supported by disease duration-cor-
rected survival analysis of visual acuity, revealing differences to reach SVI of up to 29 years. 
Contrary to the observed differences in age at onset, time to SVI development, and disease 
duration-matched BCVA, we found intersibling concordance of FAF patterns in all sibling 
pairs. Although a proper match in disease duration and FAF examination date could be 
made in only 3 families, the other families were strikingly similar in terms of atrophy type, 
presence or absence of flecks, and fleck distribution. This is also in contrast to a previous 
study among 15 sibling pairs in which the authors found intersibling discordance of the 
image on funduscopy in 9 families.15 A foveal sparing atrophy pattern was present in 3 
patients, all with late-onset disease, corroborating an earlier study that described the 
association between late-onset STGD1 and foveal sparing.28 In contrast, the only other 
sibling pair with late-onset disease in our cohort did not exhibit foveal sparing, possibly 
owing to the presence of the c.5882G>A variant discussed in more detail below. The low 
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concordance of this specific phenotype. It is possible that foveal sparing was present 
previously in the other siblings of patient 29 (family 13), but the extent of central macular 
atrophy was already too extensive at presentation.
We observed a high incidence of functional discordance between siblings carrying 
c.5882G>A, which has been the topic of multiple studies because of its high allele 
frequency and association with a specific STGD1 phenotype best described as a bull’s eye 
maculopathy.32,33 Despite patients carrying different variants on the other allele, the 
phenotype on funduscopy was consistent and in accordance with the findings of an 
earlier study.32 Age at onset among these families ranged widely, from 15 to 65 years, 
whereas both of the patients representing the extremes carried a null allele in trans (c.
[5461-10T>C;c.5603A>T] and c.768G>T).34 The other family exhibiting a relatively high 
degree of discordance carried variant c.2588G>C. Both c.5882G>A and c.2588G>C were 
deemed mild based on their significantly reduced homozygous occurrence in patients 
versus controls.12 Although ABCA4 variants in cis with these variants have been identified, 
these are less likely to cause the observed intrafamilial differences. 
We discovered intriguing differences in disease progression rate despite similar ages at 
onset and FAF phenotypes. In contrast, the disease progression rates and FAF phenotypes 
in some families were similar, whereas the ages at onset differed substantially. Phenotypes 
on funduscopy were similar regardless of age at onset or functional differences. These 
results are difficult to reconcile with the suggested simple inheritance of STGD1 and 
indicate that other as-yet unidentified environmental or genetic factors modify the 
disease course. Recently, the common c.5603A>T (p.Asn1868Ile) variant was found to 
cause STGD1 in only a small part of the individuals carrying a severe variant in trans and to 
result in variable STGD1 phenotypes with a large range in the age at onset.31,35,36 An 
increasing number of relatively common ABCA4 variants in the general population that 
were thought to be benign, were found to actually constitute mild disease-causing 
alleles.30,37 Beside genetic factors directly related to ABCA4, mitochondrial involvement in 
the pathogenesis of age-related macular degeneration has recently been hypothesized.38,39 
The mitochondria are thought to play an important role in retinal degeneration through 
regulation of apoptosis and the formation of reactive oxygen species. Furthermore, 
retrograde signalling allows the mitochondria to influence nuclear processes including 
cell behavior and gene expression.40 Alongside genetic and mitochondrial factors, 
unprotected exposure to sunlight and (supplemented) vitamin A intake are thought to 
contribute to accelarated vision loss in patients with STGD1.41-44
The present study has several limitations that are mostly related to its retrospective nature. 
First, achieving optimal comparability between siblings is difficult, and although we were 
able to match a substantial number of patients for disease duration, this was not the case 
in all sibling pairs. This problem was most prominent in FAF comparison, although this 
could be mitigated partly by considering the FAF phenotype as a longitudinal process, 
enabling qualitative comparison even in the absence of an exact match in disease 
 Highly variable disease courses in siblings with Stargardt disease | 113
4
duration. Second, although sunlight exposure and vitamin A intake may influence the 
course of disease, we were unable to investigate this further in our cohort because of a 
lack of detailed demographic and occupational information. The use of validated 
questionnaires in a prospective clinical study on the STGD1 course may shed new light on 
this matter. Third, atrophy area was measured using the image scale provided by the 
Heidelberg Spectralis without correcting for the axial length, because we have not 
performed axial length measurements in our patients. This potentially introduced some 
degree of measurement error. This was partly corrected for by the Spectralis’ ray-tracing 
model under optimal retinal focus conditions; however, minor measurement errors may 
still persist. Finally, age at onset is a subjective measure, and often it is difficult to determine 
the exact moment the disease manifests.
In summary, we found significant differences in functional visual outcomes (BCVA, time to 
SVI development, age at onset) and DDAF area between siblings with STGD1 in 11 of 17 
families, despite carrying the same ABCA4 variants and having highly comparable FAF 
phenotypes. These findings can potentially be explained by the presence of currently 
unidentified environmental and genetic modifying factors that complicate sibling-based 
prognosis further. Therefore, patient management should be aimed at identifying the 
individual disease phenotype, and ophthalmologists should be cautious about using 
sibling information in patient prognosis. 
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SUPPLEMENTARY MATERIAL
Supplemental Figure 1. Bland-Altman plots of inter-observer agreement in quantitative 
image grading. Bland-Altman plots of the inter-observer agreement in quantitative grading of 
fundus autofluorescence atrophy area in the right (A) and left (B) eyes. The blue line represents the 
mean difference, and the dotted lines adjacent to the mean difference represent its 95%-confidence 
interval (95%-CI). The red dashed lines represent the upper and lower limits of agreement, and the 
adjacent dotted lines represent their respective 95%-CI.
Mean of graders (mm2)
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ABSTRACT
Purpose: The purpose of this study was to evaluate the functional relevance of 
longitudinal changes in hyperautofluorescent areas and flecks in Stargardt disease (STGD1) 
using short-wavelength autofluorescence imaging (SW-AF).
Methods: In this prospective, longitudinal study, 31 patients with STGD1 (56 eyes) 
underwent microperimetry (MP) and SW-AF imaging twice in 3 to 5 years. A total of 760 
MP test points were included in the statistical analysis based on stable fixation and 
accurate alignment of SW-AF and MP. Autofluorescence intensity was qualitatively 
assessed in all MP test points. Small circumscriptive hyperautofluorescent lesions were 
defined as flecks. Longitudinal imaging characteristics observed on SW-AF were classified 
into the following categories: appearing, disappearing and stable flecks, stable hyperaut-
ofluorescent, and stable background autofluorescence. The relationship between SW-AF 
intensity changes and MP changes was analyzed using a linear mixed model corrected for 
baseline sensitivity.
Results: Retinal sensitivity declined most in locations without change in SW-AF intensity. 
Functional decline per year was significantly larger in flecks that disappeared (-0.72 ± 1.30 
dB) compared to flecks that appeared (-0.34 ± 0.65 dB), if baseline sensitivity was high (≥10 
dB; p<0.01). The correlation between the change observed on SW-AF and the sensitivity 
change significantly depended on the sensitivity at baseline (p=0.000).
Conclusions: Qualitative longitudinal assessment of SW-AF poorly reflected the retinal 
sensitivity loss observed over the course of 3 to 5 years. 
Translational relevance: When aiming to assess treatment effect on lesion level, a 
multimodal endpoint including MP focused on hyperautofluorescent lesions appears 
essential but needs further studies on optimizing MP grids, eye-tracking systems, and 
alignment software. 
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INTRODUCTION
Autosomal recessive Stargardt disease (STGD1) is the most prevalent inherited macular 
dystrophy and there currently are no viable treatment options.1 In STGD1, mutations in the 
gene encoding the ATP-binding cassette transporter A4 (ABCA4) impair the removal of 
retinal from the photoreceptor disks and retinal pigment epithelium (RPE) endolysosomes, 
which results in lipofuscin accumulation in the RPE.2,3 Over time, this leads to destruction 
of both the RPE and the overlying photoreceptors with severe visual impairment as a 
result.4-6 In recent years, different treatment options for STGD1 have been in development, 
some of which are currently being tested in clinical trials. Strategies vary from stem-cell 
therapy and genetic therapy (e.g., gene augmentation therapy with lentiviruses; and RNA 
therapy with antisense oligonucleotides) to pharmacological agents aimed at preventing 
lipofuscin accumulation.7,8 However, STGD1 has a relative slow rate of progression and 
sensitive endpoints to test the benefit of these newly found therapies have not been 
established yet. 
Yellow-white flecks and chorioretinal atrophy centered around the posterior pole are the 
hallmark features of STGD1. These lesions can be readily distinguished on ophthalmoscopy, 
although these are better delineated using short-wavelength fundus autofluorescence 
(SW-AF) imaging. SW-AF imaging typically shows intensely fluorescent pisciform flecks in 
the macula, often extending to the midperiphery, and macular hypo-autofluorescent 
areas corresponding to areas of RPE atrophy.9-11 SW-AF imaging allows for objective and 
fast measurement of the extent of RPE atrophy, which has been correlated to loss of 
function measured using microperimetry (MP) and visual acuity.12-14 Therefore, RPE 
atrophy measured using SW-AF imaging has become a major biomarker of disease 
progression and an endpoint in three out of six phase II/III clinical trials for STGD1 
(Supplemental Table S1). However, RPE atrophy growth generally is slow and variable, both 
challenging the ability of this biomarker to detect short-term treatment effect.15-18 
Additionally, the potential of this imaging biomarker as a primary endpoint is limited by 
trial design (e.g., trials in early disease stages, prior to RPE atrophy). 
The potential of hyperautofluorescence and particularly flecks, an early hallmark of STGD1, 
as a biomarker for progression is less evident. The small, pisciform lesions that appear hy-
perautofluorescent on SW-AF imaging correspond to hyperreflective bands on spec-
tral-domain optical coherence tomography.19 In longitudinal natural history studies, flecks 
centrifugally expand outward from the central macula and their intensity on SW-AF 
increases and subsequently declines over time leaving residual atrophy.20-26 Especially 
these regions of visible disease activity in early stages might be interesting loci to include 
in a progression biomarker. Previous studies also demonstrated a characteristic general 
background increase in autofluorescence signal in patients with STGD1.27 In clinical trials, 
especially those aimed at lipofuscin reduction, these autofluorescence patterns might 
serve as a biomarker to prove treatment effect. Knowledge on the correlation between 
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autofluorescence patterns and retinal function is required to assess the potential of SW-AF 
imaging change as treatment outcome, because primary efficacy endpoints in late-phase 
clinical trials should reflect clinical benefit to provide substantial evidence of effectiveness.28 
MP is a fundus guided visual field test, which enables functional follow-up of selected 
retinal areas or lesions in time. Microperimetric mean sensitivity showed a decline within 
1 year in patients with STGD1 and may therefore serve as useful endpoint for clinical 
trials.29,30 Indeed, STGD1 flecks that appear hyperautofluorescent on SW-AF imaging have 
been associated with a significantly lower retinal sensitivity, measured by MP, compared to 
the nearest non-flecked areas. Conversely the sensitivity of these hyperautofluorescent 
flecks is significantly higher compared to hypo-autofluorescent flecks.31,32 On the other 
hand, nasal and temporal segments of STGD1 eyes with elevated levels of autofluores-
cence had preserved retinal sensitivity.33 However, longitudinal data on the correlation 
between autofluorescence patterns of lipofuscin-laden regions on SW-AF imaging during 
follow-up and retinal function still are limited. The purpose of this study is to correlate 
SW-AF imaging changes, especially in hyperautofluorescent flecks and areas, with retinal 
sensitivity change measured using MP.
METHODS
Subjects
This prospective, longitudinal study was conducted at the Department of Ophthalmology 
at the Radboud University Medical Center. This study was approved by the local ethics 
committee and adhered to the tenets of the Declaration of Helsinki. All patients gave 
written informed consent prior to enrollment. 
Patients with a clinical diagnosis of STGD1, supported by the identification of one or two 
disease-causing ABCA4 alleles were included between 2013 and 2015. The clinical diagnosis 
was made based on the presence of macular, irregular shaped flecks, that appear yellow- 
white on ophthalmoscopy, hyperautofluorescent on SW-AF imaging in combination with 
progressive macular atrophy. Participants underwent MP and SW-AF imaging during 2 
visits; visit 1 between 2013 and 2015 and visit 2 in 2018. Other variables collected were 
best-corrected visual acuity (Snellen), age at onset, and disease duration. Age at onset was 
defined as the onset of first visual complaints attributable to STGD1 disease reported by 
the patient. The disease duration was defined as the time between the age at onset and 
the study visit. 
Image acquisition and selection of eyes 
Macular sensitivity was assessed by performing MP with the Nidek MP1 (Nidek 
Technologies, Padova, Italy). This system ensures the correct projection of stimuli on the 
corresponding infrared (IR) ophthalmoscopic image of the retina by using an integrated 
 Morphology and function of flecks in Stargardt disease | 123
5
eye tracking system. Each MP measurement was performed under mesopic light 
conditions and prior to SW-AF imaging. The non-tested eye was occluded. Patients were 
asked to focus on a 2° diameter red fixation target, leading to the preferred retinal loci 
(PRL) as the center of the MP grid. Full-threshold fundus perimetry was performed by 
using a 4-2-1 staircase and 40-point strategy. Goldmann II standard size stimuli were 
presented for 200 milliseconds. Eight points were tested at 1° from the PRL, and 16 points 
were tested at 3° and 5° from the PRL, respectively. The Nidek MP1 simultaneously assesses 
fixation stability based on the Fujii criteria.34 Fixation was classified as “stable” when 75% 
of fixations were located within a 2° diameter circle; as “relatively unstable” if ≥75% of 
fixations were located within a 4° diameter circle and as “unstable” if <75% of fixations 
were located within a 4° diameter circle. An MP training program was performed prior to 
the baseline test to reduce learning effects. During follow-up, the manufacturer’s 
follow-up protocol was used. 
SW-AF images were taken using a confocal scanning laser ophthalmoscope with an 
optically pumped solid-state laser with 488-nm excitation (Spectralis™; Heidelberg 
Engineering, Heidelberg, Germany) after adequate pupil dilatation. En face SW-AF images 
of 30° and 55° were acquired (Automatic Real Time [ART] ≥15). 
Using the Microperimeter MP1 software (Navis Software, version 1.7; Nidek Technologies, 
Inc.) SW-AF images were imported and coregistered with the MP data. Two retinal vessel 
bifurcations in each image were selected as coregistration landmarks. To correct for 
distortion, the quality of the alignment was judged by two independent graders (P.P.A.D. 
and E.H.R.). Alignment of MP1 with SW-AF imaging between baseline and follow-up was 
compared and qualitatively classified as “good” (MP test points on the exact same 
location), “moderate” (MP test points partially overlapped) or “bad” (MP test points did not 
overlap or macular sensitivity >0 was measured in the optic disk; Figure 1). 
Eyes were excluded from further analyses if the image quality was poor (n=3), alignment 
of the multimodal imaging was considered bad (n=18) or the fixation was unstable at 
either visit (n=33). As a result, only 19 eyes of 12 patients fitted both the fixation and 
alignment criteria and were included in the analysis. Supplemental Figure 1 and 
Supplemental Table 2 gives a detailed overview of the selected eyes. 
Image grading
The SW-AF intensity relative to the image background was graded at each point of the MP 
grid. Hence, points were qualified as background autofluorescence, hyperautofluorescent 
(more intense than background), or hypo-autofluorescent (less intense than background) 
(Figure 2). Hyperautofluorescent lesions were further divided into hyperautofluorescent 
areas (characteristic pattern of diffuse background increase of SW-AF)35 or a STGD1 fleck 
(small hyperautofluorescent circumscriptive lesion).19 Grading was performed by two 
independent graders (P.P.A.D. and E.H.R.) and was discussed until agreement was reached. 
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Based on the cross-sectional SW-AF image grading, five categories of longitudinal SW-AF 
imaging characteristics were defined, as specified in the Table. 
Figure 1. The alignment of fundus autofluorescence and microperimetry compared between 
baseline and follow-up. Examples of quality assessment of the data alignment between both 
visits, after coregistration of MP with SW-AF images. The data of the first visit (image A1, B1, C1, and 
D1) was compared to data of the second visit (image A2, B2, C2, and D2).
Figure 2. Grading of SW-AF images. At the MP test points SW-AF intensity was graded as background 
autofluorescence, hyperautofluorescent area, hyperautofluorescent  circumscriptive lesion (fleck), 
or hypo-autofluorescent.
2013 2018 2013 2018
2014 2018 2013 2018
A. Good Alignment (n=4) B. Bad Alignment (n=11)
C. Moderate Alignment (n=31) D. Bad Alignment over Optic Disk (n=7)
A1 A2








(more intense than background, 
circumscript lesion)
Hypo-autouorescent
(less intense than background)
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Statistical analysis
The correlation between image characteristics and microperimetry was assessed using a 
linear mixed model, in which the functional change in MP over time was the dependent 
variable and the SW-AF imaging category was the main independent variable. We accounted 
for variations between patients and between the eyes of each patient by using two levels. 
All measurements were nested within the eyes (eyes as level) and the eyes were nested 
within the patients (patients as level). To correct for possible confounding, the following 
continuous covariables were considered: baseline macular sensitivity, follow-up time and 
disease duration. From the possible confounders, only baseline sensitivity appeared to be 
associated with functional change. In order to provide a better insight in the relationship 
between the functional change and the two predictors, we also modeled baseline 
microperimetry as a dichotomous instead of a continuous outcome variable. For this 
purpose, macular sensitivity 0 to 9 was labeled as “low MP”, and macular sensitivity 10 to 
20 was labeled as “high MP”. A p<0.05 was considered to be statistically significant.
Table  Categories of longitudinal SW-AF imaging characteristics 
Category SW-AF visit 1 SW-AF visit 2






Stable hyperautofluorescent (n=17) Hyperautofluorescent area Hyperautofluorescent area


















SW-AF, short-wavelength fundus autofluorescence imaging
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RESULTS
Thirty-one patients with STGD1 (10 men and 21 women) were enrolled in this study. Four 
patients had early-onset STGD1 (age at onset ≤10 years), 22 patients had intermediate-on-
set STGD1 (age at onset 11-44 years) and 5 patients had late-onset STGD1 (age at onset 
≥45years). Median follow-up time was 4 years (range, 3-5 years). At follow-up, the mean 
age was 45 ± 15 years (range, 20-69 years), and the mean visual acuity in the right eye and 
left eye was 20/143 (decimal, 0.14 ± 0.22, range 0.16-0.80) and 20/200 (decimal, 0.10 ± 0.14, 
range 0.02-1.0), respectively. None of the patients had concomitant ocular disease and all 
included eyes were phakic with clear media. The participants’ characteristics are described 
in Supplemental Table 3. 
Because of fixation and alignment criteria only 19 of 56 eyes were included in the analysis. 
A total of 760 MP test points (40 locations for each eye) were categorized based on the 
corresponding local autofluorescence intensity. Two hundred sixty-four locations were 
graded as hyperautofluorescent, of which 98 MP test points were located on a fleck. Mean 
retinal sensitivity in these flecks was 11.75 ± 6.88 dB. Between baseline and follow-up, 38 
of these flecks disappeared and 26 flecks appeared. Mean baseline sensitivity of appearing 
flecks (16.69 ± 5.24 dB) was higher compared to disappearing flecks (10.32 ± 7.75 dB) and 
the estimated functional decline per year was larger (-0.34 ± 0.65 dB in appearing flecks 
and -0.72 ± 1.30 dB in disappearing flecks). Retinal sensitivity did not change over time 
when background SW-AF intensity remained constant (i.e. the category “stable 
background autofluorescence” [-0.16 ± 0.51 dB per year]).
A linear mixed model was conducted to model the sensitivity change as a function of the 
longitudinal imaging characteristics, the baseline sensitivity and the interaction term of 
the latter two. The other covariables “follow-up time” and “disease duration” had no 
significant correlation with the sensitivity change over time and were therefore not used 
in the model. 
The effect of the longitudinal SW-AF imaging category on the sensitivity change over 
time significantly depended on the baseline sensitivity (interaction baseline sensitivity * 
SW-AF change, p=0.000): as expected, the retinal sensitivity showed a larger decline if the 
sensitivity at baseline was relatively preserved. The relation between the retinal sensitivity 
and the defined categories of longitudinal imaging characteristics is visualized in Figure 3. 
Regions of hyperautofluorescence at baseline showed the largest sensitivity decline. 
Interestingly, the retinal sensitivity declined most in regions that did not show a change in 
SW-AF intensity over time (i.e. regions that remained hyperautofluorescent). The model 
with retinal sensitivity as a dichotomous variable (see Figure 3B) clearly shows significant 
differences in functional decline between the several defined categories in regions with 
high initial sensitivity. 
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DISCUSSION
This study addressed the relationship between qualitatively assessed longitudinal imaging 
characteristics on SW-AF imaging and retinal sensitivity over time. Knowledge on the 
correlation between autofluorescence patterns and retinal function is required to assess 
these biomarkers as treatment outcome, because primary efficacy endpoints in late-phase 
clinical trials should reflect clinical benefit to provide substantial evidence of effectiveness. 
To allow for adequate assessment of SW-AF imaging changes and the retinal sensitivity in 
time on lesion level, we included 19 out of 56 eyes (34%), of 12 out of 31 patients, because 
the other eyes had a bad fixation or there was an improper alignment of the examination 
Figure 3. The interaction between retinal sensitivity at baseline and the defined categories 
of longitudinal SW-AF intensity. The linear mixed model shows that the retinal sensitivity change 
over time not only depends on the longitudinal SW-AF intensity over time but also on the baseline 
sensitivity as is depicted in (A). Although no SW-AF imaging change over time was observed in 
lesions of category “stable hyperautofluorescent”, the retinal sensitivity in these loci decreased. (B) 
displays the model-estimated marginal means and 95% confidence interval per defined category. 
Significant differences in functional decline were found between several categories in regions with 
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modalities of follow-up to baseline. For the longitudinal analysis of subfield sensitivity 
variables in ProgStar Report No. 13, the use of follow-up function and good or fair pattern 
placement limited the count of eyes from 359 to 106 (30%).29 Limitations that cause this 
loss of data mostly relate to inclusion of patients with advanced disease stage. Despite the 
use of the integrated eye-tracking system, unstable fixation impaired the reliability of MP 
measurements. Additionally, the coregistration of MP and SW-AF imaging may have been 
imperfect because manual coregistration using two landmarks does not correct for 
distortion. We have corrected this by strictly assessing the quality of the alignment. 
However, inadequate alignment could have affected the accuracy of the correlation 
between SW-AF imaging and MP to some degree. In order to obtain comparable MP 
measurements over time, we used the same hardware and software between 2013 and 
2018. However, techniques used in microperimetry have been improved. Next to this, 
recent advances in imaging techniques have provided new ways to assess the character-
istics of flecks (e.g., fluorescence lifetime imaging ophthalmoscopy and quantitative auto-
fluorescence).36,37 With these techniques, longitudinal imaging characteristics can be 
assessed in a quantitative way instead of via qualitative analysis as we did in this study. In 
order to longitudinally study the retinal sensitivity in specific lesions in more detail, new 
data should be obtained using the most recent advancements in technology. Despite the 
limitations we encountered, a total of 760 MP test points were considered as well aligned 
and of sufficient quality to accurately assess the correlation between the longitudinal 
SW-AF imaging characteristics and the retinal sensitivity. 
Mean retinal sensitivity in flecks was comparable to the 12.89 ± 3.86 dB reported by 
others.31 This study also supports the evidence that background autofluorescence, which 
is generally hyperautofluorescent in STGD1 eyes as compared with normal eyes, is not 
associated with loss of function.27,33 To our best knowledge there are no previous reports 
on the correlation between autofluorescence patterns during follow-up and retinal 
function. Our data demonstrated that the retinal sensitivity declined in loci where a new 
fleck appeared as well as in loci where a fleck disappeared, during a follow-up time of 3 to 
5 years. Moreover, loci of stable flecks and disappearing flecks showed a larger functional 
decrease than loci of flecks that arose. These data fit the hypothesis that, during the 
pathological process of flecks appearing, fading and leaving residual atrophy, the retinal 
sensitivity shows a progressive decline over time, and progression rate might even 
increase during this process.4-6 
The structural basis of flecks is still under debate. Because lipofuscin accumulation in RPE 
cells is one of the hallmarks in STGD pathogenesis, flecks have long been assumed to be 
lipofuscin-laded RPE cells. 2,3,38 Recent examination of flecks across multiple imaging 
modalities indicated that flecks might reflect groups of photoreceptor cells degenerating 
after the loss of RPE.37 Yet recent histology correlations suggest that flecks corresponded 
to subretinal macrophages packed with pigment granules (lipofuscin, melanin and 
melanolipofuscin).39 Our data show that retinal sensitivity in flecks is not lost and even can 
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remain stable during several years of follow-up. Therefore, our data contradict hypotheses 
of flecks representing dead photoreceptor cells. Further work is required to establish the 
histopathological substrate of flecks. 
In the hyperautofluorescent regions and flecks that did not show SW-AF change over 
time, the retinal sensitivity declined most according to the statistical model. Because of 
the inability to distinguish qualitative differences, SW-AF does not seem a good measure 
of preservation of function. The same was concluded from the observation that areas of 
reduced AF were not compatible with the area of dense scotoma in patients with STGD1.40 
In our post-hoc analysis, the functional decline in a stable fleck was significantly larger 
compared to stable background autofluorescence regions and appearing flecks, when 
sensitivity at baseline was defined as high (>10dB). Because these histopathological 
changes over time were not discernable with SW-AF imaging only, a multimodal endpoint 
approach is needed when it comes to selecting outcome measures for clinical trials. 
This study focused on hyperautofluorescent lesions as the autofluorescent pattern of 
lipofuscin might serve as a biomarker to prove treatment effect of clinical trials aiming at 
lipofuscin reduction. When the tested loci were hyperautofluorescent at baseline (i.e. the 
defined categories stable hyperautofluorescent, stable fleck, and disappearing fleck), they 
showed a larger decline in sensitivity as compared to loci that were hypo-autofluorescent 
or the same level as the background autofluorescence at baseline. This makes baseline 
hyperautofluorescence an interesting biomarker as it might predict a functional decline 
over time in those areas. Baseline retinal sensitivity might serve as inclusion criterium for 
clinical trials, despite the described limitations of MP, because our data showed that 
regions with higher sensitivity at baseline allowed for a better differentiation of sensitivity 
changes over time in relation to SW-AF imaging changes over time. 
In conclusion, SW-AF does not adequately reflect the retina’s functional change over time 
and, therefore, is not suitable as the sole primary endpoint in trials. For the evaluation of 
hyperautofluorescence and STGD1 flecks in clinical trials, a multimodal endpoint including 
MP focused on hyperautofluorescent lesions could have great potential. However, further 
studies that make use of improved eye-tracking systems as well as advanced software to 
allow accurate coregistration of retinal examination modalities are required to assess the 
added value of MP in a multimodal endpoint.
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SUPPLEMENTARY MATERIAL
Supplemental Figure 1. Selection of eyes.
Baseline and follow-up imaging and MP were completed for 56 eyes, but only 19 eyes of 12 patients 
could be included for analysis based on the combination of fixation and alignment criteria.
STGD1 eyes with completed 
baseline and follow-up imaging. 
(n=56)
Fixation Analysis
7 Stable xation at both visits, 75% 
within 2° circle (*)
16 Relatively unstable xation, ≥75% 
within 4° circle at both visits, or in 
combination with stable xation at 
one visit (*)
33 Unstable xation,  <75% within 4°
circle
Alignment Analysis
4 Well aligned multimodal image (*)
31 Moderate aligned multimodal image (*)
11 Bad aligned multi modal image
7 Macular sensitivity >0 dB over optic 
disk
3 Poor image quality
Eyes included in the analysis that t both the 
xation and alignment criteria indicated by (*)
(n= 19)
Fixation
6 Stable xation at both visits, 75% 
within 2° circle 
13 Relatively unstable xation, ≥75% 
within 4° circle at both visits, or in 
combination with stable xation at 
one visit 
Alignment
3 Well aligned multimodal image
16 Moderate aligned multimodal image
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Supplemental Table S2  Patient characteristics
Patient 
number










Allele 1 / variant 1 Allele 1 / protein 1 Allele 2 / variant 2 Allele 2 / protein 2
1 Female 16 25 0,1 0,08 c.2588G>C p.[Gly863Ala,Gly863del] c.768G>T p.(Leu257Valfs*17)
2 Female 13 26 0,02 0,02 c.2588G>C p.[Gly863Ala,Gly863del] c.4539+1G>T p.(?)
3 Female 23 45 0,12 0,1 c.2588G>C p.[Gly863Ala,Gly863del] c.[5461-10T>C;5603A>T] p.[Thr1821Valfs*13, 
Thr1821Aspfs*6;Asn1868Ile]
4 Female 13 31 0,12 0,16 c.5882G>A p.(Gly1961Glu) c.4352+1G>A p.(?)
5 Female 32 53 0,02 0,4 c.3335C>A p.(Thr1112Asn) c.5603A>T p.(Asn1868Ile)
6 Female 18 48 0,02 0,02 c.2588G>C p.[Gly863Ala,Gly863del] c.4773+1G>A p.(?)
7 Female 23 44 0,1 0,1 c.2588G>C p.[Gly863Ala,Gly863del] c.4773+1G>A p.(?)





9 Female 8 31 0,02 0,02 c.5312+1G>A p.(?) c.286A>G p.(Asn96Asp)
10 Female 21 68 0,03 0,03 c.5882G>A p.(Gly1961Glu) c.4353_5460del p.(Glu1452Argfs*9)
11 Female 32 40 0,12 0,12 c.6428T>G p.(Met2143Arg) c.5603A>T p.(Asn1868Ile)
12 Female 56 69 0,05 0,03 c.4462T>C p.(Cys1488Arg) c.5603A>T p.(Asn1868Ile)





14 Female 52 67 0,02 0,8 c.1928T>G p.(Val643Gly) c.3874C>T p.(Gln1292*)
15 Female 12 36 0,02 0,02
16 Female 22 48 0,02 0,02 c.2588G>C p.[Gly863Ala,Gly863del] c.5461-10T>C p.[Thr1821Valfs*13, 
Thr1821Aspfs*6;Asn1868Ile]
17 Female 15 25 0,12 0,12 c.768G>T p.(Leu257Valfs*17) c.2588G>C p.[Gly863Ala,Gly863del]
18 Female 39 49 0,32 1 c.5461-10T>C p.[Thr1821Valfs*13, 
Thr1821Aspfs*6;Asn1868Ile]
c.5603A>T p.(Asn1868Ile)
19 Female 30 39 0,1 0,2 c.2588G>C p.[Gly863Ala,Gly863del] c.5461-10T>C p.[Thr1821Valfs*13, 
Thr1821Aspfs*6;Asn1868Ile]]
20 Female 50 63 0,02 0,2 c.4363T>C p.(Cys1455Arg) c.4253+43G>A p.[=,Ile1377Hisfs*3]
21 Female 25 46 0,1 0,1 c.4139C>T p.(Pro1380Leu) +
22 Male 9 20 0,12 0,05 c.214G>A p.(Gly72Arg) c.5461-10T>C p.[Thr1821Valfs*13, 
Thr1821Aspfs*6;Asn1868Ile]
23 Male 16 50 0,1 0,03 c.5461-10T>C p.[Thr1821Valfs*13, 
Thr1821Aspfs*6;Asn1868Ile]
c.5882G>A p.(Gly1961Glu)
24 Male 4 38 0,1 0,1 c.5882G>A p.(Gly1961Glu) c.4539+2001G>A p.(Arg1514Leufs*36)
25 Male 16 49 0,02 0,02 c.5714+5G>A p.[=,Glu1863Leufs*33] c.4773+1G>A p.(?)
26 Male 51 65 0,1 0,02 c.164A>G p.(His55Arg) c.6119G>A p.(Arg2040Gln)
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Supplemental Table S2  Patient characteristics
Patient 
number










Allele 1 / variant 1 Allele 1 / protein 1 Allele 2 / variant 2 Allele 2 / protein 2
1 Female 16 25 0,1 0,08 c.2588G>C p.[Gly863Ala,Gly863del] c.768G>T p.(Leu257Valfs*17)
2 Female 13 26 0,02 0,02 c.2588G>C p.[Gly863Ala,Gly863del] c.4539+1G>T p.(?)
3 Female 23 45 0,12 0,1 c.2588G>C p.[Gly863Ala,Gly863del] c.[5461-10T>C;5603A>T] p.[Thr1821Valfs*13, 
Thr1821Aspfs*6;Asn1868Ile]
4 Female 13 31 0,12 0,16 c.5882G>A p.(Gly1961Glu) c.4352+1G>A p.(?)
5 Female 32 53 0,02 0,4 c.3335C>A p.(Thr1112Asn) c.5603A>T p.(Asn1868Ile)
6 Female 18 48 0,02 0,02 c.2588G>C p.[Gly863Ala,Gly863del] c.4773+1G>A p.(?)
7 Female 23 44 0,1 0,1 c.2588G>C p.[Gly863Ala,Gly863del] c.4773+1G>A p.(?)





9 Female 8 31 0,02 0,02 c.5312+1G>A p.(?) c.286A>G p.(Asn96Asp)
10 Female 21 68 0,03 0,03 c.5882G>A p.(Gly1961Glu) c.4353_5460del p.(Glu1452Argfs*9)
11 Female 32 40 0,12 0,12 c.6428T>G p.(Met2143Arg) c.5603A>T p.(Asn1868Ile)
12 Female 56 69 0,05 0,03 c.4462T>C p.(Cys1488Arg) c.5603A>T p.(Asn1868Ile)





14 Female 52 67 0,02 0,8 c.1928T>G p.(Val643Gly) c.3874C>T p.(Gln1292*)
15 Female 12 36 0,02 0,02
16 Female 22 48 0,02 0,02 c.2588G>C p.[Gly863Ala,Gly863del] c.5461-10T>C p.[Thr1821Valfs*13, 
Thr1821Aspfs*6;Asn1868Ile]
17 Female 15 25 0,12 0,12 c.768G>T p.(Leu257Valfs*17) c.2588G>C p.[Gly863Ala,Gly863del]
18 Female 39 49 0,32 1 c.5461-10T>C p.[Thr1821Valfs*13, 
Thr1821Aspfs*6;Asn1868Ile]
c.5603A>T p.(Asn1868Ile)
19 Female 30 39 0,1 0,2 c.2588G>C p.[Gly863Ala,Gly863del] c.5461-10T>C p.[Thr1821Valfs*13, 
Thr1821Aspfs*6;Asn1868Ile]]
20 Female 50 63 0,02 0,2 c.4363T>C p.(Cys1455Arg) c.4253+43G>A p.[=,Ile1377Hisfs*3]
21 Female 25 46 0,1 0,1 c.4139C>T p.(Pro1380Leu) +
22 Male 9 20 0,12 0,05 c.214G>A p.(Gly72Arg) c.5461-10T>C p.[Thr1821Valfs*13, 
Thr1821Aspfs*6;Asn1868Ile]
23 Male 16 50 0,1 0,03 c.5461-10T>C p.[Thr1821Valfs*13, 
Thr1821Aspfs*6;Asn1868Ile]
c.5882G>A p.(Gly1961Glu)
24 Male 4 38 0,1 0,1 c.5882G>A p.(Gly1961Glu) c.4539+2001G>A p.(Arg1514Leufs*36)
25 Male 16 49 0,02 0,02 c.5714+5G>A p.[=,Glu1863Leufs*33] c.4773+1G>A p.(?)
26 Male 51 65 0,1 0,02 c.164A>G p.(His55Arg) c.6119G>A p.(Arg2040Gln)
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Supplemental Table S2  Continued
Patient 
number










Allele 1 / variant 1 Allele 1 / protein 1 Allele 2 / variant 2 Allele 2 / protein 2
27 Male 20 38 0,1 0,1 c.4297G>A;1853G>A p.Val1433Ile;Gly618Glu c.2588G>C p.[Gly863Ala,Gly863del]
28 Male 19 51 0,12 0,12 c.2800_2803delinsT p.(Val935del) c.2588G>C p.[Gly863Ala,Gly863del]
29 Male 14 53 0,06 0,05 c.2409_2410del p.(Phe804Trpfs*3) c.2588G>C p.[Gly863Ala,Gly863del]
30 Male 16 50 0,03 0,07 c.1822T>A p.(Phe608Ile) c.4253+43G>A p.[=,Ile1377Hisfs*3]
31 Male 14 48 0,02 0,02 c.3335C>A p.(Thr1112Asn) c.5381C>A p.(Ala1794Asp)
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Patient 
number










Allele 1 / variant 1 Allele 1 / protein 1 Allele 2 / variant 2 Allele 2 / protein 2
27 Male 20 38 0,1 0,1 c.4297G>A;1853G>A p.Val1433Ile;Gly618Glu c.2588G>C p.[Gly863Ala,Gly863del]
28 Male 19 51 0,12 0,12 c.2800_2803delinsT p.(Val935del) c.2588G>C p.[Gly863Ala,Gly863del]
29 Male 14 53 0,06 0,05 c.2409_2410del p.(Phe804Trpfs*3) c.2588G>C p.[Gly863Ala,Gly863del]
30 Male 16 50 0,03 0,07 c.1822T>A p.(Phe608Ile) c.4253+43G>A p.[=,Ile1377Hisfs*3]
31 Male 14 48 0,02 0,02 c.3335C>A p.(Thr1112Asn) c.5381C>A p.(Ala1794Asp)
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ABSTRACT
Importance: The mechanisms behind the phenotypic variability and reduced penetrance 
in autosomal recessive Stargardt disease (STGD1), often a blinding disease, are poorly 
understood. Identification of the unknown disease modifiers can improve patient and 
family counseling and provide valuable information for disease management. 
Objective: To assess the association of incompletely penetrant ABCA4 alleles with sex in 
STGD1. 
Design, setting, and participants: Genetic data for this cross-sectional study were 
obtained from 2 multicenter genetic studies of 1162 patients with clinically suspected 
STGD1. Unrelated patients with genetically confirmed STGD1 were selected. The data 
were collected from June 2016 to June 2019, and post hoc analysis was performed 
between July 2019 and January 2020.
Main Outcomes and Measures: Penetrance of reported mild ABCA4 variants was 
calculated by comparing the allele frequencies in the general population (obtained from 
the Genome Aggregation Database) with the genotyping data in the patient population 
(obtained from the ABCA4 Leiden Open Variation Database). The sex ratio among patients 
with and patient patients without an ABCA4 allele with incomplete penetrance was 
assessed. 
Results: A total of 550 patients were included in the study, among which the mean (SD) 
age was 45.7 (18.0) years and most patients were women (311 (57%)). Five of the 5 mild 
ABCA4 alleles, including c.5603A>T and 5882G>A, were calculated to have incomplete 
penetrance. The women to men ratio in the subgroup carrying c.5603A>T was 1.7 to 1; the 
proportion of women in this group was higher compared with the subgroup not carrying 
a mild allele (difference, 13%; 95% CI, 3%-23%; P= .02). The women to men ratio in the 
c.5882G>A subgroup was 2.1 to 1, and the women were overrepresented compared with 
the group carrying no mild allele (difference, 18%; 95% CI, 6%-30%; P = .005).
Conclusions and Relevance: This study found an imbalance in observed sex ratio among 
patients harboring a mild ABCA4 allele, which concerns approximately 25% of all patients 
with STGD1, suggesting that STGD1 should be considered a polygenic or multifactorial 
disease rather than a disease caused by ABCA4 gene mutations alone. The findings suggest 
that sex should be considered as a potential disease-modifying variable in both basic 
research and clinical trials on STGD1.
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INTRODUCTION
Autosomal recessive Stargardt disease (STGD1) is the most frequent inherited macular 
dystrophy.1 It is caused by mutations in both copies of the gene encoding the 
transmembrane ATP-binding cassette transporter type A4 (ABCA4 gene [OMIM 601691]).2 
Patients generally report progressive central loss of vision in the first or second decade of 
life,3-5 but cases with a much later disease onset, even past the age of 80 years, have been 
described as well.6 This large clinical variability has also been observed in siblings sharing 
the same ABCA4 mutations and has remained largely unexplained to date.7-9 The lack of 
knowledge about the mechanisms underlying this clinical variability impairs not only 
patient and family counseling but also informed decision making regarding study design 
and patient inclusion. Moreover, deciphering these mechanisms might lead to new 
targets for treating this incurable disease.
Late-onset STGD1 and clinical variability are associated with mild variants, which generally 
are clinically relevant only when in trans with a severe ABCA4 variant.8,10-12 To date, 8 mild 
ABCA4 variants have been reported.8,10-13 Four coding variants – c.2588G>C, p.[Gly-
863Ala,Gly863del]; c.3113C>T, p.(Ala1038Val); c.5882G>A, p.(Gly1961Glu); c.6089G>A, p.
(Arg2030Gln) – and 1 noncanonical splice site variant – c.5714+5G>A, p.[=,Glu1863Leufs*33] 
– were deemed mild on the basis of their considerably lower than expected homozygous 
occurrence in patients, considering the respective allele frequencies in the general 
population.13 An additional mild coding variant—i.e. c.5603A>T, p.(Asn1868Ile)—and 2 
mild deep-intronic variants—c.769-784C>T, p.[=,Leu257Aspfs*3] and c.4253+43G>A, 
p.[=,Ile1377Hisfs*3]—were identified.10,12,14 Variant c.5603A>T was calculated to cause 
disease only in a small proportion of individuals (approximately 5%) who carried this allele 
in combination with a severe one.11,15 Variant c.2588G>C is likely benign and only has 
complete penetrance when present in the same gene copy as c.5603A>T (c.
[2588G>C;5603A>T]).10 Similarly, in most cases of STGD1, with the deep-intronic variant 
c.769-784C>T, and in some cases with c.4253+43G>A, c.5603A>T was found in the same 
gene copy, and arguably only the complex alleles (c.[769-784C>T;5603A>T] and c.
[4253+43G>A;5603A>T]) have complete penetrance.8 The mechanisms underlying 
incomplete penetrance, found for some ABCA4 genotypes, are still unknown; both cis- or 
trans-acting genetic modifiers and environmental factors might alter ABCA4 gene 
expression and the clinical presentation of STGD1.16 In a small cohort of patients carrying 
the c.5603A>T allele, 22 of 34 were female patients (65%) and all 3 unaffected, compound 
heterozygous siblings were male.11 In another study, which compared STGD1 siblings, a 
sex difference appeared to be present; in 5 of 5 families in which a wide variation in age at 
onset was observed (13-39 years), the patient with the latest onset was male.9 A sex ratio 
imbalance in STGD1 has never been established despite abundant research into this 
disease. We hypothesized that only a subgroup of patients (i.e. those carrying a low 
penetrant ABCA4 allele) might harbor sex-related risk factors for STGD1. Because sex-related 
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differences are associated with the causes and severity of many common diseases as well 
as the treatment outcomes, we investigated the sex distribution in a large STGD1 patient 
cohort. To assess the penetrance of mild ABCA4 alleles and the sex distribution among 
patients with biallelic mutations, we used data from 2 recent genetic studies in which the 
ABCA4 gene of 1162 patients with a potential ABCA4-associated retinal dystrophy was fully 
sequenced.17,18 This international collaboration (ABCA4 Disease Consortium Study Group) 
allowed us to validate the sex ratio imbalance for c.5603A>T and to identify the incomplete 
penetrance and sex ratio imbalance for c.5882G>A, another ABCA4 allele. 
METHODS 
This cross-sectional study adhered to the tenets of the Declaration of Helsinki.19 Approval 
from institutional research ethics committees were obtained from all hospitals and 
medical facilities that participated in the 2 studies we analyzed (specified at the end of the 
article), and patients provided written informed consent before participation. No 
compensation or incentive was offered to patients for participation in the study. Data 
were collected from June 2016 to June 2019.
Patient selection 
Patients with genetically confirmed STGD1 were selected from 2 studies that involved 21 
international and 4 national centers.17,18 Participants in these studies were unrelated 
patients with a potential ABCA4-associated retinal dystrophy (e.g., STGD; cone-rod 
dystrophy; unspecified macular dystrophies; and pattern dystrophy, a well-known 
phenocopy) who had undergone clinical examination by a local ophthalmologist 
specializing in inherited retinal diseases. In these studies, the coding and noncoding 
regions of the ABCA4 gene were sequenced using 3866 single-molecule molecular 
inversion probes. In 555 of 1162 cases, STGD1 was genetically confirmed by the presence 
of either 2 or more (likely) pathogenic ABCA4 variants or c.5603A>T combined with a 
(likely) pathogenic ABCA4 variant. In addition, we collected data on sex, age, and age at 
onset. Age at onset was defined as the onset of initial symptoms reported by the patient. 
Patients with missing data on sex were excluded.
In this study, we used the term sex, defined by biological characteristics, rather than 
gender, which refers to a person’s identity and the sociocultural expectations of behavior 
associated with a given sex. However, the 2 terms could potentially be used interchange-
ably in the given context.
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Penetrance calculation
As previously described for variants c.5603A>T, p.(Asn1868Ile); c.769-784C>T, 
p.[=,Leu257Aspfs*3]; and c.4253+43G>A, p.[=,Ile1377Hisfs*3],8,11,15 we aimed to first assess 
whether additional mild variants could have reduced penetrance. For this purpose, we 
performed penetrance calculations for 5 other alleles, which were deemed mild because 
of their absence or low occurrence in a homozygous state in patients; these alleles were 
c.5882G>A, p.(Gly1961Glu); c.5714+5G>A, p.[=,Glu1863Leufs*33]; c.6089G>A, p.(Arg2030Gln); 
c.2588G>C, p.[Gly863Ala,Gly863del]; and c.3113C>T, p.(Ala1038Val).13 Penetrance was 
calculated by comparing the ABCA4 allele frequency data in the general population that 
were obtained from gnomAD (Genome Aggregation Database, version 2.1.1.),20 with the 
genotyping data in the patient population that were obtained from the ABCA4 LOVD 
(Leiden Open Variation Database, version 3.0). Given that most patients in the LOVD have 
a non-Finnish European ethnic background, only the non-Finnish European population in 
gnomAD was considered, which included data on 7718 genomes and 56 885 exomes. 
Patients in the LOVD who were reported to have an ethnic origin other than non-Finnish 
European were excluded, as were patients in whom fewer than 2 ABCA4 variants had been 
identified. Penetrance was calculated according to the same methods used in previous 
studies,8,11,15 which could be summarized as the ratio of the observed frequency of 
patients (cases) with the genotype of interest to the theoretically expected frequency of 
patients with this genotype. Expected frequency was calculated according to the 
respective allele frequency (AF) in the general population (controls). Thus, the formula, 
given an estimated STGD1 prevalence of 1:10 000,1 was as follows:
Penetrance =
Observed No. of Patients With Mild/Severe Genotype
=
Expected No. of Patients With Mild/Severe Genotype
0.0001 ×
Frequency of Mild/Severe Genotype in Cases
2 × Mild AF in Controls × Severe AF in Controls
The genotype of interest consisted of the combination mild variant of interest and severe 
variant. Variants in the gnomAD and LOVD were annotated as severe if they constituted 
stop mutations, frameshift mutations, or canonical splice site variants (Supplemental 
Table 1). We also added noncanonical splice site variants21 and deep-intronic variants 
shown to result in less than 25% normal messenger RNA, which we deemed to be a 
conservative cutoff for allocating variants to the status of severe.21  
Statistical analysis
To examine whether the proportion of men and women in the patient group harboring 
an allele with reduced penetrance was different from the patient group without any 
of these alleles, we conducted a 2-tailed Fisher exact test. For the statistical analysis, 
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the 2 most frequent mild variants c.5603A>T and c.5882G>A were selected from the total 
of 8 mild alleles. We applied Bonferroni correction for multiple testing in the main analysis, 
which consisted of 2 tests (α=.025). For patient groups who showed a sex ratio imbalance, 
we tested whether the age at onset differed between men and women using the Mann- 
Whitney test. A 2-tailed a=.05 indicated statistical significance. Analysis were performed 
with SPSS for Windows, version 25 (SPSS IBM), between July 2019 and January 2020.
RESULTS
Description of the cohort
After exclusion of 5 patients for missing data on sex, we included a total of 550 patients in 
this study. In this cohort, the mean (SD) age was 45.7 (18.0) years, 456 patients (83%) were 
of non-Finnish European descent (Supplemental Table 2), and 311 patients were women 
(57%) (Table 1). Mild alleles were frequently identified, in 266 (48%) participants, often in 
women (169 of 266 [64%]). Because c.5603A>T was formerly not considered to be a causal 
variant, it was (not unexpectedly) found to be the most frequent variant in this cohort, 
present as a noncomplex allele (i.e. no additional potentially pathogenic variant on the 
same gene copy) in 125 patients (23%). The other most frequent variant was c.5882G>A, 
which was found in a noncomplex configuration in 79 patients (14%). The 6 other mild 
variants were identified in a total of 64 cases (12%). These 6 variants were c.4253+43G>A, 
c.5714+5G>A, c.6089G>A, c.3113C>T, c.769-784C>T, and c.2588G>C. 
Table 1  Study participants
ABCA4 allele No. of women (%) No. of men (%)
Mild allele c.5603A>T 79 (63) 46 (37)
c.5882G>A 54 (68) 25 (32)
c.4253+43G>A 18 (58) 13a (42)
c.5714+5G>A 10 (56) 8 (44)





No mild allele 142 (50) 142 (50)
a. Two out of 125 cases who carried c.5603A>T additionally harbored the mild allele c.3113C>T or c.4253+43G>A. 
Percentages were presented if total n ≥ 10.
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Reduced penetrance of 5 additional mild variants 
A total of 2031 cases in the LOVD met the criteria of having a non-Finnish European ethnic 
background and at least 2 ABCA4 variants. For variants c.5882G>A, c.5714+5G>A, and 
c.6089G>A, dividing the frequency of the genotype of interest in cases by the frequency 
of this genotype in controls and then multiplying the number by the STGD1 prevalence of 
1:10 000 yielded reduced penetrance of 50.4% for c.5882G>A, 58.6% for c.5714+5G>A, and 
36.4% for c.6089G>A (Table 2). For variants c.3113C>T and c.2588G>C, which can be part of 
frequent complex alleles c.[1662C>T;3113C>T] and c.[2588G>C;5603A>T], penetrance was 
calculated in the same manner, not taking potential cis-variants into consideration. The 
relative proportion of these complex alleles is generally higher in patients than in controls. 
Consequently, both the observed and the expected numbers of patients carrying the 
noncomplex alleles were overestimated, but the observed number was overestimated to 
a greater extent. Therefore, the penetrance 16.8% for c.3113C>T and 11.0% for c.2588G>C 
should be interpreted as an overestimation of the actual penetrance. 
Sex ratio in STGD1 associated with c.5603A>T and c.5882G>A 
The sex ratio in the subgroup of patients with none of the mild alleles was exactly 1 to 1. 
The women to men ratio in the subgroup carrying c.5603A>T was 1.7 to 1; the proportion 
of women in this group was higher compared with the subgroup not harboring a mild 
Table 2  Penetrance of mild ABCA4 alleles when accompanied by a severe ABCA4 allele
Variable 
in calculation
c.5882G>A c.5714+5G>A c.6089G>A c.3113C>T c.2588G>C
LOVD (cases)
Observed number 
of patients with mild/
severe genotype
177 30 21 36 80
Frequency of mild/
severe genotypea
0.087149 0.014771 0.010340 0.017725 0.039389
gnomAD (controls)
AF mild variant 0.003778 0.000550 0.000620 0.002302 0.007840
Sum AF severe variants 0.002290 0.002290 0.002290 0.002290 0.002290
Frequency of mild/
severe genotypeb
0.000017 0.000003 0.000003 0.000011 0.000036
Penetrance 50.4% 58.6% 36.4% 16.8% 11.0%
AF, allele frequency; gnomAD, Genome Aggregation Database; LOVD, Leiden Open Variation Database.
a. The observed number of patients in LOVD with a mild variant in combination with a severe variant was divided 
by 2031, the total number of non-Finnish European patients with at least 2 ABCA4 variants in LOVD. 
b. The expected frequency of the mild variant in combination with a severe variant in the general population was 
obtained by 2 x mild AF x sum severe AF (Hardy-Weinberg principle).
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allele (difference, 13%; 95% CI, 3%-23%; p=.02) (Figure 1A and B). Furthermore, the sex ratio 
in the c.5882G>A group was 2.1 to 1 and the women were overrepresented compared 
with the group carrying no mild allele (difference, 18%; 95% CI, 6%-30%; p=.005) (Figure 1A 
and B). Among the patients who harbored any of the 6 other mild alleles (c.4253+43G>A, 
c.5714+5G>A, c.6089G>A, c.3113C>T, c.769-784C>T, and c.2588G>C), the overall women to 
men ratio was 1.4 to 1.  
To assess whether a survival bias from longer life expectancy of women could have a 
statistically significant implication for this study, we compared the current age of the 
women and men in the subgroups. The median age was not statistically significantly 
different between the sexes in any of the subgroups (Supplemental Figure 1). Among 
patients harboring c.5603A>T or c.5882G>A, the sex ratio imbalance was observed 
Figure 1. Comparison of sex distribution among patients with and without a mild ABCA4 
allele. A. More women than men carried the mild allele c.5882G>A (54:25) or c.5603A>T (79:46), 
whereas the female to male ratio among patients not carrying a mild allele was exactly 1 (142:142). 
B. In Stargardt disease (STGD1) caused by the mild allele c.5882G>A or c.5603A>T, the proportion of 
women (68% and 63%, respectively) was significantly higher than in STGD1 not caused by a mild 
ABCA4 allele (13% [95% CI, 3%-23%; P = .02] vs 18% [95% CI, 6%-30%; P = .005]). a p< .03.
a
a
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regardless of age and was pronounced before the age of 60 years (Supplemental Figure 2).
Based on the observed sex ratio imbalance and the calculated penetrance, the sex-specific 
penetrance of c.5603A>T and c.5882G>A, when in trans with a severe allele, was 
approximately 6% for women and 4% for men with c.5603A>T, and 68% for women and 
32% for men with c.5882G>A (Supplemental Figure 3).
Age at disease onset among patients
No difference was observed in the age of disease onset between the sexes in any of the 
genotypic subgroups (Figure 2). Among patients who were carrying c.5603A>T, women 
reported initial symptoms at a median (range) age of 40.0 (9.0-86.0) years, whereas men 
reported symptoms at a median (range) age of 43.0 (5.0-65.0) years (difference, 1.0 year; 
95% CI, -7.0 to 10.0 years; p=.78). In the c.5882G>A subgroup, age at onset was slightly 
right-skewed, with a median (range) of 21.0 (1.0-51.0) years in women and 19.5 (10.0-40.0) 
years in men (difference, 1.0 year; 95% CI, -7.0 to 9.0 years; p=.82) (Figure 2; Supplemental 
Figure 2B). As expected, the age at onset among patients who were carrying none of the 
mild alleles was lowest, with a median (range) of 13.0 (5.0-82.0) years in women and 12.0 
Figure 2. Age at onset by sex and carriers of ABCA4 allele. Horizontal lines and error bars 
represent the median with the interquartile range. No difference in age at onset was observed 
between men and women in any of the 3 subgroups (i.e. biallelic patients not carrying a known mild 
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(1.0-52.0) years in men (difference, 2.0 years; 95% CI, 0.0-4.0 years; p=.27) (Figure 2). In this 
latter subgroup, the distribution of age at onset was clearly right-skewed, likely because 
most of these individuals carried 2 (moderately) severe alleles and only some variants 
could behave like mild variants (Supplemental Figure 2C). 
DISCUSSION
To our knowledge, no sex ratio imbalance has been established before in STGD1, nor has 
it been observed in other non-sex-related inherited retinal diseases, except for the 
maternally inherited Leber hereditary optic neuropathy, in which incomplete penetrance 
was observed and more men than women were affected.25,26 The international 
Figure 3. Sex and other modifying factors associated with risk for STGD1. Shown is a 
modification of the previously proposed ABCA4 disease model that associated genotypes with 
phenotypes on the basis of the residual activity of the ABCA4 protein.22-24 In individuals heterozygous 
for 1 severe variant, ABCA4 activity was reduced to 50%, which does not lead to STGD1. In a previous 
in vitro study, individually tested variants were considered mild if the percentage of wild-type 
messenger RNA, which we extrapolated to the residual protein activity, was 60% to 80%.21 Therefore, 
a combination of a severe and a mild allele leads to a total residual activity of approximately 30% to 
40% and results in classic STGD1 (mild/severe bar). Because the expression of a mild, low-penetrant 
allele was variable, its combination with a severe variant could result either in generally late-onset 
STGD1 or in a normal phenotype (Mild, low penetrant/severe bar). Only in this latter category of 
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collaboration, complete ABCA4 sequencing data, and advanced understanding of mildly 
pathogenic ABCA4 alleles allowed us to establish that, in a genetically predefined patient 
groups, those who harbored ABCA4 alleles with potential incomplete penetrance were 
predominantly women. This observation corroborated the evidence of reduced 
penetrance in STGD1 and pointed towards to the existence of sex-related modifiers of the 
expression of reduced penetrant ABCA4 alleles (Figure 3). 
Women were overrepresented among patients who were carrying 1 of the 2 most 
frequent alleles, c.5603A>T or c.5882G>A, compared with patients who were not carrying 
a known mild allele. Approximately 10%10,11 of all patients with STGD1 harbored c.5603A>T 
and 15%13,27 had c.5882G>A as 1 of the alleles. A search for the mechanisms underlying 
incomplete penetrance and female preponderance in approximately 25% of all patients 
with STGD1 may yield new hints for the pathogenesis and management of this blinding 
disease. Although many future studies are likely needed to elucidate the cause of sex 
differences in STGD1 and other diseases, these findings warrant careful consideration of 
sex or gender as a variable in future preclinical and clinical trials. Currently, medical practice 
in general (diagnosis and treatment) is less evidence based for women than for men 
because of the underrepresentation of women in biomedical research.28 However, 
considering sex as a study variable is indispensable in this era of personalized medicine, 
given that sex differences in the prevalence, manifestation, progression, and outcome of 
multifactorial disorders are increasingly identified. For instance, studies have found that 
ischemic heart disease has a younger onset, a higher incidence, and a different 
manifestation in men vs women, and dilated cardiomyopathy has a higher prevalence, 
younger onset and worse outcome in men, whereas left ventricular hypertrophy is more 
prevalent and less modifiable in women.29,30 Female predilection has been shown in 
many autoimmune diseases, most strikingly (7-10:1) in Sjögren syndrome, systemic lupus 
erythematosus, and thyroiditis.31 
The biological mechanisms underlying the sex-based differences in multifactorial diseases 
are not completely understood, but among the likely factors are sex chromosomes, sex 
hormones, and mitochondria.29,32,33 As estrogen, progesterone, and androgen receptors’ 
messenger RNAs have been identified in the human retina and specifically the RPE,34,35 
each of these sex hormones may play a causal role in sexual differences in retinal health 
and pathology. Research to date has mainly focused on estrogen, which had a neuropro-
tective properties for retinal ganglion cells in a glaucoma rat model.36,37 Estrogen receptor 
β protected mice against RPE injury.38 Moreover, sex hormone receptors, which are 
nuclear transcription factors that bind to DNA, are known to regulate gene expression. 
Sex-based differences in retinal gene expression have been observed in male and female 
mice.39 
Mitochondria are involved in steroid hormone synthesis, production of reactive oxygen 
species, and cell death.32 Sex hormones, in turn, regulate mitochondrial function. Two 
retinal disease models, PDE6B-associated retinitis pigmentosa40 and neuronal ceroid 
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lipofuscinoses41, showed an increased susceptibility to photoreceptor degeneration of 
female mice compared with age-matched male mice.
In addition to biological processes, socioeconomic and behavioral factors seem obvious 
variables to consider in future studies of modifiers for STGD1. Environmental factors that 
could directly be associated with the pathophysiological processes (e.g., accumulation of 
vitamin A derivatives and phototoxic reaction) are diet and sunlight exposure.
Genetic modifiers independent of sex could exist that could also explain why some 
individuals harboring a mild and a severe allele develop STGD1 whereas others do not. 
First, despite sequencing of the complete 128-kb ABCA4 gene using a targeted, short read 
sequencing method, the presence of deep-intronic variants, inversions or insertions in cis 
with a small proportion of the mild variants that make them fully penetrant, could not be 
ruled out.18 Second, sequence variants within or outside the ABCA4 locus could change 
disease expression, for instance, through effects on the transcription machinery (e.g., 
owing to variants in enhancer or silencer regions) or through protein-protein interaction 
(e.g., variants in PROM1 [OMIM *604365], ROM1 [OMIM *180721], and PRPH2 [OMIM 
*179605]42,43). However, these genetic sequence variants are not likely to be factors in the 
observed sex ratio imbalance.
Although we hypothesized that the factors associated with a female predilection in 
STGD1 could also be associated with a more severe or earlier onset phenotype in women, 
the data on age at onset did not support this hypothesis. Instead, specific disease modifiers 
might play a role at specific stages in life and could be different for men and women. 
Therefore, female patients are not necessarily expected to have more severe cases. 
Limitations
This study has limitations that are mostly associated with its cross-sectional design. Cause 
and effect could not be determined. Selection bias (e.g., potential sex differences in health 
seeking behavior or willingness to participate in research) could not be eliminated but 
was unlikely a major factor given that a reference group of patients from the same cohort 
was used. In addition, the finding that age at onset was not associated with sex argues 
against a substantial difference in health-seeking behavior that explains the sex ratio 
imbalance. This study corroborated a finding of a small, independent cohort study that a 
female predilection existed in the c.5603A>T genotypic subgroup.11 The female 
predilection in c.5882G>A cases was a novel finding and should be corroborated in an 
independent cohort. Self-reported age at onset might not reflect the actual disease onset, 
although this method is often employed because of lack of a superior, accessible measure. 
The limitations of penetrance calculations have been previously discussed.11,15 These 
calculations rely on assumptions regarding disease prevalence, ethnic diversity, and 
absence of unidentified causal variants in cis with the mild variants. If disease prevalence 
was higher, the actual penetrance would be higher. If patients carried unidentified causal 
variants in cis with the mild variant, the actual penetrance of the mild variant would be 
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lower. Thus, these calculations provided robust indications of incomplete penetrance 
rather than the exact penetrance rates.
Conclusions
This cross-sectional study demonstrated a female predilection in STGD1 among patients 
who were carrying either of the 2 most frequent and mild ABCA4 alleles compared with 
patients who were not carrying a putative mild ABCA4 allele. This finding adds to the 
evidence of reduced penetrance for some frequent ABCA4 genotypes and highlights the 
potentially crucial role of sex in human health and disease that needs to be taken into 
consideration in future studies of STGD1.
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SUPPLEMENTARY MATERIAL
Supplemental Table 1   The allele frequencies of mild and severe ABCA4 variants in  
the general non-Finnish European population
Genomic position rs ID cDNA notation Protein notation AC gnomAD nFE AF gnomAD nFE
Selected mild variants13
94473807 rs1800553 c.5882G>A p.(Gly1961Glu) 488 0.0037783
94476351 rs61751407 c.5714+5G>A p.[=,Ile1377Hisfs*3] 71 0.0005501
94471055 rs61750641 c.6089G>A p.(Arg2030Gln) 80 0.0006196
94508969 rs61751374 c.3113C>T p.(Ala1038Val) 297 0.0023018
94517254 rs76157638 c.2588G>C p.[Gly863Ala,Gly863del] 1012 0.0078403
Protein truncating variants
94586601 rs201738997 c.1A>G p.(Met1?) 0 0.0000000
94586557 rs62645957 c.45G>A p.(Trp15*) 1 0.0000088
94586541 rs770272033 c.61C>T p.(Gln21*) 1 0.0000088
94586536 rs775770837 c.65delA p.(Lys22Argfs*18) 0 0.0000000
94578624 rs398123339 c.67-2A>G p.? 1 0.0000088
94578623 rs778908435 c.67-1G>A p.? 0 0.0000000
94578596 rs1191816747 c.93G>A p.(Trp31*) 0 0.0000000
94578567 rs61751410 c.122G>A p.(Trp41*) 1 0.0000088
94578566 rs748357067 c.123G>A p.(Trp41*) 1 0.0000088
94578532 rs764744217 c.157G>T p.(Glu53*) 0 0.0000000
94577045 rs778817150 c.247_250dupCAAA p.(Ser84Thrfs*16) 1 0.0000088
94577038 c.256_257delAC p.(Thr86Profs*12) 1 0.0000088
94576993 rs61751413 c.302+1G>A p.? 0 0.0000000
94574256 rs765429911 c.319C>T p.(Arg107*) 8 0.0000619
94574242 rs749252902 c.331_332delGA p.(Glu111Thrfs*49) 1 0.0000088
94574209 rs1275663715 c.365_366insCA p.(Gly123Metfs*32) 1 0.0000088
94574203 rs745550261 c.353_371dupAGAGCCAGCACCTTGGCCG p.(Ile125Glufs*42) 1 0.0000088
94574132 rs754112731 c.442+1G>A p.? 0 0.0000000
94568699 rs755916591 c.443-2dupA p.? 0 0.0000000
94568699 rs755916591 c.443-5_443-2delTGTA p.? 0 0.0000000
94568687 rs62646861 c.454C>T p.(Arg152*) 4 0.0000352
94568649 rs747950242 c.488_491delTGAC p.(Leu163Hisfs*18) 1 0.0000088
94564549 rs61748534 c.571-2A>T p.? 1 0.0000091
94564463 rs757557272 c.655A>T p.(Arg219*) 0 0.0000000
94564439 rs63749081 c.666_678delAAAGACGGTGCGC p.(Lys223Metfs*14) 0 0.0000000
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Supplemental Table 1   The allele frequencies of mild and severe ABCA4 variants in  
the general non-Finnish European population
Genomic position rs ID cDNA notation Protein notation AC gnomAD nFE AF gnomAD nFE
Selected mild variants13
94473807 rs1800553 c.5882G>A p.(Gly1961Glu) 488 0.0037783
94476351 rs61751407 c.5714+5G>A p.[=,Ile1377Hisfs*3] 71 0.0005501
94471055 rs61750641 c.6089G>A p.(Arg2030Gln) 80 0.0006196
94508969 rs61751374 c.3113C>T p.(Ala1038Val) 297 0.0023018
94517254 rs76157638 c.2588G>C p.[Gly863Ala,Gly863del] 1012 0.0078403
Protein truncating variants
94586601 rs201738997 c.1A>G p.(Met1?) 0 0.0000000
94586557 rs62645957 c.45G>A p.(Trp15*) 1 0.0000088
94586541 rs770272033 c.61C>T p.(Gln21*) 1 0.0000088
94586536 rs775770837 c.65delA p.(Lys22Argfs*18) 0 0.0000000
94578624 rs398123339 c.67-2A>G p.? 1 0.0000088
94578623 rs778908435 c.67-1G>A p.? 0 0.0000000
94578596 rs1191816747 c.93G>A p.(Trp31*) 0 0.0000000
94578567 rs61751410 c.122G>A p.(Trp41*) 1 0.0000088
94578566 rs748357067 c.123G>A p.(Trp41*) 1 0.0000088
94578532 rs764744217 c.157G>T p.(Glu53*) 0 0.0000000
94577045 rs778817150 c.247_250dupCAAA p.(Ser84Thrfs*16) 1 0.0000088
94577038 c.256_257delAC p.(Thr86Profs*12) 1 0.0000088
94576993 rs61751413 c.302+1G>A p.? 0 0.0000000
94574256 rs765429911 c.319C>T p.(Arg107*) 8 0.0000619
94574242 rs749252902 c.331_332delGA p.(Glu111Thrfs*49) 1 0.0000088
94574209 rs1275663715 c.365_366insCA p.(Gly123Metfs*32) 1 0.0000088
94574203 rs745550261 c.353_371dupAGAGCCAGCACCTTGGCCG p.(Ile125Glufs*42) 1 0.0000088
94574132 rs754112731 c.442+1G>A p.? 0 0.0000000
94568699 rs755916591 c.443-2dupA p.? 0 0.0000000
94568699 rs755916591 c.443-5_443-2delTGTA p.? 0 0.0000000
94568687 rs62646861 c.454C>T p.(Arg152*) 4 0.0000352
94568649 rs747950242 c.488_491delTGAC p.(Leu163Hisfs*18) 1 0.0000088
94564549 rs61748534 c.571-2A>T p.? 1 0.0000091
94564463 rs757557272 c.655A>T p.(Arg219*) 0 0.0000000
94564439 rs63749081 c.666_678delAAAGACGGTGCGC p.(Lys223Metfs*14) 0 0.0000000
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Genomic position rs ID cDNA notation Protein notation AC gnomAD nFE AF gnomAD nFE
Protein truncating variants
94564428 rs763596438 c.690C>A p.(Cys230*) 0 0.0000000
94564402 rs755733328 c.716G>A p.(Trp239*) 1 0.0000088
94548999 rs754536977 c.769-2A>G p.? 0 0.0000000
94548926 rs757774731 c.838_839delAT p.(Met280Valfs*41) 0 0.0000000
94548907 rs750954445 c.858+1G>T p.? 0 0.0000000
94546276 rs769352013 c.859-2A>G p.? 0 0.0000000
94546247 rs747346334 c.885delC p.(Leu296Cysfs*4) 4 0.0000354
94546182 rs761093501 c.950delG p.(Gly317Alafs*57) 1 0.0000088
94546151 rs61751418 c.982G>T p.(Glu328*) 1 0.0000088
94546094 rs764915204 c.1025_1038delACAATAACTATAAG p.(Asp342Glyfs*6) 0 0.0000000
94544906 rs150686179 c.1211C>G p.(Ser404*) 1 0.0000088
94544895 rs61748550 c.1222C>T p.(Arg408*) 3 0.0000232
94544877 rs765707028 c.1239+1G>C p.? 1 0.0000077
94544199 rs948132728 c.1302delA p.(Gln437Argfs*12) 1 0.0000088
94544185 rs61752391 c.1317G>A p.(Trp439*) 3 0.0000264
94543380 rs780874319 c.1419delT p.(Thr474Leufs*6) 0 0.0000000
94543244 rs763808930 c.1554+2T>C p.? 1 0.0000089
94528866 rs1279522242 c.1561delG p.(Val521Serfs*47) 0 0.0000000
94528787 rs1043103980 c.1640delT p.(Phe547Serfs*21) 1 0.0000088
94528731 rs943713680 c.1696delC p.(His566Thrfs*2) 0 0.0000000
94528311 rs754765164 c.1761-2A>G p.? 1 0.0000089
94528240 rs771051333 c.1830T>A p.(Tyr610*) 1 0.0000088
94528164 rs145961131 c.1906C>T p.(Gln636*) 5 0.0000441
94528147 rs1256814849 c.1922dupG p.(Cys641Trpfs*125) 0 0.0000000
94528132 rs61752401 c.1937+1G>A p.? 0 0.0000000
94526316 rs61751263 c.1938-1G>A p.? 0 0.0000000
94526258 rs757302286 c.1995C>A p.(Tyr665*) 0 0.0000000
94526212 rs61749423 c.2041C>T p.(Arg681*) 1 0.0000088
94526154 rs61749425 c.2099G>A p.(Trp700*) 1 0.0000088
94526092 rs61749427 c.2160+1G>C p.? 1 0.0000088
94522379 rs1401924846 c.2161-1G>A p.? 0 0.0000000
94564463 rs757557272 c.655A>T p.(Arg219*) 0 0.0000000
94564439 rs63749081 c.666_678delAAAGACGGTGCGC p.(Lys223Metfs*14) 0 0.0000000
94564428 rs763596438 c.690C>A p.(Cys230*) 0 0.0000000
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Supplemental Table 1   Continued
Genomic position rs ID cDNA notation Protein notation AC gnomAD nFE AF gnomAD nFE
Protein truncating variants
94564428 rs763596438 c.690C>A p.(Cys230*) 0 0.0000000
94564402 rs755733328 c.716G>A p.(Trp239*) 1 0.0000088
94548999 rs754536977 c.769-2A>G p.? 0 0.0000000
94548926 rs757774731 c.838_839delAT p.(Met280Valfs*41) 0 0.0000000
94548907 rs750954445 c.858+1G>T p.? 0 0.0000000
94546276 rs769352013 c.859-2A>G p.? 0 0.0000000
94546247 rs747346334 c.885delC p.(Leu296Cysfs*4) 4 0.0000354
94546182 rs761093501 c.950delG p.(Gly317Alafs*57) 1 0.0000088
94546151 rs61751418 c.982G>T p.(Glu328*) 1 0.0000088
94546094 rs764915204 c.1025_1038delACAATAACTATAAG p.(Asp342Glyfs*6) 0 0.0000000
94544906 rs150686179 c.1211C>G p.(Ser404*) 1 0.0000088
94544895 rs61748550 c.1222C>T p.(Arg408*) 3 0.0000232
94544877 rs765707028 c.1239+1G>C p.? 1 0.0000077
94544199 rs948132728 c.1302delA p.(Gln437Argfs*12) 1 0.0000088
94544185 rs61752391 c.1317G>A p.(Trp439*) 3 0.0000264
94543380 rs780874319 c.1419delT p.(Thr474Leufs*6) 0 0.0000000
94543244 rs763808930 c.1554+2T>C p.? 1 0.0000089
94528866 rs1279522242 c.1561delG p.(Val521Serfs*47) 0 0.0000000
94528787 rs1043103980 c.1640delT p.(Phe547Serfs*21) 1 0.0000088
94528731 rs943713680 c.1696delC p.(His566Thrfs*2) 0 0.0000000
94528311 rs754765164 c.1761-2A>G p.? 1 0.0000089
94528240 rs771051333 c.1830T>A p.(Tyr610*) 1 0.0000088
94528164 rs145961131 c.1906C>T p.(Gln636*) 5 0.0000441
94528147 rs1256814849 c.1922dupG p.(Cys641Trpfs*125) 0 0.0000000
94528132 rs61752401 c.1937+1G>A p.? 0 0.0000000
94526316 rs61751263 c.1938-1G>A p.? 0 0.0000000
94526258 rs757302286 c.1995C>A p.(Tyr665*) 0 0.0000000
94526212 rs61749423 c.2041C>T p.(Arg681*) 1 0.0000088
94526154 rs61749425 c.2099G>A p.(Trp700*) 1 0.0000088
94526092 rs61749427 c.2160+1G>C p.? 1 0.0000088
94522379 rs1401924846 c.2161-1G>A p.? 0 0.0000000
94564463 rs757557272 c.655A>T p.(Arg219*) 0 0.0000000
94564439 rs63749081 c.666_678delAAAGACGGTGCGC p.(Lys223Metfs*14) 0 0.0000000
94564428 rs763596438 c.690C>A p.(Cys230*) 0 0.0000000
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Genomic position rs ID cDNA notation Protein notation AC gnomAD nFE AF gnomAD nFE
Protein truncating variants
94564402 rs755733328 c.716G>A p.(Trp239*) 1 0.0000088
94548999 rs754536977 c.769-2A>G p.? 0 0.0000000
94548926 rs757774731 c.838_839delAT p.(Met280Valfs*41) 0 0.0000000
94548907 rs750954445 c.858+1G>T p.? 0 0.0000000
94546276 rs769352013 c.859-2A>G p.? 0 0.0000000
94546247 rs747346334 c.885delC p.(Leu296Cysfs*4) 4 0.0000354
94546182 rs761093501 c.950delG p.(Gly317Alafs*57) 1 0.0000088
94546151 rs61751418 c.982G>T p.(Glu328*) 1 0.0000088
94546094 rs764915204 c.1025_1038delACAATAACTATAAG p.(Asp342Glyfs*6) 0 0.0000000
94544906 rs150686179 c.1211C>G p.(Ser404*) 1 0.0000088
94544895 rs61748550 c.1222C>T p.(Arg408*) 3 0.0000232
94544877 rs765707028 c.1239+1G>C p.? 1 0.0000077
94544199 rs948132728 c.1302delA p.(Gln437Argfs*12) 1 0.0000088
94544185 rs61752391 c.1317G>A p.(Trp439*) 3 0.0000264
94543380 rs780874319 c.1419delT p.(Thr474Leufs*6) 0 0.0000000
94543244 rs763808930 c.1554+2T>C p.? 1 0.0000089
94528866 rs1279522242 c.1561delG p.(Val521Serfs*47) 0 0.0000000
94528787 rs1043103980 c.1640delT p.(Phe547Serfs*21) 1 0.0000088
94528731 rs943713680 c.1696delC p.(His566Thrfs*2) 0 0.0000000
94528311 rs754765164 c.1761-2A>G p.? 1 0.0000089
94528240 rs771051333 c.1830T>A p.(Tyr610*) 1 0.0000088
94528164 rs145961131 c.1906C>T p.(Gln636*) 5 0.0000441
94528147 rs1256814849 c.1922dupG p.(Cys641Trpfs*125) 0 0.0000000
94528132 rs61752401 c.1937+1G>A p.? 0 0.0000000
94526316 rs61751263 c.1938-1G>A p.? 0 0.0000000
94526258 rs757302286 c.1995C>A p.(Tyr665*) 0 0.0000000
94526212 rs61749423 c.2041C>T p.(Arg681*) 1 0.0000088
94526154 rs61749425 c.2099G>A p.(Trp700*) 1 0.0000088
94526092 rs61749427 c.2160+1G>C p.? 1 0.0000088
94522379 rs1401924846 c.2161-1G>A p.? 0 0.0000000
94520873 rs777634165 c.2383-2A>G p.? 1 0.0000089
94520733 rs143100856 c.2521C>T p.(Gln841*) 1 0.0000088
94520690 rs61752406 c.2564G>A p.(Trp855*) 4 0.0000352
94520666 rs61749439 c.2587+1G>A p.? 0 0.0000000
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Supplemental Table 1   Continued
Genomic position rs ID cDNA notation Protein notation AC gnomAD nFE AF gnomAD nFE
Protein truncating variants
94564402 rs755733328 c.716G>A p.(Trp239*) 1 0.0000088
94548999 rs754536977 c.769-2A>G p.? 0 0.0000000
94548926 rs757774731 c.838_839delAT p.(Met280Valfs*41) 0 0.0000000
94548907 rs750954445 c.858+1G>T p.? 0 0.0000000
94546276 rs769352013 c.859-2A>G p.? 0 0.0000000
94546247 rs747346334 c.885delC p.(Leu296Cysfs*4) 4 0.0000354
94546182 rs761093501 c.950delG p.(Gly317Alafs*57) 1 0.0000088
94546151 rs61751418 c.982G>T p.(Glu328*) 1 0.0000088
94546094 rs764915204 c.1025_1038delACAATAACTATAAG p.(Asp342Glyfs*6) 0 0.0000000
94544906 rs150686179 c.1211C>G p.(Ser404*) 1 0.0000088
94544895 rs61748550 c.1222C>T p.(Arg408*) 3 0.0000232
94544877 rs765707028 c.1239+1G>C p.? 1 0.0000077
94544199 rs948132728 c.1302delA p.(Gln437Argfs*12) 1 0.0000088
94544185 rs61752391 c.1317G>A p.(Trp439*) 3 0.0000264
94543380 rs780874319 c.1419delT p.(Thr474Leufs*6) 0 0.0000000
94543244 rs763808930 c.1554+2T>C p.? 1 0.0000089
94528866 rs1279522242 c.1561delG p.(Val521Serfs*47) 0 0.0000000
94528787 rs1043103980 c.1640delT p.(Phe547Serfs*21) 1 0.0000088
94528731 rs943713680 c.1696delC p.(His566Thrfs*2) 0 0.0000000
94528311 rs754765164 c.1761-2A>G p.? 1 0.0000089
94528240 rs771051333 c.1830T>A p.(Tyr610*) 1 0.0000088
94528164 rs145961131 c.1906C>T p.(Gln636*) 5 0.0000441
94528147 rs1256814849 c.1922dupG p.(Cys641Trpfs*125) 0 0.0000000
94528132 rs61752401 c.1937+1G>A p.? 0 0.0000000
94526316 rs61751263 c.1938-1G>A p.? 0 0.0000000
94526258 rs757302286 c.1995C>A p.(Tyr665*) 0 0.0000000
94526212 rs61749423 c.2041C>T p.(Arg681*) 1 0.0000088
94526154 rs61749425 c.2099G>A p.(Trp700*) 1 0.0000088
94526092 rs61749427 c.2160+1G>C p.? 1 0.0000088
94522379 rs1401924846 c.2161-1G>A p.? 0 0.0000000
94520873 rs777634165 c.2383-2A>G p.? 1 0.0000089
94520733 rs143100856 c.2521C>T p.(Gln841*) 1 0.0000088
94520690 rs61752406 c.2564G>A p.(Trp855*) 4 0.0000352
94520666 rs61749439 c.2587+1G>A p.? 0 0.0000000
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Genomic position rs ID cDNA notation Protein notation AC gnomAD nFE AF gnomAD nFE
Protein truncating variants
94517238 rs751791095 c.2603delC p.(Pro868Hisfs*33) 0 0.0000000
94517188 rs1212420029 c.2653+1G>T p.? 2 0.0000176
94517187 rs762823337 c.2653+2T>C p.? 1 0.0000088
94517186 rs766646086 c.2653+2delT p.? 0 0.0000000
94512528 rs773330082 c.2864delA p.(Glu955Glyfs*22) 1 0.0000088
94512504 rs61752410 c.2888delG p.(Gly963Alafs*14) 0 0.0000000
94512501 rs761689153 c.2891delA p.(His964Profs*13) 0 0.0000000
94511452 rs1180769486 c.2765delC p.(His922Leufs*10) 1 0.0000210
94511450 c.2768G>A p.(Trp923*) 0 0.0000000
94511397 rs1373701354 c.2814_2820delCCCACGT p.(Glu939Valfs*9) 0 0.0000000
94511391 rs1436534085 c.2825_2826delCA p.(Gly942Alafs*53) 0 0.0000000
94511353 rs1474617872 c.2864delC p.(Glu955Glyfs*22) 0 0.0000000
94511313 rs1032359778 c.2905A>T p.(Lys969*) 0 0.0000000
94508456 rs61752415 c.3191-2A>G p.? 1 0.0000088
94508455 rs767854160 c.3191-1G>T p.? 2 0.0000176
94508433 rs61750065 c.3210_3211dupGT p.(Ser1071Cysfs*14) 4 0.0000352
94506960 rs1324958803 c.3329-2A>T p.? 2 0.0000176
94506959 rs544428779 c.3329-1G>A p.? 1 0.0000088
94506884 rs1057517701 c.3403C>T p.(Gln1135*) 1 0.0000650
94506785 rs1472949364 c.3501delG p.(Ser1168Alafs*28) 0 0.0000000
94506764 rs1265840106 c.3522+1G>T p.? 0 0.0000000
94505685 rs1168144507 c.3523-2A>G p.? 0 0.0000000
94505684 rs766239144 c.3523-1G>A p.? 4 0.0000331
94502847 rs755283743 c.3665_3666delTG p.(Val1222Glyfs*14) 0 0.0000000
94502832 rs751987031 c.3681dupA p.(Glu1228Argfs*9) 0 0.0000000
94502760 rs61752423 c.3754G>T p.(Glu1252*) 0 0.0000000
94497601 rs769687104 c.3863-2A>G p.? 0 0.0000000
94497591 rs746541266 c.3871C>T p.(Gln1291*) 1 0.0000090
94497588 rs61752426 c.3874C>T p.(Gln1292*) 2 0.0000158
94497564 rs61752427 c.3898C>T p.(Arg1300*) 0 0.0000000
94497427 rs760519654 c.4033_4034dupAA p.(Asn1345Lysfs*45) 0 0.0000000
94497417 rs1184956177 c.4044dupA p.(Gln1349Thrfs*73) 0 0.0000000
94496665 rs139109485 c.4139delC p.(Pro1380Argfs*9) 0 0.0000000
94496610 rs62642573 c.4195G>T p.(Glu1399*) 0 0.0000000
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Supplemental Table 1   Continued
Genomic position rs ID cDNA notation Protein notation AC gnomAD nFE AF gnomAD nFE
Protein truncating variants
94517238 rs751791095 c.2603delC p.(Pro868Hisfs*33) 0 0.0000000
94517188 rs1212420029 c.2653+1G>T p.? 2 0.0000176
94517187 rs762823337 c.2653+2T>C p.? 1 0.0000088
94517186 rs766646086 c.2653+2delT p.? 0 0.0000000
94512528 rs773330082 c.2864delA p.(Glu955Glyfs*22) 1 0.0000088
94512504 rs61752410 c.2888delG p.(Gly963Alafs*14) 0 0.0000000
94512501 rs761689153 c.2891delA p.(His964Profs*13) 0 0.0000000
94511452 rs1180769486 c.2765delC p.(His922Leufs*10) 1 0.0000210
94511450 c.2768G>A p.(Trp923*) 0 0.0000000
94511397 rs1373701354 c.2814_2820delCCCACGT p.(Glu939Valfs*9) 0 0.0000000
94511391 rs1436534085 c.2825_2826delCA p.(Gly942Alafs*53) 0 0.0000000
94511353 rs1474617872 c.2864delC p.(Glu955Glyfs*22) 0 0.0000000
94511313 rs1032359778 c.2905A>T p.(Lys969*) 0 0.0000000
94508456 rs61752415 c.3191-2A>G p.? 1 0.0000088
94508455 rs767854160 c.3191-1G>T p.? 2 0.0000176
94508433 rs61750065 c.3210_3211dupGT p.(Ser1071Cysfs*14) 4 0.0000352
94506960 rs1324958803 c.3329-2A>T p.? 2 0.0000176
94506959 rs544428779 c.3329-1G>A p.? 1 0.0000088
94506884 rs1057517701 c.3403C>T p.(Gln1135*) 1 0.0000650
94506785 rs1472949364 c.3501delG p.(Ser1168Alafs*28) 0 0.0000000
94506764 rs1265840106 c.3522+1G>T p.? 0 0.0000000
94505685 rs1168144507 c.3523-2A>G p.? 0 0.0000000
94505684 rs766239144 c.3523-1G>A p.? 4 0.0000331
94502847 rs755283743 c.3665_3666delTG p.(Val1222Glyfs*14) 0 0.0000000
94502832 rs751987031 c.3681dupA p.(Glu1228Argfs*9) 0 0.0000000
94502760 rs61752423 c.3754G>T p.(Glu1252*) 0 0.0000000
94497601 rs769687104 c.3863-2A>G p.? 0 0.0000000
94497591 rs746541266 c.3871C>T p.(Gln1291*) 1 0.0000090
94497588 rs61752426 c.3874C>T p.(Gln1292*) 2 0.0000158
94497564 rs61752427 c.3898C>T p.(Arg1300*) 0 0.0000000
94497427 rs760519654 c.4033_4034dupAA p.(Asn1345Lysfs*45) 0 0.0000000
94497417 rs1184956177 c.4044dupA p.(Gln1349Thrfs*73) 0 0.0000000
94496665 rs139109485 c.4139delC p.(Pro1380Argfs*9) 0 0.0000000
94496610 rs62642573 c.4195G>T p.(Glu1399*) 0 0.0000000
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94496571 rs61750137 c.4234C>T p.(Gln1412*) 2 0.0000155
94496045 rs745544039 c.4290delT p.(Ala1431Glnfs*5) 0 0.0000000
94496027 rs1283350532 c.4309A>T p.(Lys1437*) 0 0.0000000
94495983 rs200967229 c.4352+1G>A p.? 2 0.0000176
94495143 rs1341069538 c.4383_4396delGAAGACTCCTTCTG p.(Trp1461Cysfs*89) 0 0.0000000
94495097 rs1311903227 c.4442dupA p.(Val1482Glyfs*73) 0 0.0000000
94495034 rs61750149 c.4506C>A p.(Cys1502*) 1 0.0000123
94495003 rs281865377 c.4537del p.(Gln1513Argfs*13) 0 0.0000000
94495001 c.4538_4539insC p.(Gln1513Hisfs*42) 0 0.0000000
94490606 rs61752435 c.4540-2A>G p.? 1 0.0000088
94490605 rs754703493 c.4540-1G>C p.? 0 0.0000000
94490530 rs754897752 c.4614T>A p.(Tyr1538*) 1 0.0000088
94490509 rs767312869 c.4634+1G>A p.? 0 0.0000000
94488972 rs1131691612 c.4637T>A p.(Leu1546*) 1 0.0000089
94488941 rs751319688 c.4667+1G>A p.? 1 0.0000089
94488940 rs61752436 c.4667+2T>C p.? 1 0.0000089
94487508 rs1439783011 c.4668-1G>T p.? 1 0.0000648
94487456 rs1340989734 c.4715_4718dupCGGG p.(Glu1574Glyfs*24) 0 0.0000000
94487455 rs1282472315 c.4720G>T p.(Glu1574*) 0 0.0000000
94487454 c.4720delG p.(Glu1574Lysfs*7) 0 0.0000000
94487442 rs758862120 c.4731_4732delTG p.(Gly1578Valfs*18) 0 0.0000000
94487401 rs61751376 c.4773+1G>A p.? 0 0.0000000
94486966 rs61750156 c.4849-1G>A p.? 4 0.0000353
94486960 rs61752439 c.4854G>A p.(Trp1618*) 0 0.0000000
94486933 rs763911476 c.4880delT p.(Leu1627Argfs*35) 1 0.0000088
94486886 rs760706416 c.4924_4927delAGCC p.(Ser1642Cysfs*19) 0 0.0000000
94486818 rs773880325 c.4996G>T p.(Glu1666*) 2 0.0000176
94485171 rs144619288 c.5161_5162delAC p.(Thr1721Hisfs*65) 2 0.0000181
94485164 rs867654589 c.5169delC p.(Trp1724Glyfs*2) 0 0.0000000
94485158 rs1057518955 c.5175dupG p.(Thr1726Aspfs*61) 1 0.0000091
94485145 rs886044747 c.5189G>A p.(Trp1730*) 1 0.0000094
94485137 rs61751377 c.5196+1G>A p.? 2 0.0000193
94481294 rs886044750 c.5312+1G>A p.? 1 0.0000649
94481293 rs1307108997 c.5312+2T>G p.? 1 0.0000088
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94496571 rs61750137 c.4234C>T p.(Gln1412*) 2 0.0000155
94496045 rs745544039 c.4290delT p.(Ala1431Glnfs*5) 0 0.0000000
94496027 rs1283350532 c.4309A>T p.(Lys1437*) 0 0.0000000
94495983 rs200967229 c.4352+1G>A p.? 2 0.0000176
94495143 rs1341069538 c.4383_4396delGAAGACTCCTTCTG p.(Trp1461Cysfs*89) 0 0.0000000
94495097 rs1311903227 c.4442dupA p.(Val1482Glyfs*73) 0 0.0000000
94495034 rs61750149 c.4506C>A p.(Cys1502*) 1 0.0000123
94495003 rs281865377 c.4537del p.(Gln1513Argfs*13) 0 0.0000000
94495001 c.4538_4539insC p.(Gln1513Hisfs*42) 0 0.0000000
94490606 rs61752435 c.4540-2A>G p.? 1 0.0000088
94490605 rs754703493 c.4540-1G>C p.? 0 0.0000000
94490530 rs754897752 c.4614T>A p.(Tyr1538*) 1 0.0000088
94490509 rs767312869 c.4634+1G>A p.? 0 0.0000000
94488972 rs1131691612 c.4637T>A p.(Leu1546*) 1 0.0000089
94488941 rs751319688 c.4667+1G>A p.? 1 0.0000089
94488940 rs61752436 c.4667+2T>C p.? 1 0.0000089
94487508 rs1439783011 c.4668-1G>T p.? 1 0.0000648
94487456 rs1340989734 c.4715_4718dupCGGG p.(Glu1574Glyfs*24) 0 0.0000000
94487455 rs1282472315 c.4720G>T p.(Glu1574*) 0 0.0000000
94487454 c.4720delG p.(Glu1574Lysfs*7) 0 0.0000000
94487442 rs758862120 c.4731_4732delTG p.(Gly1578Valfs*18) 0 0.0000000
94487401 rs61751376 c.4773+1G>A p.? 0 0.0000000
94486966 rs61750156 c.4849-1G>A p.? 4 0.0000353
94486960 rs61752439 c.4854G>A p.(Trp1618*) 0 0.0000000
94486933 rs763911476 c.4880delT p.(Leu1627Argfs*35) 1 0.0000088
94486886 rs760706416 c.4924_4927delAGCC p.(Ser1642Cysfs*19) 0 0.0000000
94486818 rs773880325 c.4996G>T p.(Glu1666*) 2 0.0000176
94485171 rs144619288 c.5161_5162delAC p.(Thr1721Hisfs*65) 2 0.0000181
94485164 rs867654589 c.5169delC p.(Trp1724Glyfs*2) 0 0.0000000
94485158 rs1057518955 c.5175dupG p.(Thr1726Aspfs*61) 1 0.0000091
94485145 rs886044747 c.5189G>A p.(Trp1730*) 1 0.0000094
94485137 rs61751377 c.5196+1G>A p.? 2 0.0000193
94481294 rs886044750 c.5312+1G>A p.? 1 0.0000649
94481293 rs1307108997 c.5312+2T>G p.? 1 0.0000088
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94480248 rs759513613 c.5313-2A>G p.? 1 0.0000088
94480244 rs776757706 c.5315G>A p.(Trp1772*) 1 0.0000088
94480243 rs61750571 c.5316G>A p.(Trp1772*) 1 0.0000088
94480222 rs61750573 c.5337C>A p.(Tyr1779*) 1 0.0000088
94480098 rs61753030 c.5460+1G>C p.? 1 0.0000088
94480098 rs61753030 c.5460+1G>T p.? 0 0.0000000
94476817 rs773876335 c.5584+1G>A p.? 1 0.0000088
94476454 rs748184137 c.5616G>A p.(Trp1872*) 1 0.0000088
94476355 rs1232476760 c.5714+1G>A p.? 0 0.0000000
94474362 rs1305924893 c.5778_5779delAA p.(Arg1927Asnfs*7) 0 0.0000000
94474306 rs1475966997 c.5835+1G>T p.? 0 0.0000000




94473277 rs61751389 c.5917delG p.(Val1973*) 2 0.0000177
94473259 rs61753037 c.5935delA p.(Thr1979Glnfs*13) 0 0.0000000
94471056 rs61751383 c.6088C>T p.(Arg2030*) 2 0.0000176
94471036 rs779751119 c.6108T>A p.(Tyr2036*) 0 0.0000000
94471026 rs61753038 c.6118C>T p.(Arg2040*) 1 0.0000077
94467550 rs1162214541 c.6148-2A>G p.? 1 0.0000088
94467413 rs770453727 c.6282+1G>C p.? 2 0.0000176
94466649 rs1176862742 c.6283-6_6294delCCCCAGGATGAGCCCACC p.? 1 0.0000088
94466630 rs779353744 c.6313delG p.(Ala2105Hisfs*10) 1 0.0000088
94466557 rs745654673 c.6386+1G>A p.? 0 0.0000000
94466556 rs61753043 c.6386+2C>G p.? 1 0.0000088
94466426 rs61750654 c.6445C>T p.(Arg2149*) 3 0.0000264
94463532 rs1193437578 c.6606_6613delCTACAACA p.(Tyr2203Alafs*45) 0 0.0000000
94463488 rs61753046 c.6658C>T p.(Gln2220*) 0 0.0000000
94463476 rs1425217062 c.6639_6669dupCTCCCTGGCGAGGATCTTCCAGCTCCTCCTC p.(Ser2224Leufs*37) 1 0.0000088
94461694 rs998363634 c.6787C>T p.(Arg2263*) 2 0.0001296
94461676 rs372234578 c.6805C>T p.(Arg2269*) 2 0.0000176
94461664 rs773599043 c.6816+1G>A p.? 0 0.0000000
94461664 rs773599043 c.6816+1G>T p.? 0 0.0000000
94458799 rs775865861 c.6817-1G>A p.? 1 0.0000088
Total truncating variants 135 0.0014685
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94480248 rs759513613 c.5313-2A>G p.? 1 0.0000088
94480244 rs776757706 c.5315G>A p.(Trp1772*) 1 0.0000088
94480243 rs61750571 c.5316G>A p.(Trp1772*) 1 0.0000088
94480222 rs61750573 c.5337C>A p.(Tyr1779*) 1 0.0000088
94480098 rs61753030 c.5460+1G>C p.? 1 0.0000088
94480098 rs61753030 c.5460+1G>T p.? 0 0.0000000
94476817 rs773876335 c.5584+1G>A p.? 1 0.0000088
94476454 rs748184137 c.5616G>A p.(Trp1872*) 1 0.0000088
94476355 rs1232476760 c.5714+1G>A p.? 0 0.0000000
94474362 rs1305924893 c.5778_5779delAA p.(Arg1927Asnfs*7) 0 0.0000000
94474306 rs1475966997 c.5835+1G>T p.? 0 0.0000000




94473277 rs61751389 c.5917delG p.(Val1973*) 2 0.0000177
94473259 rs61753037 c.5935delA p.(Thr1979Glnfs*13) 0 0.0000000
94471056 rs61751383 c.6088C>T p.(Arg2030*) 2 0.0000176
94471036 rs779751119 c.6108T>A p.(Tyr2036*) 0 0.0000000
94471026 rs61753038 c.6118C>T p.(Arg2040*) 1 0.0000077
94467550 rs1162214541 c.6148-2A>G p.? 1 0.0000088
94467413 rs770453727 c.6282+1G>C p.? 2 0.0000176
94466649 rs1176862742 c.6283-6_6294delCCCCAGGATGAGCCCACC p.? 1 0.0000088
94466630 rs779353744 c.6313delG p.(Ala2105Hisfs*10) 1 0.0000088
94466557 rs745654673 c.6386+1G>A p.? 0 0.0000000
94466556 rs61753043 c.6386+2C>G p.? 1 0.0000088
94466426 rs61750654 c.6445C>T p.(Arg2149*) 3 0.0000264
94463532 rs1193437578 c.6606_6613delCTACAACA p.(Tyr2203Alafs*45) 0 0.0000000
94463488 rs61753046 c.6658C>T p.(Gln2220*) 0 0.0000000
94463476 rs1425217062 c.6639_6669dupCTCCCTGGCGAGGATCTTCCAGCTCCTCCTC p.(Ser2224Leufs*37) 1 0.0000088
94461694 rs998363634 c.6787C>T p.(Arg2263*) 2 0.0001296
94461676 rs372234578 c.6805C>T p.(Arg2269*) 2 0.0000176
94461664 rs773599043 c.6816+1G>A p.? 0 0.0000000
94461664 rs773599043 c.6816+1G>T p.? 0 0.0000000
94458799 rs775865861 c.6817-1G>A p.? 1 0.0000088
Total truncating variants 135 0.0014685
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94577135 rs150774447 c.161G>T p.[Cys54Serfs*14,Cys54Tyr] 0 0.0000000
94576990 c.302+4A>C p.(Cys54Serfs*14) 0 0.0000000
94574275 c.303-3C>G p.[Cys54*,Leu102Alafs*14] 0 0.0000000
94564350 rs62645944 c.768G>T p.(Leu257Valfs*17) 24 0.0001858
94545023 rs780127258 c.1100-6T>A p.(Thr367Serfs*6) 1 0.0000088
94528128 c.1937+5G>A p.(Tyr603_Ser646del) 0 0.0000000
94528120 c.1937+13T>G p.[Phe647*,=] 0 0.0000000
94522386 c.2161-8G>A p.(His721_Val794del) 0 0.0000000
94514521 rs765263670 c.2654-8T>G p.[Gly863Valfs*47,=] 0 0.0000080
94510164 rs61751262 c.3050+5G>A p.(Leu973_His1017delinsPhe) 0 0.0000000
94508465 c.3191-11T>A p.(Gly1064delinsValProProGly) 0 0.0000000
94505599 rs1064793011 c.3607G>A p.(Thr1176Metfs*2) 0 0.0000000
94505596 c.3607+3A>T p.(Thr1176Metfs*2) 0 0.0000000
94502702 c.3812A>G p.(Gly1203Aspfs*10) 0 0.0000000
94502701 c.3813G>C p.(Gly1203Aspfs*10) 0 0.0000000
94497334 rs1064797113 c.4128G>A p.(Gln1376_Ile1377ins4) 0 0.0000000
94497334 rs1064797113 c.4128G>C p.(Gln1376_Ile1377insValLeuLeuSer) 0 0.0000000
94496679 c.4129-3C>T p.[=,Ile1377Hisfs*3,Gly1288Aspfs*45] 0 0.0000000
94496548 rs61754044 c.4253+4C>T p.(Ile1377Hisfs*3) 2 0.0000176
94496547 rs61750138 c.4253+5G>A p.(Ile1377Hisfs*3) 1 0.0000088
94496547 c.4253+5G>T p.[Ile1377Hisfs*3,=] 0 0.0000000
94495002 c.4538A>C p.[Pro1513_Arg1514ins10,Cys1490Glufs*12, Gln1513Pro] 0 0.0000000
94495002 rs281865402 c.4538A>G p.[Arg1513_Arg1514ins10,Cys1490Glufs*12] 0 0.0000000
94495001 c.4539G>A p.[Cys1490Glufs*12,=] 0 0.0000000
94490612 c.4540-8T>A p.(Gln1513insProGln) 0 0.0000000
94488942 rs1385119665 c.4667G>C p.(Ser1545_Gln1555del) 0 0.0000000
94488942 c.4667G>A p.(Ser1545_Gln1555del) 0 0.0000000
94487402 c.4773G>C p.[Tyr1557_Val1673del,Tyr1557Alafs*18] 0 0.0000000
94487399 rs759672616 c.4773+3A>G p.[Tyr1557Alafs*18,=] 18 0.0001394
94487397 c.4773+5G>A p.[Tyr1557Alafs*18,=,Tyr1557_Val1673del] 0 0.0000000
94487193 c.4848+3A>G p.[Gly1592_Lys1616del,=] 0 0.0000000
94486791 c.5018+5G>A p.(Val1617Alafs*113) 0 0.0000000
94485131 rs61753023 c.5196+3_5196+6delAAGT p.(Val1617_Ile1732del) 1 0.0000099
94481292 c.5312+3A>T p.(Asn1734Glyfs*14) 0 0.0000000
94480249 c.5313-3C>G p.(Trp1772Aspfs*7) 0 0.0000000
94480094 c.5460+5G>A p.(Trp1772Argfs*9) 0 0.0000000
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94577135 rs150774447 c.161G>T p.[Cys54Serfs*14,Cys54Tyr] 0 0.0000000
94576990 c.302+4A>C p.(Cys54Serfs*14) 0 0.0000000
94574275 c.303-3C>G p.[Cys54*,Leu102Alafs*14] 0 0.0000000
94564350 rs62645944 c.768G>T p.(Leu257Valfs*17) 24 0.0001858
94545023 rs780127258 c.1100-6T>A p.(Thr367Serfs*6) 1 0.0000088
94528128 c.1937+5G>A p.(Tyr603_Ser646del) 0 0.0000000
94528120 c.1937+13T>G p.[Phe647*,=] 0 0.0000000
94522386 c.2161-8G>A p.(His721_Val794del) 0 0.0000000
94514521 rs765263670 c.2654-8T>G p.[Gly863Valfs*47,=] 0 0.0000080
94510164 rs61751262 c.3050+5G>A p.(Leu973_His1017delinsPhe) 0 0.0000000
94508465 c.3191-11T>A p.(Gly1064delinsValProProGly) 0 0.0000000
94505599 rs1064793011 c.3607G>A p.(Thr1176Metfs*2) 0 0.0000000
94505596 c.3607+3A>T p.(Thr1176Metfs*2) 0 0.0000000
94502702 c.3812A>G p.(Gly1203Aspfs*10) 0 0.0000000
94502701 c.3813G>C p.(Gly1203Aspfs*10) 0 0.0000000
94497334 rs1064797113 c.4128G>A p.(Gln1376_Ile1377ins4) 0 0.0000000
94497334 rs1064797113 c.4128G>C p.(Gln1376_Ile1377insValLeuLeuSer) 0 0.0000000
94496679 c.4129-3C>T p.[=,Ile1377Hisfs*3,Gly1288Aspfs*45] 0 0.0000000
94496548 rs61754044 c.4253+4C>T p.(Ile1377Hisfs*3) 2 0.0000176
94496547 rs61750138 c.4253+5G>A p.(Ile1377Hisfs*3) 1 0.0000088
94496547 c.4253+5G>T p.[Ile1377Hisfs*3,=] 0 0.0000000
94495002 c.4538A>C p.[Pro1513_Arg1514ins10,Cys1490Glufs*12, Gln1513Pro] 0 0.0000000
94495002 rs281865402 c.4538A>G p.[Arg1513_Arg1514ins10,Cys1490Glufs*12] 0 0.0000000
94495001 c.4539G>A p.[Cys1490Glufs*12,=] 0 0.0000000
94490612 c.4540-8T>A p.(Gln1513insProGln) 0 0.0000000
94488942 rs1385119665 c.4667G>C p.(Ser1545_Gln1555del) 0 0.0000000
94488942 c.4667G>A p.(Ser1545_Gln1555del) 0 0.0000000
94487402 c.4773G>C p.[Tyr1557_Val1673del,Tyr1557Alafs*18] 0 0.0000000
94487399 rs759672616 c.4773+3A>G p.[Tyr1557Alafs*18,=] 18 0.0001394
94487397 c.4773+5G>A p.[Tyr1557Alafs*18,=,Tyr1557_Val1673del] 0 0.0000000
94487193 c.4848+3A>G p.[Gly1592_Lys1616del,=] 0 0.0000000
94486791 c.5018+5G>A p.(Val1617Alafs*113) 0 0.0000000
94485131 rs61753023 c.5196+3_5196+6delAAGT p.(Val1617_Ile1732del) 1 0.0000099
94481292 c.5312+3A>T p.(Asn1734Glyfs*14) 0 0.0000000
94480249 c.5313-3C>G p.(Trp1772Aspfs*7) 0 0.0000000
94480094 c.5460+5G>A p.(Trp1772Argfs*9) 0 0.0000000
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94476951 rs1800728 c.5461-10T>C p.[Thr1821Aspfs*6,Thr1821Valfs*13] 58 0.0004509
94476949 c.5461-8T>G p.(Thr1821Aspfs*6) 0 0.0000000
94476947 c.5461-6T>G p.(Thr1821Aspfs*6) 0 0.0000000
94476813 rs61750576 c.5584+5G>A p.[Thr1821Aspfs*6,Thr1821Valfs*13] 0 0.0000000
94476812 rs61750633 c.5584+6T>C p.[Thr1821Aspfs*6,Thr1821Valfs*13,Glu1863Leufs*33] 0 0.0000000
94476818 c.5584G>C p.(Thr1821Aspfs*6) 0 0.0000000
94474432 c.5715-5T>G p.[Thr1821Serfs*34,=] 0 0.0000000
94473856 rs1064793013 c.5836-3C>A p.(Lys1945_Ile1946Pheins10) 0 0.0000000
94473786 rs922818626 c.5898+5del p.(Cys1967Valfs*24) 0 0.0000000
94470997 c.6147G>A p.(Ser2002Argfs*11) 0 0.0000000
94466388 c.6479+4A>G p.(Ser2129_Lys2160delinsArg) 0 0.0000000
94463397 rs749526785 c.6729+5_6729+19delGTTGGCCCTGGGGCA p.(Phe2161Cysfs*3) 0 0.0000000
Total severe non-canonical splice site variants 105 0.0008211
Deep-intronic variants with <25% normal RNA12,17,18,27,44-48 
94566773 rs888731641 c.570+1798A>G p.(Phe191Leufs*6) 0 0.0000000
94549785 c.769-788A>T p.[Leu257Aspfs*3,=] 0 0.0000000
94546914 c.859-640A>G p.(Phe287Tyrfs*69) 0 0.0000000
94546814 c.859-540C>G p.(Phe287Tyrfs*33) 0 0.0000000
94546780 c.859-506G>C p.[Phe287Thrfs*32,=] 0 0.0000000
94528096 c.1937+37C>G p.(Phe647*) 0 0.0000000
94526934 c.1938-619A>G p.[Phe647Alafs*22,Phe647Serfs*22,=] 0 0.0000000
94526829 c.1938-514A>G p.[Phe647Serfs*155,Phe647Serfs*22,=] 0 0.0000000
94517960 c.2588-706C>T p.[Gly863Alafs*3,=] 0 0.0000000
94511126 c.2919-826T>A p.[Leu973Phefs*1,=] 0 0.0000000
94509799 c.3050+370C>T p.(Leu1018Glufs*4) 0 0.0000000
94495923 c.4352+61G>A p.[Glu1452*,=] 0 0.0000000
94493901 c.4539+1100A>G p.[Arg1514Valfs*31,Arg1514Glyfs*3,=] 0 0.0000000
94493895 c.4539+1106C>T p.[Arg1514Glyfs*3,Arg1514Valfs*31,=] 0 0.0000000
94492937 c.4539+2064C>T p.[Arg1514Leufs*36,=] 0 0.0000000
94489769 c.4634+741A>G p.[Ser1545Serfs*51,=] 0 0.0000000
94484125 rs886044748 c.5196+1013A>G p.(Met1733Valfs*2) 0 0.0000000
94484082 rs886044749 c.5196+1056A>G p.[Met1733Valfs*2,=] 0 0.0000000
94481967 c.5197-557G>T p.(Met1733*) 0 0.0000000
Total severe deep-intronic variants 0 0.0000000
Total loss-of-function variants 240 0.0022896
AC, allele count; AF, allele frequency; gnomAD, genome Aggregation Database; nFE, non-Finnish European
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Supplemental Table 1   Continued
Genomic position rs ID cDNA notation Protein notation AC gnomAD nFE AF gnomAD nFE
Non-canonical splice site variants with <25% normal RNA17,18,21,44,45 
94476951 rs1800728 c.5461-10T>C p.[Thr1821Aspfs*6,Thr1821Valfs*13] 58 0.0004509
94476949 c.5461-8T>G p.(Thr1821Aspfs*6) 0 0.0000000
94476947 c.5461-6T>G p.(Thr1821Aspfs*6) 0 0.0000000
94476813 rs61750576 c.5584+5G>A p.[Thr1821Aspfs*6,Thr1821Valfs*13] 0 0.0000000
94476812 rs61750633 c.5584+6T>C p.[Thr1821Aspfs*6,Thr1821Valfs*13,Glu1863Leufs*33] 0 0.0000000
94476818 c.5584G>C p.(Thr1821Aspfs*6) 0 0.0000000
94474432 c.5715-5T>G p.[Thr1821Serfs*34,=] 0 0.0000000
94473856 rs1064793013 c.5836-3C>A p.(Lys1945_Ile1946Pheins10) 0 0.0000000
94473786 rs922818626 c.5898+5del p.(Cys1967Valfs*24) 0 0.0000000
94470997 c.6147G>A p.(Ser2002Argfs*11) 0 0.0000000
94466388 c.6479+4A>G p.(Ser2129_Lys2160delinsArg) 0 0.0000000
94463397 rs749526785 c.6729+5_6729+19delGTTGGCCCTGGGGCA p.(Phe2161Cysfs*3) 0 0.0000000
Total severe non-canonical splice site variants 105 0.0008211
Deep-intronic variants with <25% normal RNA12,17,18,27,44-48 
94566773 rs888731641 c.570+1798A>G p.(Phe191Leufs*6) 0 0.0000000
94549785 c.769-788A>T p.[Leu257Aspfs*3,=] 0 0.0000000
94546914 c.859-640A>G p.(Phe287Tyrfs*69) 0 0.0000000
94546814 c.859-540C>G p.(Phe287Tyrfs*33) 0 0.0000000
94546780 c.859-506G>C p.[Phe287Thrfs*32,=] 0 0.0000000
94528096 c.1937+37C>G p.(Phe647*) 0 0.0000000
94526934 c.1938-619A>G p.[Phe647Alafs*22,Phe647Serfs*22,=] 0 0.0000000
94526829 c.1938-514A>G p.[Phe647Serfs*155,Phe647Serfs*22,=] 0 0.0000000
94517960 c.2588-706C>T p.[Gly863Alafs*3,=] 0 0.0000000
94511126 c.2919-826T>A p.[Leu973Phefs*1,=] 0 0.0000000
94509799 c.3050+370C>T p.(Leu1018Glufs*4) 0 0.0000000
94495923 c.4352+61G>A p.[Glu1452*,=] 0 0.0000000
94493901 c.4539+1100A>G p.[Arg1514Valfs*31,Arg1514Glyfs*3,=] 0 0.0000000
94493895 c.4539+1106C>T p.[Arg1514Glyfs*3,Arg1514Valfs*31,=] 0 0.0000000
94492937 c.4539+2064C>T p.[Arg1514Leufs*36,=] 0 0.0000000
94489769 c.4634+741A>G p.[Ser1545Serfs*51,=] 0 0.0000000
94484125 rs886044748 c.5196+1013A>G p.(Met1733Valfs*2) 0 0.0000000
94484082 rs886044749 c.5196+1056A>G p.[Met1733Valfs*2,=] 0 0.0000000
94481967 c.5197-557G>T p.(Met1733*) 0 0.0000000
Total severe deep-intronic variants 0 0.0000000
Total loss-of-function variants 240 0.0022896
AC, allele count; AF, allele frequency; gnomAD, genome Aggregation Database; nFE, non-Finnish European
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Supplemental Table 2  Origin of participants
Country of residence Number  
of cases
Predominant ethnicity Non-Finnish 
European cases 
count
Argentina 8 non-Finnish European 90% 7
Australia 33 non-Finnish European 85% 28
Brazil 6 non-Finnish European 90% 5
Canada 2 non-Finnish European 100% 2
Czech Republic 42 non-Finnish European 100% 42
France 110 non-Finnish European 95% 104
Germany 62 non-Finnish European 90% 55
Greece 3 non-Finnish European 100% 3
Ireland 17 non-Finnish European 90% 15
Israel 17 Ashkenazi Jewish 100% 0
Italy 20 non-Finnish European 90% 18
Japan 5 East Asian 100% 0
Netherlands 34 non-Finnish European 100% 34
New Zealand 12 non-Finnish European 75% 9
Palestine 10 Arab 100% 0
Poland 14 non-Finnish European 100% 14
Slovenia 11 non-Finnish European 100% 11
South-Africa 94 non-Finnish European 70% 65
Spain 36 non-Finnish European 90% 32
United States 14 non-Finnish European 90% 12
550 456 (83%)
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Supplemental Figure 1. Age distribution by sex
A. Among c.5603A>T cases, median age was 51 years and 53 years for women and men, respectively 
(Mann-Whitney U, p=.971). B. Female patients carrying c.5882G>A had a median age of 44 years and 
male patients of 45 years (Mann-Whitney U, p=.664). C. Women and men who did not carry a mild 
allele had a median age of 40 and 42 years, respectively (Mann-Whitney U, p=.633).
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Supplemental Figure 2. Age of onset distribution by sex
A. The distribution of age of onset among female patients carrying c.5603A>T was primarily 
bell-shaped, whereas its distribution among men appeared bimodal, although patient numbers 
were low. B. In the c.5882G>A subgroup, age at onset was slightly right-skewed. C. Among patients 
carrying none of the mild alleles, the distribution of age of onset was clearly right-skewed, likely due 
to the fact that the vast majority of these individuals carried two (moderately) severe alleles and only 
a minority of variants could have a mild effect. 
 Association of sex with ABCA4 alleles in Stargardt disease | 175
6
Supplemental Figure 3. Sex-specific penetrance estimates for ABCA4 alleles c.5603A>T and 
c.5882G>A
In a hypothetical population with the genotype ‘severe allele and c.5603A>T’ in which 10/200 (~5%) 
individuals have Stargardt disease (STGD1),11,15 with a STGD1 female:male ratio of 63:37 (Table 1), 
~6/100 (~6%) women and ~4/100 (~4%) men would be affected. In a population with the genotype 
‘severe allele and c.5882G>A’, in which ~100/200 (~50%) individuals have STGD1 (Table 2), with a 
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ABSTRACT
Purpose: To assess the incidence of Stargardt disease (STGD1) and to evaluate demographics 
of incident cases.
Methods: For this retrospective cohort study, demographic, clinical and genetic data of 
patients with a clinical diagnosis of STGD1 were registered between September 2010 and 
January 2020 in a nationwide disease registry. Annual incidence (2014-2018) and point 
prevalence (2018) were assessed on the basis of this registry.
Results: A total of 800 patients were registered, 56% were female and 83% were of 
European ancestry. The incidence was 1.67-1.95:1,000,000 per year and the point prevalence in 
2018 was approximately 1:22,000-19,000 (with and without 10% of potentially unregistered 
cases). Age at onset was associated with sex (Fisher’s exact: p=0.027); notably, 1.9x more 
women than men were observed (140 vs 74) among patients with an age at onset 
between 10 and 19 years, while the sex ratio in other age-at-onset categories approximated 
one. Late-onset STGD1 (≥45 years) constituted 33% of the diagnoses in 2014-2018 
compared to 19% in 2004-2008. Diagnostic delay (≥2 years between first documentation 
of macular abnormalities and diagnosis) was associated with older age of onset (p=0.001). 
Misdiagnosis for age-related macular degeneration (22%) and incidental STGD1 findings 
(14%) were common in patients with late-onset STGD1. 
Conclusions: The observed prevalence of STGD1 in real-world data was lower than 
expected on the basis of population ABCA4 allele frequencies. Late-onset STGD1 was 
more frequently diagnosed in recent years, likely due to higher awareness of its phenotype. 
In this pre-therapeutic era, mis- and underdiagnosis of especially late-onset STGD1 and 
the role of sex in STGD1 should receive special attention.
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INTRODUCTION
Stargardt disease (STGD) is an inherited retinal disease (IRD) that was first described com-
prehensively over a century ago as a rare, progressive, familial macular degeneration that 
manifested in childhood or adolescence.1 In 1997, mutations in the retina-specific ATP 
binding cassette transporter (ABCA4) gene were found to cause this disease, from that 
moment abbreviated as STGD1.2,3 Since then, the phenotypic spectrum of STGD1 has 
greatly expanded. When presenting in early childhood, STGD1 often evolves to a cone-rod 
dystrophy (CRD) that eventually leads to a panretinal degeneration.4,5 Late-onset STGD1 
(onset ≥45 years) is hallmarked by sharply demarcated atrophy in a foveal-sparing 
pattern.6,7 Another STGD1 phenotype is the bull’s eye maculopathy in which macular 
atrophy is often accompanied by exceptionally little lipofuscin.8,9 
STGD1 is widely regarded as the most common Mendelian inherited eye disorder. The 
exact prevalence, however, is unknown. A prevalence of 1:10,000 to 1:8,000 is frequently 
quoted in the literature, but this estimate was not accompanied by substantive analyses 
and originates from 1988.10 Since then, the disease-causing gene has been identified, the 
phenotypic spectrum of ABCA4 disease has been further elucidated, and diagnostic tools, 
e.g., imaging and genetic tests, have greatly evolved. Genetic studies have estimated a 
much higher prevalence of STGD1 of 1:6,578 to even 1:870.11,12 However, these estimates 
– based on ABCA4 mutation carrier frequencies – do not relate to the observed disease 
prevalence because the ABCA4 gene holds many variants of unknown significance and 
because disease expression depends on the severity of the mutation on the other ABCA4 
allele.13-16  
Several recent developments require data on the frequency of STGD1. Although there is 
no cure for STGD1 to date, the first market approval of gene augmentation therapy for an 
IRD (RPE65, LuxturnaTM) has raised the expectations of patients, physicians, researchers 
and the industry. Many strategies to treat IRDs (e.g., gene augmentation, genome editing, 
splice modulation, pharmacological compounds, optogenetics, cell replacement and 
retinal prostheses) are being tested in preclinical studies or clinical trials (www.clinicaltrials.
gov).17 Prevalence data are relevant for the planning of clinical trials and are required for 
pharmacoeconomic evaluation of orphan drugs. Furthermore, rare diseases are notably 
underdiagnosed.18,19 Monitoring of diagnostic trends can provide insight into the degree 
of underdiagnosis, which would become a critical issue once therapy becomes available. 
Moreover, recent studies gave novel insight into and raised new questions about the 
inheritance of STGD1. Several frequent ABCA4 variants were found to be associated with 
STGD1 and to have incomplete penetrance.14-16,20-23 Most notably, c.5603A>T (p.Asn1868Ile), 
which has an allele frequency between 0% (East Asians) and 6.6% (non-Finnish Europeans), 
had a calculated penetrance of ~5% when it occurred in combination with an ABCA4 allele 
with a severe mutation.16,22,24 In the employed calculations, the actually observed 
prevalence of disease remained an uncertain variable. A prevalence estimate supported 
182 | Chapter 7
by substantive data would improve research on penetrance of individual ABCA4 variants. 
In this nationwide retrospective cohort study, we assessed the annual incidence and the 
point prevalence of STGD1. To this purpose, we used our collaborative RD5000 disease 
registry that allows ongoing systematic collection, analysis and interpretation of health 
data and diagnostic trends.25 
METHODS
Subjects 
For this retrospective cohort study, patients with a registered diagnosis of STGD were 
identified in all referral centers for ophthalmogenetics in The Netherlands. These centers 
participate in the Dutch registry for Inherited Retinal Dystrophies ‘RD5000’.25 The diagnosis 
STGD1 was registered if the inclusion criteria and none of the exclusion criteria in Table 1 
were met. For this study, records were reviewed to confirm these diagnostic criteria, and 
patients with a permanent residence outside of The Netherlands were excluded. 
The Medical Research Ethics Committee ‘CMO region Arnhem-Nijmegen’ ruled that 
approval was not required for this study. The study is not subject to the Medical Research 
Involving Human Subjects Act (WMO) because participants were not required to follow 
procedures or rules of behavior. The study and data collection were in conformity with all 
country laws and adhered to the tenets of the Declaration of Helsinki.
Data collection
Data were extracted from medical records between September 2010 and January 2020. 
Collected variables included demographics, year of STGD1 diagnosis, ABCA4 variants and 
the family history (Table 2). Also, the year of initial report of macular abnormalities that 
retrospectively were considered to be the initial manifestation of STGD1 (i.e. flecks, retinal 
pigment epithelium atrophy, photoreceptor loss) was recorded. The self-reported 
geographic ancestry (first or second generation migration) was recorded if these data 
were available. An age at onset of complaints <11 years was considered ‘early-onset 
STGD1’, age at onset of complaints ≥45 years was considered ‘late-onset STGD1’, based on 
cut-offs commonly used in literature.4,7 Between 1998 and 2018, patients were screened 
for disease-causing variants in the coding regions and flanking splice sites and/or 
non-coding regions of ABCA4, as part of routine patient care or previous studies. The 
employed methods included: allele-specific primer extension microarray (Asper Biotech, 
Tartu, Estonia), multiplex ligation-dependent probe amplification (SALSA MLPA kit 
P151-P152 ABCA4; MRC-Holland, Amsterdam, The Netherlands), Sanger sequencing of all 
50 ABCA4 exons, custom Haloplex Target Enrichment kit (Agilent, Santa Clara, CA),21 whole 
exome sequencing (Illumina HiSeq2000 platform by BGI (Copenhagen, Denmark),27 and/
or single-molecule molecular inversion probes-based sequencing.28,29 Sanger sequencing 
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was performed to confirm all identified mutations. Genotypes were classified based on 
their pathogenicity rating in accordance with the American College of Medical Genetics 
classification.26
Annual incidence and point prevalence
The annual incidence was assessed for the years 2014 to 2018. This period allowed for the 
most complete data collection due to digitalization of medical records and improved 
diagnostic opportunities due to availability of optical coherence tomography (OCT) and 
short-wave autofluorescence (SW-AF) and advances in genetic techniques. The centers 
participating in this study are the national centers specialized in ophthalmogenetics and 
cover the vast majority of patient care involving IRDs in The Netherlands. To quantify the 
smaller proportion of patients with a diagnosis of STGD1 who had never been under the 
care of an ophthalmologist in any of these centers, we administered an anonymous 
Table 1  Conditions for STGD1 diagnosis registration
Criteria
Inclusion − Macular dystrophy with binocular presence of yellow-white irregularly shaped 
flecks in the (peri)macular region or throughout the posterior pole, [if OCT 
available] corresponding to hyperreflective material at the level of the retinal 
pigment epithelium and/or traversing photoreceptor attributable bands on OCT, 
[if SW-AF available] corresponding to hyperautofluorescent lesions on SW-AF.
− Cone(-rod) dystrophy as assessed by reduced ERG responses (photopic<<scotopic), 
AND a history of visual complaints in accordance with a retinal dystrophy in a cone 
(-rod) pattern, AND ≥ 2 potentially pathogenic ABCA4 variants (ACMG, uncertain 
significance-pathogenic)26 or a positive family history for STGD1.
− Macular dystrophy not further specified, AND ≥1 potentially pathogenic ABCA4 
variant (ACMG, uncertain significance-pathogenic)26 or a positive family history for 
STGD1.
Exclusion − Patients with ≥2 potentially pathogenic variants (ACMG, uncertain significance-
pathogenic)26 in a gene associated with autosomal recessively inherited retinal 
dystrophy other than ABCA4.
− Patients with ≥1 potentially pathogenic variant (ACMG, uncertain significance-
pathogenic)26 in a gene associated with dominantly inherited retinal dystrophy.
− Macular dystrophy not further specified with the presence of drusen defined as 
yellow round spots in the macula corresponding to deposits between Bruch’s 
membrane and the retinal pigment epithelium. 
− Macular dystrophy, not further specified, with one or multiple vitelliform lesions.
ACMG = American College of Medical Genetics; ERG = electroretinography; OCT = optical coherence tomography; 
SW-AF = short-wavelength autofluorescence.
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questionnaire among members of a patient association for macular diseases. Patients with 
a self-reported diagnosis of STGD1 were asked whether they currently were or ever had 
been under the care of an ophthalmologist in any of the participating medical centers. 
The proportion of respondents who had not visited any of the nationally specialized 
centers, each participating in the registry, was added to the incidence total. To define 
incidence, the average size of the population of The Netherlands between January 2014 
and December 2018 was used, which was 17,042,315 individuals.30 The point prevalence 
on 31 December 2018 was assessed. To define prevalence, the size of the entire population 
of The Netherlands at the end of the year 2018 was used, which was 17,282,163 individuals.30
Annual Incidence and point prevalence were calculated as follows:
Annual incidence =
Mean number of new cases per year 
between 1 January 2014 and 31 December 2018
Mean population size of The Netherlands 
between 1 January 2014 and 31 December 2018
Point prevalence =
Number of patients (alive) in registry on 31 December 2018
Population size of The Netherlands on 31 December 2018
Table 2  Database variables
Variable




Clinical data Year of diagnosis Stargardt disease
Year of initial report of macular STGD1 characteristics
Year of diagnosis age-related macular degeneration, if applicable
Age at onset of complaints
Genetic test performed yes/no
Year of genetic testing
Identified genetic variants associated with the retinal dystrophy
Family history Number of affected relatives
Relation to affected relatives
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Statistical analysis
Descriptive statistics were presented of the complete STGD1 population. The distribution 
of sex across age at onset categories was evaluated using Fisher’s exact test (two-sided, 
α=0.05). Wilcoxon Signed Rank test was used to assess whether age at onset was 
associated with sex in siblings with STGD1 (two-sided, α=0.05). Additionally, the Mann- 
Whitney test and the Fisher’s Exact test were performed to assess whether age at onset of 
complaints, ancestry or sex were associated with diagnostic delay (two-sided, α=0.015). 
Diagnostic delay was defined as ≥2 years between the moment that first macular 
abnormalities were documented and the moment that STGD1 diagnosis was documented.











Female, n (%) 8654043 (50%) 445 (56%) 78 (56%)
Age, mean (SD) 42 yrs 47 (19) yrs 38 (20) yrs
Deceased, n (%) 28 (4%) 0 (0%)
Age at diagnosis, median (range) 24 (5-83) yrs 36 (6-83) yrs
Geographic ancestry
European, n (%)
North African / Middle Eastern, n (%)
Southeast Asian, n (%)























Genetic test in patient or sibling  
performed, n (%) 664 (83%) 131 (94%)
Genetically confirmed diagnoses in  
patient or sibling, n (%)
615 (77%; 93% 
of performed 
tests) 
125 (89%; 95% 
of performed 
tests) 
Patient’s and family history
Age at onset, median (range) 20 (1-82) 32 (3-82)
Positive family history STGD1, n (%) 308 (40%) 32 (23%)
Consanguinity, n (%) 61 (10%) 12 (11%)
Incident cases in 2014-2018 are all cases who received the diagnosis STGD1 in 2014-2018. STGD1 = Stargardt 
disease.
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RESULTS
Subjects 
A total of 800 patients with STGD1 in accordance with the diagnostic and study criteria 
were nationally registered until January 2020. Patients had a mean current age of 47 (SD, 
19) years, 445 patients (56%) were female and 603 patients (83%) were of European 
ancestry (Table 3). Geographic ancestry in the patient population largely paralleled its 
distribution in the general population of the Nederlands, except for a seemingly higher 
proportion of patients with a North African or Middle Eastern background diagnosed in 
2014-2018. Figure 1 shows the distribution of age at onset plotted by sex, the two of which 
were associated (Fisher’s exact, p=0.027); Remarkably, 1.9x more women than men were 
observed (140 vs 74) among patients with an age at onset between 10 and 19 years, while 
the sex ratio in the other age-at-onset categories approximated 1. Cases with a macular 
dystrophy not further specified who carried only one ABCA4 variant – who represented 
the less certain STGD1 diagnoses – accounted for only 48 (6%) of the registered patients.
Annual incidence and point prevalence
Figure 2 shows an increasing frequency of STGD1 diagnoses over the years 1999-2018. 
Between 1 January 2014 and 31 December 2018, 140 incident cases were documented, 
which corresponded to a mean annual incidence of 28. In the total population of 17,042,315 
individuals,30 the annual incidence based on this registry was 1.64 (95% CI, 1.03-2.25) per 
1,000,000 persons per year. However, this likely is an underestimation of the true incidence, 
Figure 1. Distribution of the age at onset of Stargardt disease by sex. Age at onset was 
associated with sex (p=0.027). Women were overrepresented (1.9:1) among patients with an age at 
onset of 10-19 years (n=214).
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because of potentially unregistered cases. Table 4 shows the results of the questionnaire 
among patients in a patient association for macular diseases. Five of 49 (10%; 95% CI, 
2%-19%) respondents who had received the diagnosis STGD1 had not visited any of the 
specialized centers for ophthalmogenetics participating in the registry. Considering the 
95% CI of potentially unregistered cases, the annual incidence was between 1.67 and 1.95 
per 1,000,000 persons per year. 
Until 31 December 2018, a total of 790 patients had been diagnosed of whom 762 patients 
were alive in 2018. Therefore, the point prevalence in 2018 based solely on the registry was 
1 in 22,680 (95% CI, 1:24,413-1:21,176). Considering potentially unregistered cases (2-19%), 
the point prevalence was between 1 in 22,295 and 1 in 19,110 individuals. 
Diagnostic trends: Increasing frequency of late-onset STGD1 diagnoses 
and stable non-negligible diagnostic delay
Of all patients registered, 193 (24%) experienced initial complaints ≤10 years, 466 (58%) 
between 11-44 years and 140 (18%) ≥45 years. Over the years, the proportion of patients 
diagnosed with late-onset STGD1 increased gradually as visualized in Figure 2. The median 
(range) age at onset of patients diagnosed in 2014-2018 was 32 (3-82) years, compared to 
19 (1-72) years in 2004-2008. Prior to the diagnosis of STGD1, 28 (22%) patients with 
late-onset STGD1 (≥45 years) had been diagnosed with age-related macular degeneration 
(AMD). Another 17 (14%) late-onset patients were diagnosed before onset of complaints, 
during screening visits for diabetic/plaquenil retinopathy or glaucoma (n=8), regular care 
for comorbidities (n=6) or screening because of a positive family history (n=2) (alternative 
reason for visit not registered in n=1). 
In 58% (8%) of 694 cases it took more than 2 (2-21) years between the first macular 
abnormalities were documented and the moment that STGD1 diagnosis was documented. 
This diagnostic delay (≥2 years) was associated with a higher age at onset of complaints 
(Mann-Whitney, p=0.001) and was not associated with sex (Fisher’s Exact, p=0.582) or 
non-Western European ancestry (Fisher’s Exact, p=0.584). No trend in the frequency or 
extent of delay was observed over time. Of patients with a diagnostic delay, 12 patients 
(21%) had received a diagnosis of AMD prior to STGD1. ABCA4 analysis, performed in 52 
patients or a sibling of a patient (n=1) with a diagnostic delay (91%), confirmed the 
presence of ≥2 (potentially) pathogenic variants in 50 patients (94%). 
Table 4  Patient questionnaire outside of participating centers
Respondents diagnosed with Stargardt disease, n 49
Age, mean (SD) 51 (14)
Age at diagnosis, median (range) 28 (8-64)
Respondents under care in any of the participating centers, n (%) 44 (90%)
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ABCA4 genotypes
ABCA4 analysis had been performed in 641 patients (80%). Another 23 patients (3%) had 
an affected sibling who had undergone ABCA4 testing. A total of 542 of the diagnoses was 
genetically confirmed by the presence of ≥2 potentially disease-causing variants in the 
patient or an affected sibling of the patient (82% of the patients/siblings tested). Another 
73 diagnoses (11% of the patients (or siblings) tested) were considered genetically 
confirmed by the presence of the mild variant c.5603A>T as the second allele. The most 
frequent variants by far were c.5603A>T, c.5461-10T>C, c.2588G>C (only considered 
penetrant when in cis with c.5603A>T), c.768G>T and c.5882G>A (Table 5).
Family history
A total of 623 patients (78%) were considered a ‘proband’, the first patient in the family. Of 
these probands, 167 (27%) had a family history of STGD1: 137 (22%) had 1 or more affected 
siblings and 33 (5%) had an affected 2nd or 3rd degree relative. Pseudodominant inheritance 
was recorded in 9 (1%) families, only 1 of which was known to have consanguinity.
Age at onset could differ many years between siblings, with a median difference of 3 
(0-48) years. Differences of more than 10 years were observed in 18 of 84 families in which 
multiple siblings were affected (21%) (Table 6). In most of these families with large 
differences in age at onset (n=14, 78%), a known mild variant c.2588G>C (n=5), c.5603A>T 
(n=4), c.5882G>A (n=3), c.[769-784C>T;5603A>T] (n=1) or c.4253+43G>A (n=1) had been 
identified. In 44 families in which the sibling with the highest and lowest age at onset had 
Figure 2. Annual incidence of Stargardt disease based on the national registry. The number 
of registered STGD1 diagnoses increased over time, which was mostly attributed to an increase in 
the diagnosis and registration of late-onset STGD1 (≥45 years). The incidence of early-onset Stargardt 
disease (<11 years) remained fairly constant.  
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a different sex, lower age at onset was associated with female sex (Wilcoxon Signed Rank, 
p=0.025): in 24 families, the sister had an earlier onset than the brother, with a median 
difference of 8 (1-48) years; in 16 families, the brother was affected earlier, with a median 
difference of only 2 (1-7) years. 







c.5603A>T 167 b 0.0677
c.5461-10T>C 133 0.1002 0.0003
c.2588G>Cc 115 0.0866 0.0074
c.768G>T 103 0.0776 0.0006
c.5882G>A 101 0.0761 0.0049
c.1822T>A 47 0.0354 0.0003
c.3113C>Td 35 0.0264 0.0022
c.4539+1G>T 27 0.0203 0
c.5714+5G>A 23 0.0173 0.0004
c.4139C>T 22 0.0166 0.0001
a ABCA4 frequencies in 21,559 control individuals from The Netherlands.22
b This variant was only recently associated with STGD1 and therefore not accurately represented in the database. It 
was found as a single variant in 73 alleles.
c Only considered penetrant when in cis with c.5603A>T. In the general population of The Netherlands, the allele 
frequency of c.[2588G>C;5603A>T] is estimated to be 0.0007.22
d Found in cis with c.1622T>C in 37% of the alleles containing c.3113C>T in patients.
Not included in this table are deep-intronic variants c.4253+43G>A and c.769-784C>T, which were identified in 
17 and 10 patients. These variants were only recently associated with the disease and therefore not accurately 
represented in the database.
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Table 6  Sibling pairs with a discordant age at onset
Family ABCA4 nucleotide 
changes










5 c.5537T>C(;)5603A>T p.(Ile1846Thr)(;)(Asn1868Ile) 37 Female Male
c.5882G>A p.(Gly1961Glu)
12 c.5603A>T p.(Asn1868Ile) 33 Female Male
c.5762_5763dup p.(Ala1922Trpfs*18)
15 c.3191-2_3191del p.(?) 11 Male Male
c.5603A>T p.(Asn1868Ile)
16 Not tested 11 Male Male
17 c.1822T>A p.(Phe608Ile) 13 Male Male
c.2588G>Ca p.[Gly863Ala,Gly863del]
23 c.2921_3328+2del p.(Ser974_Gly1110delinsCys) 26 Male Male
c.5059A>T p.(Ile1687Phe)
27 c.768G>T p.(Leu257Valfs*17) 22 Female Female
c.5603A>T p.(Asn1868Ile)
28 c.4539+2001G>A p.[=,Arg1514Leufs*36] 31 Female Male
c.5882G>A p.(Gly1961Glu)
35 c.859-506G>C p.[Phe287Thrfs*32,=] 15 Female Male
c.5196+1137G>A p.[=,Met1733Glufs*78]
37 c.768G>T p.(Leu257Valfs*17) 16 Female Male
c.5882G>A p.(Gly1961Glu)





48 c.768G>T p.(Leu257Valfs*17) 24 Female Male
c.5603A>T p.(Asn1868Ile)
78 c.656G>Cb p.(Arg219Thr) 20 Female Male
c.2588G>Ca p.[Gly863Ala,Gly863del]
88 c.2588G>Ca p.[Gly863Ala,Gly863del] 20 Female Male
c.5461-10T>Ca p.[Thr1821Valfs*13,Thr1821Aspfs*6]
90 c.3322C>T p.(Arg1108Cys) 14 Female Female
c.3398T>C p.(Ile1133Thr)
92 c.768G>T p.(Leu257Valfs*17) 14 Female Female
c.4253+43G>A p.[=,Ile1377Hisfs*3]
 The incidence of Stargardt disease | 191
7
DISCUSSION
To the best of our knowledge, this is the first study that collected epidemiological data on 
STGD1 – the full spectrum of ABCA4-associated disease – supported by genetic data. The 
Netherlands might be unique in having a nationwide collaborative IRD registry, which 
allows for assessment of incidence and monitoring diagnostic trends of these rare 
diseases. Point prevalence of STGD1 in The Netherlands in 2018 was approximately 
1:22,000-19,000 individuals, which is far less than the genetically estimated prevalence 
1:6,578-1:870, based on ABCA4 mutation carrier frequencies.11,12 It clearly is difficult to relate 
the genetically estimated prevalence to the observed disease prevalence. This is not only 
due to the fact that the ABCA4 gene still holds many variants of unknown significance, and 
disease expression depends on the severity of the mutation on the other ABCA4 allele.13-16 
Also recent evidence for reduced penetrance of several mild ABCA4 variants causes a 
mismatch between the observed prevalence and the genetically calculated prevalence. 
The point prevalence in this study did also not exceed the crude estimate 1:10,000-8,000 
dating back to 1988, despite huge diagnostic advances in both imaging and genetic 
techniques since then. In contrast, the annual incidence of STGD1 in The Netherlands 
(1.67-1.95:1,000,000) was 1.5x higher than reported in the only previous epidemiological 
study on STGD1, performed in the United Kingdom.33 This discrepancy might be explained 
by differences in the definition of STGD1 (bull’s eye maculopathy and CRD were considered 
other disease entities in that study), study design (a survey among ophthalmologists with 
an inherent incomplete response-rate), and genetic testing (then rarely performed 
although it considerably expands the phenotypic range of STGD1).
Table 6  Continued
Family ABCA4 nucleotide 
changes










94 c.[769-784C>T;5603A>T] p.[=,Leu257Aspfs*3;Asn1868Ile] 48 Female Male
c.4539+1G>T p.(?)
200 c.768G>T p.(Leu257Valfs*17) 18 Male Male
c.2588G>Ca p.[Gly863Ala, Gly863del]
Allele 1 in white, allele 2 in grey. Family 5, 35, 37, 44 were previously described by Valkenburg et al.32 
a Variant c.5603A>T is often present on the same allele as c.2588G>C and c.5461-10T>C. The c.5603A>T was not 
associated with the disease at the time of genetic analysis in these patients and therefore not reported. 
b Variants c.656G>C and c. 2588G>C are known to occur on the same allele. Segregation analysis was however 
not performed.
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Late-onset STGD1 constituted an increasing proportion of the total STGD1 population 
over the years. This is likely explained by increasing awareness of its existence among 
ophthalmologists since its phenotype was first comprehensively described eight years 
ago.7 An unknown proportion might still be undiagnosed, for instance due to the absence 
of symptoms (14% of late-onset STGD1 was an incidental finding) or misdiagnosis as AMD 
(22% of late-onset STGD1). Although late-onset STGD1 incidence tended to stabilize in The 
Netherlands over recent years, the low age at onset reported in literature suggests that 
late-onset STGD1 worldwide is still often not recognized: maximum age at onset being 
≤42 years;34 ≤40 years;35 ≤55 years;36 and maximum age at presentation, ≤64 years.33 
Considering the current median age at onset of 32 years, and a maximum age at onset of 
82 years, the term ‘juvenile’ macular dystrophy is outdated, as previously suggested,33 and 
misleading to patients and physicians. Indeed, diagnostic delay (≥2 years) was associated 
with higher age at onset (p=0.001). In a forthcoming era of therapeutic options for STGD1, 
the awareness that this illness can manifest at all ages could prevent blindness.
In rare diseases, a limited number of patients is available to participate in clinical studies. 
The combination of dealing with a rare and progressive disease and a stringent set of 
eligibility criteria can make the enrollment process difficult and time-consuming. This, in 
addition to an increasing number of clinical trials and natural history studies, could even 
result in competition to the degree that studies stay underpowered. The 19 clinical trials 
for STGD1 currently registered in www.clinicaltrials.gov and www.clinicaltrialsregister.eu 
documented a total enrolment of as many as 1584 participants. Especially for therapeutic 
phase 2/3 trials, only a limited number of patients is eligible, due to strict criteria regarding 
genotype, age, best-corrected visual acuity and imaging characteristics. Even when 
selecting patients on the basis of very basic criteria such as age ≥18 and visual acuity 
≥20/200 (40% in an unselected US cohort)37 alone, 64% of patients in our current registry 
would not be eligible. National disease registries employing clear case definitions allow for 
a realistic planning of trials, and a time- and cost-efficient patient selection.
In addition to therapeutic developments underscoring the importance of correct 
diagnosis, each undiagnosed case with a rare disease represents an opportunity to gain 
pathophysiological insight. Recently, we observed a female predilection among patients 
carrying the mild ABCA4 allele c.5603A>T or c.5882G>A compared to patients who did not 
carry any known mild allele.23 Although the current study did not allow a genotype- 
specific analysis due to different DNA testing methods employed over time, it did show a 
remarkable female preponderance among patients with age at onset between 10-19 
years. This female predilection in puberty provides food for thought on the role of 
sex-specific disease modifiers. Moreover, a younger age at onset was associated with the 
female sex when comparing siblings. The fact that the observed prevalence in The 
Netherlands was not higher than the estimate of 1:10,000, employed in previous 
penetrance calculations, further corroborates the evidence for incomplete penetrance of 
several mild ABCA4 variants.16,20,22 Uncovering the mechanisms underlying sex differences 
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and incomplete penetrance in STGD1 could be of great interest for therapeutic 
development.
Finally, these data can aid in today’s practice of family counseling. Genetic studies have 
found sum allele frequencies of potentially pathogenic ABCA4 variants of 5-6% in the 
general population of European descent, corresponding to a carrier (heterozygous) 
frequency of approximately 1:10 individuals (10%).12,38 This knowledge is often used in 
family counseling, and even in estimating disease prevalence (1:6,578–1:870),11,12 but is 
clearly difficult to interpret due to uncertain pathogenicity and unknown expression of 
many ABCA4 alleles. Indeed, we observed a pseudodominant inheritance in only eight 
reportedly non-consanguineous families (1.3%), suggesting that at least 1.3% of individuals 
in the general population carry a pathogenic ABCA4 variant. Although the number of 
carriers could well be double due to autosomal recessive inheritance, the large gap 
between this carrier frequency of 1.3-2.6% derived from the observed pseudo-dominant 
inheritance and the aforementioned 10% found in genetic studies exemplifies a large 
counseling difficulty for ABCA4-associated disease. A differentiated counseling approach 
for early-onset STGD1, caused by severe ABCA4 variants, and late-onset STGD1, associated 
with frequent mild variants, could allow for a more accurate prediction of disease risk. The 
common (20%) discordance between siblings in terms of age at onset (≥ 10 years) was 
associated with mild alleles and further highlights the need for developing a differentiated 
counseling approach.
There are a few limitations to this study. First, the study was not designed to evaluate 
phenotypic differences between patients: for instance, patients with a CRD caused by 
ABCA4 mutations often received the diagnosis ‘STGD1’, i.e. all ABCA4-associated retinopathy, 
rather than ‘CRD’. Second, disease registration in the database might be incomplete. Also, 
a known limitation of surveillance studies is the fact that these depend on correct 
diagnosis. The observed prevalence inherently underestimates the true prevalence. The 
diagnostic trends that are discussed in this study, such as increasing incidence over the 
years and the increasing frequency of late-onset STGD1 diagnoses, indeed illustrate this. 
Ongoing diagnostic advances in combination with continued disease registration would 
provide data that increasingly reflect the true prevalence and help guide diagnostic and 
management strategies. Third, ascertainment may have been incomplete due to disease 
registration in specialized centers only. However, we anticipated that the standard of care 
in The Netherlands is to at least once send a patient suspected of a retinal dystrophy to 
one of the participating specialized centers, to allow a full diagnostic work-up including 
genetic testing and genetic counseling. This was confirmed by the questionnaire in a 
patient association: a minority of patients (10%) with a clinical diagnosis of STGD1 had not 
visited a center of expertise. 
In conclusion, collaborative national disease registries offer a unique opportunity to study 
longitudinal epidemiological data on rare diseases, giving insight into diagnostic 
challenges, and providing valuable information for planning of trials and genetic 
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counseling. Mis- and underdiagnosis were common in late-onset STGD1 and should 
receive special attention in this pretherapeutic era to prevent avoidable blindness in the 
future. 
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ABSTRACT
Background: Genetic counseling in autosomal recessive Stargardt disease (STGD1) is 
complicated because of unknown frequencies of pathogenic ABCA4 alleles across 
populations, variable and unknown severity of ABCA4 alleles, and incomplete penetrance.
Methods: Published ABCA4 variants were categorized by severity based on previous 
functional and clinical studies and current statistical comparisons of their allele frequencies 
in patients versus the general population, their observed versus expected homozygous 
occurrence in patients, and their occurrence in combination with established mild alleles 
in patients. The sum allele frequencies of these severity categories were used to estimate 
inheritance risks for offspring of STGD1 patients and carriers of pathogenic ABCA4 variants.
Results: The risk for offspring of a STGD1 patient with the ‘severe|severe’ genotype or a 
‘severe|mild with complete penetrance’ genotype to develop STGD1 at some moment in 
life was estimated at 2.8-3.1% (1 in 35-32 individuals) and 1.6-1.8% (1 in 62-57 individuals), 
respectively. The risk to develop STGD1 in childhood was estimated to be 2 to 4-fold 
lower: 0.7-0.8% (1 in 148-124) and 0.3-0.4% (1 in 295-248), respectively. For offspring of an 
unaffected ABCA4 variant carrier from a STGD1 family who carries one severe or one mild 
ABCA4 variant with complete penetrance, the risk to develop STGD1 throughout life is 
1.4-1.6% (1 in 71-64) and 0.19-0.21% (1 in 516-487), respectively. 
Conclusion: We propose a genotype-based personalized counseling approach to 
appreciate the large differences in inheritance risk between individuals. We advocate 
considering the lower risk of early-onset STGD1 compared with the total STGD1 risk.
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INTRODUCTION
Autosomal recessive Stargardt disease due to bi-allelic variants in ABCA4 (STGD1; MIM 
248200) represents the most prevalent inherited maculopathy, estimated to occur in 1 in 
10,000 individuals.1 Although originally considered a juvenile macular degeneration, 
patients may experience initial visual complaints between the first and the eighth decade 
of life.2-7 STGD1 results in visual impairment due to central or pericentral vision loss, 
impaired color vision, distorted vision and/or visual field defects, with legal blindness after 
a median of 12 disease years.3,8,9 Currently, in the absence of a treatment for STGD1, a 
major part of its management involves counseling about prognosis e.g. to help make 
career choices, and inheritance risk e.g. to aid in family planning. 
The risk of passing the disease to (future) children is a common concern of STGD1 patients 
and their relatives. This concern needs careful consideration because of the high frequency 
of pathogenic ABCA4 variants in the general population. High ABCA4 carrier frequencies 
are illustrated by common observations of pseudodominant inheritance,10-14 and different 
combinations of disease-causing ABCA4 variants among siblings.9,15 
The large difference in the age of onset of STGD1 between patients is hypothesized to be 
mainly caused by the variable amount of residual ABCA4 activity. The combination of 
ABCA4 variants of different severity, ranging from null (severe) alleles, moderately severe 
alleles, to mild alleles, influences the clinical expression.13,16,17 Especially relevant to 
inheritance risk is that combinations of pathogenic ABCA4 variants may or may not cause 
STGD1 depending on the variant severity. Two mild alleles, in principle, do not cause 
STGD1. Another layer of complexity was added to the existing ABCA4 genotype-pheno-
type correlation model, and thus genetic counseling, by evidence of incomplete 
penetrance.18,19 We calculated that the very frequent hypomorphic variant c.5603A>T (p.
(Asn1868Ile)) (allele frequency (AF) of 4.2% in the Genome Aggregation Database 
(gnomAD)), when in trans with a null allele, has a very low penetrance (<5%).9,20 Moreover, 
a female predilection among patients was observed for this variant and for another 
frequent variant, c.5882G>A (p.Gly1961Glu).9,21 These findings led to the hypothesis that 
~25% of STGD1 patients display multifactorial or polygenic inheritance in which two 
ABCA4 alleles are a prerequisite to develop STGD1 but additional genetic or non-genetic 
modifiers play a significant role.
The ABCA4 mutational landscape has further been expanded by the discovery of causative 
deep-intronic variants and structural variants. Targeted whole gene and genome 
sequencing has revealed 42 causal deep-intronic variants in ~5% of ABCA4 alleles and 
~10% of STGD1 cases.22-26 These deep-intronic variants can have a partial or full effect on 
mRNA levels.25-27 Moreover, 46 different structural variants have been identified in ~2% of 
STGD1 cases.24-26 Finally, at least 53 complex ABCA4 alleles have been identified, consisting 
of multiple disease-causing variants in cis,25,28 illustrating the importance of establishing 
the phase of the variants found in diagnostic studies.
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Despite the advances in genetic testing and increased knowledge of pathogenic variants, 
most variants are of unknown severity.4 As shown by the proposed ABCA4 genotype- 
phenotype correlation model, knowledge of not only the pathogenicity but also the 
severity of ABCA4 variants is crucial in estimating inheritance risk. Existing guidelines for 
the interpretation of pathogenicity of variants are not tailored to assess variant severity. 
The commonly used 5-tier American College of Medical Genetics and Genomics and the 
Association for Molecular Pathology (ACMG-AMP) system addresses the likelihood of a 
variant’s pathogenicity on a scale from benign (1) to causal (5) which in no way relates to 
its severity.29 For instance, the frequent mild ABCA4 variant c.5882A>G (p.(Gly1961Glu)) is 
considered ‘likely pathogenic’ according to the ACMG-AMP guidelines, whereas variants 
classified as variants of unknown significance by ACMG-AMP may well be severe. Therefore, 
genetic counseling of STGD1 families demands a genotype-based approach that 
considers variant severity.
In this study, we aimed to calculate the risk for offspring of STGD1 patients and carriers to 
develop STGD1. We used published ABCA4 genotype data from patients and ABCA4 AF 
data from the general population to assess the severity of 1,619 ABCA4 variants. The sum 
frequencies of ABCA4 alleles of different severities were calculated in the general population 
ethnically matched to the patient population. Using Hardy-Weinberg’s principle, inheritance 
risk was assessed for offspring of STGD1 patients and ABCA4 variant carriers.
METHODS
Currently non-existing terminology limits the use of inclusive language. By ‘offspring’ and 
‘child’ we refer to the genetic offspring and child, and by ‘partner’ we refer to the other 
genetic parent of the offspring. Similarly, we use the term ‘ethnicity’ to refer to groups of 
people who share a certain degree of genetic similarity; not to refer to cultural elements. 
We stress that we distance ourselves from problematic use of the term ethnicity as it is 
sometimes used to describe ‘normal’ and ‘other’ groups or people. 
1.  Dataset compositions: the bi-allelic patient (BAP) dataset and 
the ethnically- matched gnomAD (EM-gnomAD) dataset 
Inheritance risk calculations require knowledge of all ABCA4 variants that contribute to the 
disease in the given population, i.e. which variants are disease-causing and how severe are 
those variants. Furthermore, the inheritance risk calculations require knowledge of the 
sum AF of each severity category in the general population ethnically matched to the 
patient population under study. In order to obtain this information, a patient and a control 
dataset must be established. 
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Selection of the BAP dataset
We collected all publications until January 1st, 2020 that contain ABCA4 variants in patients 
with an autosomal recessive retinal dystrophy (Supplemental Materials and Methods). 
Reported variants in bi-allelic patients were collected per patient. Only bi-allelic patients 
were selected because mono-allelic patients are less likely to have ABCA4 related 
retinopathy. Patient records with the same variants that had been published by overlapping 
authors were considered duplicates and were removed from the dataset when there was 
no conflicting data on gender, ethnicity or age at onset (n=751). Furthermore, affected 
family members were excluded from the dataset (n=58). The resulting dataset (n=5,579) 
will be referred to as the bi-allelic patient dataset (BAP dataset).
Composition of the EM-gnomAD dataset
ABCA4 AF data were derived from the Genome Aggregation Database (gnomAD), 
downloaded on 13 April 2021 and were used to establish a control dataset that ethnically 
matches the BAP dataset: the ethnically matched-gnomAD (EM-gnomAD) dataset 
(Supplemental Materials and Methods). 
2.  The sum AFs of ABCA4 alleles categorized by severity: severe, 
moderately severe, mild with complete penetrance (mildCP), 
mild with incomplete penetrance (mildIP)
The combination of test results from the following three tests were used for the severity 
category assignment: AF test, Homozygosity test, Severity odds ratio test.
AF test: Benign test
To identify benign variants, we compared the frequency of each variant in the BAP dataset 
to the frequency of that variant in the EM-gnomAD dataset using Fisher Exact and creating 
an odds ratio (OR) for each variant. An OR <1 points toward a benign nature of the variant.
Homozygosity test: Mild variant test
Mild variants are not expected to cause STGD1 in a homozygous configuration. Therefore, 
a lower homozygous frequency in the BAP dataset than expected based on the AF in 
the general population indicates that a variant is mild. We compared the observed 
homozygous frequency of each variant in the BAP dataset to the expected homozygous 
frequency based on the AF in the EM-gnomAD dataset assuming they would cause 
disease in a homozygous state using Fisher Exact: Assuming a disease prevalence of 
1:10,000, every person in the BAP dataset represents a population of 10,000 people. 
To calculate the expected homozygous occurrence of each variant in the BAP dataset, 
we therefore multiplied the EM-gnomAD AF squared with the inverse of the assumed 
STGD1 prevalence (1:10,000) and with the BAP dataset size
(variant AFEM-gnomAD)2 * 10,000 * (BAP dataset size)  
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An OR was calculated for each variant. A low OR equals a low frequency of homozygous 
configuration and therefore points toward a mild nature of the variant.
Severity odds ratio: Severe variants test
Mild and moderately severe variants are not expected to cause STGD1 disease when in 
trans with a mild variant. Therefore, to distinguish severe variants from mild and moderately 
severe variants the ratio of each variant occurring in trans with previously established mild 
variants and previously established severe variants (Supplemental Materials and Methods) 
was compared to the same ratio in a reference group of previously established severe 
variants in the BAP dataset, using Fisher Exact. An OR was calculated for each variant. 
A high severity OR (>0.8) means that a variant has a relatively high frequency with mild 
variants and therefore points toward a severe nature of the variant, whereas a low severity 
OR (<0.8) points toward a mild or moderately severe nature of the variant. 
Severity category assignment 
In order to get a best estimate of sum AFs per severity category, we assigned variants to 
the categories ‘benign’, ‘mildIP’, ‘mildCP’, ‘moderately severe’ and ‘severe’ or multiple on the 
basis of the outcomes of the three aforementioned tests; the steps are described in detail 
in the Supplemental Materials and Methods and Supplemental Figure 1. 
3. Sum AFs per severity category
Initial sum AFs were created per severity category. Because of the subset of variants 
(n=190) that were inconclusively allocated to two severity categories, we made an 
underestimate and an overestimate of severity AFs. In the underestimate AF, all ambiguous 
variants were allocated to the least severe category, while those same variants were 
allocated to the most severe category in the overestimate AF. The sum AFs of variants that 
were categorized as one of three or more categories were proportionally divided over the 
three pathogenic severity categories, for ‘causative of unknown severity’ and over benign, 
mildCP, moderately severe and severe for ‘not categorized’. For this, the sum AF of benign 
variants only included those variants with an AF <0.01 across all gnomAD populations, as 
we considered the more frequent benign variants as erroneously included in studies 
despite a high AF. The sum AF of 66 null alleles from gnomAD that were absent from the 
BAP dataset were added to the sum AF of the severe category. The sum AFs were further 
adjusted according to the factors described below. 
Consideration of frequent complex alleles
Several frequent mild alleles occur in cis with other pathogenic ABCA4 variants. Therefore, 
the AF was corrected for c.[769-784C>T;5603A>T], c.[1622T>C;3113C>T], c.[2588G>C;5603A>T], 
c.[5461-10T>C;5603A>T]. In the calculation of the sum AF of mildIP, variants c.769-784C>T 
and c.2588G>C were only partially considered (25% (Genome of The Netherlands)30 and 
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10%,17 respectively), because these are likely benign if c.5603A>T is not located on the 
same allele. Also, the AF of the severe c.5461-10T>C variant was subtracted from the AF of 
c.5603A>T, since they are in linkage disequilibrium.25   
Likewise, c.3113C>T was only partially considered in the sum AF of mildCP alleles, because 
it has a confirmed severe effect when in cis with c.1622C>T. Eighty-five percent of the AF 
of c.1622C>T was therefore subtracted from the sum AF of mildCP alleles with complete 
penetrance, because 85% of all c.1622C>T alleles in our patient data also contains c.3113C>T 
and this is expected to be a similar proportion in the general population.
4. Inheritance risk calculations
ABCA4 genotype frequencies of unaffected individuals in  
the EM-gnomAD dataset
We assessed the ABCA4 genotype frequencies in the EM-gnomAD dataset, based on the 
Hardy-Weinberg principle (p2+2pq+q2=1). Consequently, genotypes with two alleles from 
the same severity category, have an occurrence of that category’s sum AF squared, while 
genotypes of two variants of two different categories, have an occurrence of two times 
the multiplication of the categories’ sum AFs. We assume that the frequencies of severe, 
moderately severe, mildCP, mildIP (p.(Asn1868Ile)), and wildtype alleles add up to a total of 
100%, that allele and genotype frequencies remain rather stable throughout time, that the 
STGD1 prevalence is equal in all analyzed populations and that genetic variation was spread 
evenly through the population, even though this is not the reality. Inheritance risks are 
calculated for situations where one of the biological parents has an unknown ABCA4 
genotype, a situation that applies to most unaffected individuals in the general population. 
However, some individuals with a pathogenic ABCA4 genotype may be clinically diagnosed 
after their child is born and are therefore likely considered an unaffected individual at the 
time of risk assessment. The mean age of biological parents of children born in 2018 in the 
European Union was 32 years (http://appsso.eurostat.ec.europa.eu/nui/submitViewTableAction.
do; https://www.cbs.nl/en-gb/news/2011/39/one-in-six-first-time-fathers-over-40). Patients 
with the genotypes severe|mildCP and moderate|moderate are generally diagnosed with 
STGD1 around this age. Therefore, only the proportion of individuals with these genotypes and 
a diagnosis >32 age in our patient cohort (E.H.R., personal communication) was taken into 
consideration in the calculations of inheritance risk involving an unaffected parent; 21% of the 
moderate|moderate genotype frequency and 44% of the mildCP|severe genotype frequency. 
Penetrance of c.5603A>T (p.(Asn1868Ile)): 5% to 65%
It is likely that incomplete penetrance occurs for several – if not all – known mild variants. 
However, in this study only the allele with the strongest evidence of incomplete 
penetrance was considered: the non-complex p.(Asn1868Ile). We implemented a 
penetrance of 5% when this allele is passed on from an unaffected carrier, as its penetrance 
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is estimated at 5% in the general population.9,20 An alternative penetrance of 65% is 
implemented when a STGD1 patient passes p.(Asn1868Ile) to their child, which is the 
penetrance rate we observed among relatives in a study cohort of 27 families.9,20 
For comparison, we included both a65% and a 5% penetrance calculation when the 
p.(Asn1868Ile) variant was inherited from an unaffected ABCA4 variant carrier. The higher 
penetrance rate should be considered when the carrier has first-degree relatives with 
STGD1, most often a sibling or a parent with STGD1.
RESULTS
Composition of datasets
In total, data on ABCA4 variants in 5,579 patients were collected (BAP dataset), consisting 
of 1,619 unique variants. Ethnicity data showed the following ancestries: non-Finnish 
European (67.8%), East Asian (9.7%), Latinx/Admixed American (7.0%), African (6.8%), Other 
(4.5%), South Asian (4.1%), Finnish (0.02%) and Ashkenazi Jewish (0.02%) (Supplemental 
Table 1). An EM-gnomAD dataset was constructed with corresponding ethnicity rates 
containing 132,890 alleles.
Cumulative AF of severe, moderately severe and mild alleles
Of the 1,619 variants in the BAP dataset, 1,250 variants (77.2%) could be categorized into 
one or multiple severity groups (Table 1, Supplemental Table 2). 1,065 variants were 
categorized to a single severity group, the other 185 corresponded to more than one 
potential severity category. In total, 82 variants were categorized as benign (Supplemental 
Material and Supplemental Figure 1: categorization steps 3, 4 and 14). Furthermore, 66 null 
alleles from the EM-gnomAD dataset that were absent from the BAP dataset were added 
to the sum AF of severe variants. Finally, the sum AF of potential pathogenic alleles in the 
EM-gnomAD dataset was 7-8%.The total sum AFs per severity category per ethnic group 
can be found in Supplemental Table 3.
All ABCA4 variants from the BAP group were categorized into severity categories and 
additional null variants from gnomAD were added to the total. Of these, one variant was 
considered mildIP (step 1). Twenty-three variants were categorized as mildCP (steps 1, 5, 9 
and 15). Seventy-six variants were considered moderately severe (steps 1, 6 and 8). Hun-
dred-and-forty-seven variants were considered either mildCP or moderately severe (step 
12). Concerning the severe variants: 817 variants were categorized as severe (step 1, 2 and 
10; no variants were categorized in step 7). Another 66 null variants were added from the 
gnomAD data that were absent in the BAP dataset list. Forty-three variants were considered 
to be either moderately severe or severe (step 11). Two variants were categorized as either 
benign or mildCP (step 13). Fifty-nine variants were considered to be a causative variant of 
unknown severity (step 16). Finally, the sum AF of the 369 variants that could not be 
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classified was proportionally divided over the known categories benign, mildCP, moderately 
severe and severe.
Genotype-based inheritance risk
The genotype frequencies per severity category in the general population based on the 
EM-gnomAD dataset are shown in Table 2. It shows that 5% of individuals carry at least 
one p.(Asn1868Ile) allele and 10% of individuals carry at least one (potentially) pathogenic 
ABCA4 allele other than p.(Asn1868Ile). The inheritance risks for five genotype scenarios 
were calculated based on the EM-gnomAD dataset (Figure 1 and Supplemental Table 4). 
Results per gnomAD ethnic population can be found in Supplemental Figures 2-8. 
The risk of STGD1 for the offspring of a STGD1 patient highly depends on the patient’s 
genotype (Figure 1A). As the combination of a severe ABCA4 variant with any other 
pathogenic ABCA4 variant will cause STGD1, the inheritance risk for offspring of a patient 
with two severe alleles and a non-tested unaffected individual is highest, estimated at 
2.8%-3.1% (1 in 35-32) in our population. This is twice the risk of STGD1 for offspring of a 
patient who harbors a severe and a mildCP allele: 1.6%-1.8% (1 in 62-57). Of important note: 
The risk that offspring will develop STGD1 already in childhood (0.68%-0.81%, 1 in 148-124, 
for a patient who harbors two severe variants) is estimated 2 to 4-fold lower than the risk 
that offspring will develop STGD1 at any moment in life (2.8%-3.1%, 1 in 35-32, for a patient 
who harbors two severe variants). This is because the genotype severe|mild – which 
typically does not lead to an onset in childhood – is most prominently present in any 
offspring genotype scenario. 
The risks for offspring of unaffected ABCA4 variant carriers varies tremendously, again the 
severity of the ABCA4 allele being the most important determinant. When an ABCA4 
variant carrier from a STGD1 family (for instance, a child or genetically tested sibling of a 
patient) will have a child with an unaffected non-tested individual who does not have 
relatives with STGD1, the inheritance risk varies between 0.13% (1 in 794, for carriers of a 
mildIP allel) and 1.6% (1 in 64, for carriers of a severe allele; Figure 1B). The risk that offspring 
develops STGD1 in childhood is estimated at practically zero for a known carrier of a mild 
allele to 0.34%-0.40% (1 in 295-248) for a known carrier of a severe allele.
Table 1  Variant categorization
Severity category Benign Mild Moderate Severe
Number of unique 
variants per severity 
category
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DISCUSSION
Genetic counseling in STGD1 demands a personalized approach. Generalized counseling 
in autosomal recessive diseases based on the premise that a genotype consisting of two 
pathogenic alleles causes disease is inadequate in STGD1 because of the considerable 
genotypic and phenotypic variability. Two main aspects highlight the relevance of a 
personalized, genotype-directed counseling approach. First, the inheritance risk of STGD1 
highly depends on the severity of the ABCA4 alleles the parent carries. Accordingly, risks in 
our population were estimated to range 0.68%-3.1% (1 in 148-32), in case of one parent 
being a STGD1 patient, and 0.13-1.6% (1 in 794-64), in case of one parent being a known 
carrier of an ABCA4 variant from a STGD1 family. As such, a sibling or child of a patient 
should be informed that, depending on the severity of the allele they carry, the inheritance 
risk of STGD1 at any moment in life for their children is either negligible or quite real. 
Second, people who seek counseling for family planning often involve a patient with an 
early onset of the disease. They might want to be counseled specifically for the risk that 
their offspring develops STGD1 at a young age. The inheritance risks for genotypes that 
generally lead to STGD1 in childhood are 2 to 4-fold lower than the total STGD1 inheritance 
risks. 
These personalized risk estimates enable STGD1 patients and their family to make 
informed decisions regarding carrier testing of a healthy partner and/or reproductive 
decisions. Consequently, one may consider ABCA4 testing of an unaffected partner. Today, 
whole-gene sequencing will reveal up to 95% of causal variants in clinically well-charac-
terized STGD1 cases. If no putative causal ABCA4 variants are identified in the partner, the 
risk of STGD1 for the offspring accordingly will decrease 20-fold. When a (likely) causal 
variant is found, prenatal or pre-implantation genetic diagnostics or prenatal testing could 
be discussed with the prospective parents, taking into account knowledge of the 
pathogenicity as well as the severity of the variant. 
Our study provides data on variant severity for many variants in the ABCA4 gene. This data 
can help clinicians interpret the consequences of a specific ABCA4 variant for their patient 
only if the robustness of the data underlying the variant categorization is carefully 
considered. It is likely that a proportion of variants, allocated on the basis of lesser robust 
data, have been assigned to the wrong severity category. However, the methods we used 
did not create a bias of variant allocation into one category over the other, and thus 
provide an adequate estimate of the overall sum AF per severity category. Due to 
insufficient data, 428/1,619 unique ABCA4 variants could not be assigned to one specific or 
either of two severity categories. Their total AF in the EM-gnomAD dataset was only 
0.29%. Excluding these variants from the analysis completely, would only be justified if 
each of these was benign, which is unlikely. Finally, stop-gain variants may not always lead 
to a null allele, but of all the stop-gain variants that had a low severity odds ratio, none was 
found homozygously less often than expected in the BAP dataset, indicating that they are 
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moderately severe or severe. Genetic counseling for individuals carrying a variant that was 
assigned a severity category on the basis of the lesser robust data, should especially 
consider that the inheritance risk lies on a range of estimates provided by several possibly 
relevant genotypic scenarios.
STGD1 inheritance risks are greatly influenced by differences in penetrance, due to the 
high frequency of the incompletely penetrant p.(Asn1868Ile) allele. The estimated 
penetrance rates of 5% for the general population to 65% for familial cases are based on 
the only data available to date: population data and data of a small number of STGD1 
families, respectively.9,20 When p.(Asn1868Ile) is inherited from an unaffected 1st degree 
relative of a STGD1 case, the penetrance might be lower than 65% as also the total number 
of genetic modifiers outside the ABCA4 gene may be lower, as compared to the situation 
where the p.(Asn1868Ile) allele has been penetrant in a first degree relative. We recommend 
counselors to carefully consider these potential differences in penetrance on the basis of 
the family history of both (future) parents.
When estimating the risk of STGD1 for the offspring of STGD1 cases or unaffected carriers 
of ABCA4 alleles, several other factors need to be considered. First, given the hypothesized 
polygenic or multifactorial nature of STGD1 for a significant fraction of cases (~25%), the 
risk estimates may vary depending on the culture, population and country. Second, ABCA4 
carriership reported in literature varies tremendously (6-20%),17,31,32 and accordingly the 
chances of meeting an unaffected partner who carries a (potentially) pathogenic ABCA4 
allele may vary. This variability is highly influenced by genetic testing method, variant 
interpretation, new insights over time, and possibly by population. In our study, the AF of 
(potentially) pathogenic alleles totals 7-8%, meaning that 14-15% of individuals in the 
general population carries at least one potentially pathogenic ABCA4 allele. 
We calculated risks on the basis of the AFs in different ethnic subpopulations, which in 
theory would result in a more precise, personalized estimate. Risks in subpopulations 
differed up to 230% from the general population that was ethnically matched to the 
patient group. However, risk estimates for separate ethnicities should be considered with 
special caution. First and most importantly, genetic variation within populations is likely 
much larger than between populations.33 Moreover, one’s self-reported ethnicity might 
not correspond with ethnicity grouping on the basis of genetic similarities. Local AFs can 
highly impact the risk assessment, e.g. the c.5882G>A is extremely frequent in the Somali 
population, potentially increasing the risk of STGD1 in this population.34 Local AFs may 
have to be incorporated into the risk assessment when they differ highly from the 
published data here. Another source of uncertainty concerns insufficient knowledge on 
complex alleles, especially in understudied populations. Inheritance risk is overestimated 
when unrecognized complex alleles are included in sum AFs in duplicate. Furthermore, 
the causal variants as well as the severity of variants are less studied especially in 
populations outside Europe and North America. For some populations both the STGD1 
patient group as well as the control group are relatively small or non-existing. Consequently, 
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causal variants in these populations may be underreported and unidentified, leading to 
an underestimation of the total risk in these populations. Finally, prevalence studies in 
understudied populations might help indicate if the risk of STGD1 and of passing on 
STGD1 to offspring indeed varies across populations or whether there still remain a lot of 
disease variants to be identified. 
The tremendous advances in genetic testing and knowledge of the ABCA4 gene made 
over the past decade should now be followed by the improvement of genetic counseling 
to STGD1 patients and their families. In the future, inheritance risk estimations need to be 
optimized on the basis of new studies on the functional effect of ABCA4 variants and 
increased knowledge on genotype frequencies worldwide as well as differences between 
populations and within populations, haplotypes, allele severity, and penetrance. For 
patients and their families today, the presented genotype-directed approach can help 
inform them about their personalized inheritance risks more reliably than generalized 
autosomal recessive risk counseling.
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Supplemental Material and Methods
Variant data collection
We collected all the papers that were published until 2020 that contain ABCA4 variants in 
patients with an autosomal recessive retinal dystrophy by searching the following terms in 
PubMed:
(ABCA4[All Fields] OR ((“Stargardt disease”[All Fields] OR “Macula Lutea”[All Fields]) AND 
(“Genetics”[All Fields] OR “mutation”[All Fields] OR “Sequence Analysis”[All Fields] OR “gene 
panel”[TiAb]))) OR (“Retinal Dystrophies”[All Fields] AND (“mutation”[All Fields] OR 
“Sequence Analysis”[All Fields] AND “gene panel”[TiAb])) (Cornelis et al, in preparation).27
Creating an ethnically matched control group
ABCA4 allele frequency data from the general population were taken from the Genome 
Aggregation Database (gnomAD), downloaded on 13 April 2021. We aimed to take the 
largest gnomAD sample that ethnically matches our bi-allelic patient (BAP) dataset as best 
as possible. Of note: In gnomAD, ethnicity categories have been created by principal 
component analyses, grouping together those genetic data most alike. This approach 
likely does not match the patient-reported ethnicity, which is the most common means of 
ethnicity collected in medicine. We therefore used one combined “general population” 
allele frequency that was matched to the ethnicities reported in published ABCA4 data, 
which likely mainly represents the populations of Europe and North-America. 
We ethnically matched the gnomAD allele data to the BAP data, taking the following 
steps:
First, we adjusted the published ethnicities from the BAP dataset data to the gnomAD 
populations: Black and people of African ancestry à African; Latinx, Hispanic, people of 
ancestry of Latin American countries à Latino/Admixed American; Ashkenazi Jewish à 
Ashkenazi Jewish; Chinese, Japanese, Mongolian, North Korean, South Korean, Taiwanese 
and people of East Asian ancestry à East Asian; Finnish à Finnish European; White and 
people of European ancestry à non-Finnish European; Afghan, people from Pakistan anc
estry, Indian, Nepalese, people from Bhutan ancestry, Bangladeshi, Sri Lankan and people 
of South Asian ancestry à South Asian; People with mixed or other reported ethnicities 
à Other. 
Second, approximately half of the studies that did not report ethnicities were published in 
the USA. We therefore assigned ethnicity proportions in the USA population, as reported 
by https://statisticalatlas.com/United-States/Race-and-Ethnicity, to 50% of the data in 
which no ethnicity was reported. The other 50% of data with unknown ethnicities 
originated from European papers and were assigned according to English and Welsh 
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ethnicity data (https://www.ethnicity-facts-figures.service.gov.uk/uk-population-by-ethnicity/ 
national-and-regional-populations/population-of-england-and-wales/latest) by lack of 
more detailed data, due to many European laws on recording ethnic data (https://www.
researchgate.net/publication/233314223_Collecting_ethnic_statistics_in_Europe_A_
review). 
Third, per gnomAD population we calculated the average allele number from exonic and 
splice site variants – as annotated in gnomAD - to create the largest possible ethnically 
matched gnomAD (EM-gnomAD) dataset (Suppl. Table 1): To find the gnomAD ethnic 
population size that limits and thereby determines the total size of the EM-dataset, we 
calculated the ratio between BAP group % / gnomAD group % per ethnic population. The 
ratio of the ‘Other’ ethnic group was the largest and therefore determined the size of the 
EM-dataset: had the ‘Other’ group been larger in gnomAD, the EM-gnomAD could have 
been larger as well. We therefore took the size (average exonic allele number (AN)) of the 
‘Other’ group in gnomAD as a reference size for the EM-gnomAD dataset:
∑ BAP(gnomAD Other AN)* (BAP dataset population group %) / (BAP dataset Other %)
We multiplied the original gnomAD AN of the ‘Other’ category with each of the ethnicity 
groups percentages in the BAP dataset and divided these by the Other group percentage 
in the BAP dataset. The resulting numbers of each ethnic group were then summed up to 
get to the total EM-gnomAD control AN. In this way the total adjusted gnomAD allele 
number became smaller than the actual gnomAD dataset but we maintained the trust-
worthiness of the smaller ‘Other’ group size from gnomAD, as this will affect the Fisher 
Exact tests that were used.
Severe variants test: previously established severity of variants
The following variants were defined as ‘previously established mild’, based on their 
reduced occurrence in homozygous configuration among patients, i.e. c.2588G>C, 
c.3113C>T, c.5882G>A, and c.6089G>A,27 or based on their behavior in genotype-pheno-
type correlations: c.769-784C>T and c.4253+43G>A,5,18 c.5603A>T,9,17 and/or based on 
expression levels c.6320G>A.30 To increase the robustness of this test, we defined variants 
‘previously established severe’ only if they most likely lead to no effective ABCA4 activity. 
Therefore, severe variants in this analysis only included frameshift, stop-gain and canonical 
splice site variants as well as noncanonical splice site variants that were shown to lead to 
≤5% of the WT product in vitro, the 5% being a conservative cut-off (Z. Corradi and F.P.M. 
Cremers, personal communication).18,21-25,31-34 
Severity category assignment
We assigned variants to the categories ‘benign’, ‘mildIP’, ‘mildCP’, ‘moderately severe’ and 
‘severe’ using the steps described below, each represented as well in a flow chart in 
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Supplemental Figure 1. Of note, this categorization is meant to create a sum AF per severity 
category and not to categorize individual variants robustly. For severity allocation of 
individual variants, steps 1-3 and 5-7 make use of Fisher-Exact p-values <0.05 or <0.025 
and are therefore more robust than steps 4 and 8-15. However, no correction for multiple 
testing has been performed and therefore the results should be appreciated with caution. 
1. Variants with a previously determined severity. Established likely severe variants have 
been listed in previous studies: stop-gain, frameshift, canonical splice site variants, in 
addition to non-canonical splice site (NCSS) and deep-intronic (DI) variants that result 
in ≤25% normal RNA.17,19-24,8,183,28-31 Variants that were previously functionally or 
clinically determined to be mild, were assigned ‘Mild-complete penetrance’ 
(‘MildCP’).17,19-23,25,28-31 NCSS and DI variants that are known to lead to >25-<70% of 
wild type RNA levels were assigned ‘Moderately severe’ and NCSS and DI variants 
known to lead to >70% and <85% of wild type RNA product were assigned ‘MildCP’. 
Recently, the effect of a small selection of missense variants was assessed using 
expression levels, ATPase activity and genotype-phenotype correlations.27 Severity 
of variants was assigned accordingly. 
2. The frequent c.5603A>T (p.(Asn1868Ile)) variant appears to have such a mild effect 
that it only causes STGD1 when in trans with a severe allele. As also suggested by 
others,16 this p.(Asn1868Ile) allele can serve as a litmus test to assign variants in trans 
(on the other allele) the status ‘severe’.4,32 Variants that were found in trans with the 
non-complex p.(Asn1868Ile) variant (i.e. p.(Asn1868Ile) without additionally potentially 
pathogenic variants on the same allele) in patients (confirmed by segregation analysis 
or by homozygous configuration) were assigned ‘severe’.8,16,23
3. AF test OR<1, p<0.05: benign
4. AF test OR<1: benign 
5. AF test OR>1, p<0.05 AND homozygosity test OR<1, p<0.025 AND severity OR<1, 
p<0.025: mildCP
6. Homozygosity test OR≥1 AND severity OR<1, p<0.025:: moderately severe
7. Homozygosity test OR≥1 AND severity OR>1, p<0.025:: severe (no variants were 
categorized this way)
8. Homozygosity test OR≥1 AND severity OR<0.8: moderately severe
220 | Chapter 8
9. AF test OR>1, p<0.05 AND homozygosity test OR<1 AND severity OR<0.8: mildCP
10. Homozygosity test OR≥1 (also if the expected occurrence was 0) AND severity OR>1: 
severe
11. (Homozygosity test OR≥1 AND no data available for the severity OR,) OR 
(Homozygosity test OR≥1 AND severity OR>0.8): moderately severe/severe
12. AF test OR>1 AND variants do not occur homozygously and aren’t expected to occur 
homozygously AND severity OR <0.8: mildCP/moderately severe
13. AF test OR: >0.75, <1 AND severity OR<1: benign/mildCP
14. AF test OR >1, <1.3  that have a p-value of >0.5: benign  
15. AF test OR>1.3 AND homozygosity test OR<1: mildCP
16. AF test OR>1, p<0.05 AND variants do not occur homozygously and are not expected 
to occur homozygously AND variants do not occur with known mild or known severe 
variants in trans (i.e. the severity OR test could not be performed): VUS but likely 
causative 
The sum allele frequency of all the variants that could not be categorized as either of the 
aforementioned categories, was divided into those categories according to the ratio of 
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Supplemental Table 1  Ethnic makeup of the BAP based control group. (Online only)
Supplemental Table 2  Data analysis for pathogenicity and severity allocation (i.e. allele 
frequency test, homozygosity test and occurrence with mild/severe ratio test). (Online only)
Supplemental Table 3  The allele frequencies of severe, moderately severe, and mild 
ABCA4 variants per gnomAD population. (Online only)
Supplemental Table 4  Calculation sheet for the risk of STGD1 for offspring of STGD1 
patients or known carriers of an ABCA4 variant. (Online only)
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1.  PRIMARY FINDINGS AND IMPLICATIONS 
Exciting news headlines on hurdles that have been overcome on the long road to a cure 
for inherited retinal diseases appear on a regular basis. Meanwhile, ‘Will I become blind?’ 
and ‘Will my (future) child or my sibling get the disease as well?’ remain the frequently asked 
questions of patients with STGD1 and other inherited retinal diseases. Needless to say, 
both (future) treatment and counseling – on prognostics, expected extra-ocular 
complications and inheritance – depend on a correct diagnosis. This, however, is not 
straightforward since diagnosis is challenged by variable phenotypic manifestations, 
phenotypically overlapping diseases and inconclusive genetic tests. Especially late-onset 
STGD1 is easily missed due to its relatively mild course and its overlap with age-related 
macular degeneration. Therefore, the aim of this thesis was to gain knowledge of the 
genetic background, the genotype-phenotype correlation and the natural progression of 
STGD1, particularly its late-onset manifestation. This discussion will elaborate on the main 
findings, placing these in a broader perspective and discussing their future relevance. 
Frequent, mild ABCA4 variants account for a significant part of 
the missing heritability in late-onset STGD1, improve diagnostics and 
hold promise for therapeutic development
Mild variants
Until recently, only one of the two disease-causing alleles could be identified in 
approximately 30% of the patients.1 The fact that genetically unexplained cases mostly 
manifested disease later in life led to misdiagnosis, a putative association between ABCA4 
and age-related macular degeneration,2,3 and the hypothesis that one ABCA4 mutation 
could be sufficient to cause late-onset STGD1.4,5 The explanation for this missing heritability 
has also been sought – and found – in the large uncharted introns and in the fact that 
deletions, duplications, insertions and inversions can be missed during the sequence 
analysis of 50 ABCA4 coding elements and flanking splice sites.6 Chapter 2 gives yet 
another explanation: the fact that unidentified disease-causing variants can reside in 
coding regions previously considered non-pathogenic. 
Chapter 2 describes a coding mild ABCA4 variant (c.5603A>T) and chapter 3 describes 
two non-coding mild ABCA4 variants (c.4253+43G>A and c.769-784C>T) which together 
confirmed the genetic diagnosis in more than half of previously unexplained monoallelic 
patients in our cohort.1 Their mild nature was inferred from the fact that they appeared to 
be phenotypically expressed only in individuals who harbored a severe variant on the 
other allele,7,8 and from the fact that they were associated with a high age at onset of 
complaints (range mean, 42-55 years). Moreover, the two intronic variants caused 
considerably more correctly spliced RNA (>70%) than miss-spliced RNA (exon skipping by 
c.4253+43G>A, and pseudo-exon insertion by c.769-784C>T). 
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Interestingly, c.5603A>T was found in the vast majority of the alleles that contain 
c.769-784C>T in patients, but not in controls.1,9 Likewise, c.5603A>T appears to be the 
missing link to pathogenicity for the common c.2588G>C variant, which has long been 
considered pathogenic.10,11 Several groups have confirmed that it consistently forms a 
complex allele with c.5603A>T in their patient cohort (c.[2588G>C;5603A>T]),7,10,12 whereas 
the combination is rare in controls: only ~10% of European controls carrying c.2588G>C 
also carries c.5603A>T.11 These variants might have an additive or a synergistic effect. It is 
now considered that two very mild variants on the same allele make one mild but fully 
penetrant allele, when in trans with a severe allele. 
Implications for diagnostics and treatment  
Late-onset STGD1 cases are now genetically explained at similar rates as patients with 
earlier-onset disease, which undeniably anchors the phenotype in the ABCA4 disease 
spectrum. Still, late-onset STGD1 is underdiagnosed, clearly indicated by the low maximum 
age at onset reported in international literature. In The Netherlands, growing incidence of 
late-onset STGD1 over recent years likely reflects increased recognition of the phenotype 
(chapter 7). Yet, there is room for improvement since we observed differences in the 
frequency of late-onset STGD1 diagnoses across centers. Moreover, prior (mis)diagnosis 
with age-related macular degeneration was common among patients with late-onset 
STGD1 (22%). The high age at presentation in addition to the possible absence of flecks or 
the presence of only vague flecks on ophthalmoscopy, and the frequent negative family 
history for a retinal dystrophy or a positive family history for putative age-related macular 
degeneration, seemed to induce this error. However, characteristics of STGD1, i.e. hyper-
autofluorescent and hypoautofluorescent fleck-shaped lesions in the macula or throughout 
the posterior pole and midperiphery in combination with sharply demarcated para- or 
pericentral atrophy, were observed in the vast majority of late-onset cases we studied. 
The awareness that STGD1 can start at all ages and may mimic age-related macular 
degeneration is indispensable in order to benefit from the above described genetic 
diagnostic advances. To refer to STGD1 as a “juvenile” macular dystrophy is misleading 
since 57% of patients in The Netherlands developed first complaints in adulthood, with an 
overall median age at onset of 32 years and a maximum up to 82 years (chapter 7). In case 
of doubt about the diagnosis, due to for instance geographic atrophy in the absence of 
drusen, fundus autofluorescence (or referral to a center with availability of fundus auto-
fluorescence) is recommended. 
Although we often refer to late-onset STGD1 as a milder form of the disease, and although 
foveal sparing results in prolonged intact visual acuity, these patients typically suffer from 
a serious visual handicap due to a pericentral scotoma. The correct diagnosis is not only 
key to accurate patient counseling (see ‘Implications for genetic counseling’ below) and 
future treatment, but potentially also to current therapeutic development. Hopes are that 
a treatment will soon be available for the full spectrum of STGD1, but some treatments 
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(e.g., mutation-specific treatment using antisense-oligonucleotides) might prove feasible 
for some patients and not for others. Interestingly, mild variants c.4253+43G>A and 
c.769-784C>T were already found to be amenable targets for antisense oligonucle-
otide-based splice correction in vitro.1 Note that late-onset STGD1 patients find themselves 
just below the functional threshold of ABCA4, so only a small increase of normal ABCA4 
RNA, accomplished through antisense-oligonucleotides, might restore ABCA4 function. 
Moreover, these patients – with predominantly late-onset disease – should be considered 
for large-scale natural history studies to gain knowledge on the diverse disease progression. 
The urgent need of gaining knowledge on the natural course of this disease has become 
apparent with the advent of the first clinical trials in STGD1 (see the General Introduction 
for an overview of trials; and see ‘Implications for trials’ below). A second way in which 
improved diagnostics and studies of late-onset STGD1 could be beneficial to therapeutic 
developments is by the fact that this patient group might reveal information about the 
disease’s pathophysiology: This is suggested by the observation of variable expression 
and reduced penetrance, which will be discussed in the next chapters.   
STGD1 might be a multifactorial condition in at least a quarter of all cases 
Variable expression
Although often considered a result of the tremendous genetic heterogeneity (>1200 dis-
ease-causing variants; www.lovd.nl/ABCA4), chapters 2, 3, and 4 show that phenotypic 
heterogeneity cannot be explained by the ABCA4 genotype alone. The high frequency 
of mild alleles c.5603A>T, c.4253+43G>A or c.[769-784C>T;5603A>T] allowed us to study 
relatively many patients with these variants: they exhibited large differences in age at 
onset of complaints and visual acuity courses, despite harboring genotypes of (predicted) 
equal severity. Illustratively, patients carrying c.5603A>T in combination with a null allele 
manifested initial complaints between 18 and 72 years. In the sibling study of chapter 4, 
we furthermore observed large intersibling discordances (in terms of age at onset, up to 
39 years, and time to reach severe visual impairment, up to 29 years) despite the presence 
of the same ABCA4 genotype. This corroborated the hypothesis that clinical variability 
among patients with STGD1 is not fully explained by the ABCA4 genotype. Intersibling 
discordances were particularly pronounced among patients carrying known mild ABCA4 
alleles (c.[2588G>C;5603A>T] and c.5882G>A).
Incomplete penetrance
We calculated that each of eight reported mild alleles potentially have incomplete 
penetrance: coding variants c.2588G>C, c.3113C>T, c.5603A>T, c.5882G>A, c.6089G>A, 
noncanonical splice site variant c.5714+5G>A,13 and deep-intronic variants c.4253+43G>A 
and c.769-784C>T (chapter 2, 3, and 6). Penetrance calculations involve many variables 
on which literature provides an interval rather than one definite number. Moreover, 
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knowledge of the functional consequence of especially missense variants, haplotypes 
and disease prevalence is incomplete. Consequently, penetrance was estimated and 
presented as a range, rather than one exact number. The most convincing incomplete 
penetrance was assessed for c.5603A>T: When accompanied by a severe ABCA4 variant on 
the other allele, c.5603A>T had a penetrance of less than 5%. In agreement with this 
finding, putative nonpenetrant cases were encountered during segregation analysis of 
the c.5603A>T variant. Out of 11 relatives who carried c.5603A>T in combination with a 
loss-of-function allele, four were asymptomatic. In two of them, the absence of disease 
was confirmed by ophthalmological examination at an age 14 and 15 years older than the 
age their siblings had when they became symptomatic. The third asymptomatic sibling 
had passed the age at onset of the brother already by 37 years. While nonpenetrance on 
the individual level cannot be irrefutably proven since unaffected individuals might 
develop STGD1 later in life, the tremendous expression variability is clear. Although terms 
with distinct meanings, ‘penetrance’ and ‘expression’ are closely inter-related and possibly 
have similar underlying mechanisms.  
A subsequent finding of a sex ratio imbalance corroborated the evidence for incomplete 
penetrance in STGD1. In chapter 6, we showed that women were statistically significantly 
overrepresented among patients carrying mild allele c.5603A>T (x1.7) or c.5882G>A (x2.1), 
compared to patients not carrying a known mild allele (x1.0).14,15 In The Netherlands and 
the US, approximately one quarter of all STGD1 cases carries one of these two alleles.7,13,16,17 
To our knowledge, only one previous study reported on potential incomplete penetrance 
in STGD1: two unaffected biallelic siblings were identified in two families upon segregation 
analysis in a study of 25 families involving at least one relatively late-onset case (>35 
years).18 These families carried mild variants c.2588G>A or c.6089G>A, which were of 
interest in this thesis as well. To the best of our knowledge, no sex ratio imbalance had 
been established in STGD1 before. Upon basic inquiry for a recent review on STGD1, 
researchers in a large US cohort observed an overall female-to-male ratio of 54:46 (No. 
1060), and 57:43 in the sub-cohort of p.(Asn1868Ile) allele carriers (No. 100). Although they 
found a female predilection, there was no statistically significant sex difference between 
the mild allele group and the no mild allele group.6 These discrepant findings across 
cohorts might be explained by genetic or environmental differences across populations, 
or by differences in access to (specialized) health care and research. Follow-up studies in 
other STGD1 cohorts are needed to shed further light on our observations.
 
Implications for genetic counseling
The phenomena incomplete penetrance and variable expression are major practical 
caveats for the prognosis of an individual’s disease outcome based on their genetic data. 
They challenge the interpretation of a person’s family history and the prediction of the risk 
of passing a genetic condition to future generations. In patients, genetic analysis taking 
into account the extremely low penetrant c.5603A>T variant allows distinguishing patients 
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(possibly monoallelic carriers) affected with age-related macular degeneration from 
biallelic late-onset STGD1. In unaffected individuals, the meaning of c.5603A>T is less clear. 
The presence of the c.5603A>T allele in combination with a pathogenic allele in trans is a 
poor prognosticator for STGD1 as long as we have little knowledge of the disease 
modifiers. Based on our penetrance calculations, the unaffected carrier of the genotype 
c.5603A>T + severe allele only has a 1:20 chance of developing STGD1. Informative, 
however, is the additional presence of c.2588G>C, c.4253+43G>A or c.769-784C>T on the 
c.5603A>T allele: the combination likely results in disease past adolescence (c.
[2588G>C;5603A>T], median age at onset, 20 years)(chapter 7) or even past middle 
adulthood (c.[769-784C>T;5603A>T], median age at onset, 55 years)(chapter 3). 
The presence of currently unidentified environmental and genetic modifying factors 
complicate sibling-based prognosis in the genotypic group of mild allele carriers. This 
concerns a considerable number of cases because already 25% of cases carries c.5603A>T 
or c.5882A>G (associated with sex, in patients). A differentiated counseling approach for 
early-onset and late-onset STGD1 is expedient. For example with regard to reproductive 
medicine: The risk at STGD1 in offspring greatly depends on the severity of the ABCA4 
mutations of the patient or carrier that seeks family counseling. When a patient who 
carries two severe ABCA4 variants and a non-tested unaffected individual have a child, the 
chance that the offspring will develop STGD1 at some point in life is estimated between 1 
in 35-32 (chapter 8), whereas the chance that the offspring will manifest STGD1 already in 
childhood is estimated much lower: 1 in 148-124. The inheritance risks greatly depend on 
the severity of the ABCA4 variants of the patient or carrier that seeks family counseling: In 
case of a patient with late-onset STGD1 with a mild, incompletely penetrant allele and a 
severe allele, the chance that the offspring will eventually manifest STGD1 is estimated at 
1 in 65-59, whereas the chance at STGD1 already in childhood due to a severe|severe 
genotype or a severe|moderately severe genotype is estimated at 1 in 295-248 (chapter 8). 
Undetermined value of fundus autofluorescence as an early endpoint
in clinical trials 
Several treatment strategies have been and are currently being explored (see ‘General 
Introduction’). Inconveniently, unsuccessful clinical trials might not only be caused by 
ineffective therapies, but also by insensitive clinical endpoints, underpowered studies or 
an unsuitable patient population (e.g., too heterogeneous or too advanced disease 
stages). Progression biomarkers that are insensitive to short-term changes are a frequently 
proposed cause of trial “failure”. For instance, RPE atrophy measured using short-wave 
autofluorescence currently is a major endpoint in trials (www.clinicaltrials.gov), but this 
imaging biomarker is of exclusive use for advanced disease, while strategies like gene 
therapy or lipofuscin reduction hold most promise in early disease stages. Disease activity 
in early stages can be captured by autofluorescence patterns indicating lipofuscin 
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accumulation, and theoretically has greater potential as a clinical endpoint. In chapter 5, 
we found that qualitatively assessed autofluorescence change on lesion level did not 
adequately reflect the retina’s functional change assessed by microperimetry over time. 
Our data did, however, fit the hypothesis that the retinal sensitivity shows a progressive 
decline during the pathological process of flecks appearing, fading and leaving residual 
atrophy, and functional decay rate might increase during this process.19-21 Also, hyper-
autofluorescent loci at baseline were associated with a larger decline in sensitivity over 
time (compared to hypo- and iso-autofluorescent loci). Natural history studies with more 
than two time points, quantitively assessed autofluorescence, advanced eye tracking and 
co-registration software and patients in earlier disease stages are required to assess the 
value of local autofluorescence as clinical endpoint.
Implications for trials
Large disease registries using standardized protocols that combine clinical care and 
research would facilitate this type of time-consuming though important studies. For 
natural history studies to optimize trial design, data needs to be collected from the 
intended patient population. Today, patient groups are unknowingly heterogeneous due 
to the earlier described discrepancy in genotypes, interacting modifiers and diagnostic 
impedements for especially late-onset STGD1. A prerequisite to be able to evaluate a 
treatment effect in a trial with limited patient numbers is inclusion of participants with 
sufficient prognostic and etiologic homogeneity. Attention to this growing group of 
patients in clinical trials is warranted, especially when using one group of patients as a 
control sample, because patients with mild variants may exhibit large differences in 
disease courses depending on unidentified factors.
2.  FUTURE DIRECTIONS IN THE QUEST FOR MODIFIERS
The literature
After several decades of gene and mutation finding, a genetic diagnosis, i.e. the 
identification of both ABCA4 alleles, can be made in 80 to 95% of STGD1 cases:6 80% when 
only the exons are sequenced and 95% when the complete gene is analyzed also for 
deep-intronic variants and copy-number variants. Current findings of non-linearity between 
genotype and phenotype pose the next challenge: understanding the additional factors 
that impact whether and how disease manifests in the presence of specific genetic 
variants. Hypotheses on the existence of modifiers in genetic diseases are not new. Rather, 
it is a long-standing theme that exists from early in the studies of mammalian genetics.22 
Research into these phenomena has two main drivers: to improve counseling for patients 
and relatives and to find a therapy. Although especially the latter can be far out of reach, 
the classic example of gyrate atrophy shows the high therapeutic potential of knowledge 
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on modifiers. In that disease, mutations in the OAT gene lead to accumulation of ornithine, 
an amino acid that is toxic to the retina. Diet serves as a modifier: dietary restriction of 
arginine (and for some: supplementation of vitamin B6) lowers systemic levels of ornithine, 
and slows the progression of chorioretinal degeneration.23
Some direction in the search for STGD1 modifiers has been obtained, but the list of 
candidate modifiers is long. First, ABCA4 variants on the same allele might well influence 
penetrance. For instance, we hypothesized that c.769-784C>T constitutes a modifying 
effect on the c.5603A>T allele causing the combination of the two – c.[769-784C>T;5603A>T] 
– to be completely penetrant (chapter 3). A similar situation could exist for variant 
c.2588G>C, which likely is benign or extremely low penetrant on its own and only has 
complete penetrance when present in the same gene copy as c.5603A>T (c.
[2588G>C;5603A>T]).7 Although known and unknown ABCA4 variants in cis could explain 
the (non-)penetrance in some cases, they unlikely offer the explanation for the larger 
group: The described intersibling differences and sex differences suggest that modifiers 
(also) exist outside the ABCA4 gene. These could reside in another gene (genetic modifiers) 
or outside of the genome (epigenetic of non-genetic modifiers). In theory, proven and 
hypothesized contributors to STGD1 pathophysiology described in the ‘General 
Introduction’ of this thesis could play a role. These include the classical and alternative 
visual cycle components, vitamin A, carotenoids, the complement system, microglia and 
other immune cells, mitochondria and antioxidants. 
The other piece of information we have is the implication of sex. In addition to the female 
predilection among patients carrying frequent mild alleles (chapter 6), some sex 
differences were notable in other chapters as well. The three putative nonpenetrant 
siblings in chapter 2 were male; more severe disease of sisters compared to brothers 
(chapter 7); a remarkable female preponderance was observed among patients with an 
onset in puberty (age at onset 10-19 years) (chapter 7). The role of sex hormones in the 
retina is unknown, but the presence of estrogen, progesterone and androgen receptors’ 
mRNAs in the human retina and specifically the RPE suggest they may play a causal role in 
sexual differences in retinal health and pathology.24,25 Sex differences in hormone status 
and hormone receptor distribution have the ability to affect retinal gene expression, 
anti-oxidant activity, retinal and choroidal blood flow, and pigment epithelial cell 
survival.26-33 Another hypothetical biological contributor to sex differences in multifactorial 
diseases other than sex hormones are mitochondria. Photoreceptors have an extremely 
high oxygen-consumption rate for which ATP is synthesized in the mitochondria, densely 
packed in the inner segments.34 Also the function of ABCA4 is ATP dependent. 
Furthermore, mitochondria are involved in steroid hormone synthesis, production of 
reactive oxygen species and cell death.35 Sex hormones, in turn, regulate mitochondrial 
function. Coincidence or not: maternally inherited diabetes and deafness, which is caused 
by a mitochondrial mutation, is a phenocopy of late-onset STGD1, due to hyperautofluo-
rescence and sharply demarcated atrophic lesions with foveal sparing. If sex is implicated 
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due to general effects on retinal physiology like gene up/down regulation, antioxidant 
activity and blood flow regulation, one would expect to encounter sex differences in 
other retinal degenerations as well. Indeed, two retinal disease mouse models, one of 
PDE6B-associated retinitis pigmentosa36 and one of neuronal ceroid lipofuscinoses37, 
showed an increased susceptibility to photoreceptor degeneration of female mice 
compared to age-matched male mice. To the best of our knowledge, the inherited retinal 
disease in which previously a sex imbalance has been observed is maternally inherited 
Leber hereditary optic neuropathy, in which incomplete penetrance has been observed 
and more males are affected.38-40 A protective role of estrogens was implicated in that 
disease based on the observation that onset ratios in childhood and past menopause 
approximated 1:1 (instead of 3:1 across age-groups).40
Alternatively, recent findings involving other diseases may help guide future studies into 
STGD1 modifiers. Variation in gene expression levels has been fairly consistently recognized 
as a potent modifier. Cis and trans-acting elements, like variants in promotor regions or 
SNPs in the 3’ untranslated region (3’UTR) of the gene, can modulate disease severity and 
gene and/or allele expression levels in examples of familial hypercholesterolemia,41 
autosomal dominant long QT syndrome42 and Birt-Hogg-Dubé syndrome43. A 
well-studied example of an IRD gene associated with incomplete penetrance and variable 
expression is PRPF31, which causes autosomal dominant retinitis pigmentosa, based on a 
haplo-insufficiency disease model.44 Variable expression levels of the ‘normal’ PRPF31 
allele can be explained by expression quantitative trait loci (eQTLs) in trans with PRPF31,45 
by a variable level of expression of CNOT3, a trans-acting epistatic factor which is genetically 
linked (distance is 6 kb) to PRPF31 and regulates expression of PRPF31,46,47 and by the 
number of minisatellite repeat elements adjacent to the PRPF31 promotor which influence 
transcriptional repression of the non-mutant allele48. These phenomena might also act in 
a non-dominant disease like STGD1, by influencing the mild allele. One study using 
genomic and transcriptomic data from healthy retinal donors found frequent (>10%) 
allelic expression imbalance in 20 IRD-associated genes, among which genes regularly 
associated with incomplete penetrance and variable expression (BEST1, RP1, PROM1, and 
PRPH2) but also ABCA4.49 Another study found that IRD-associated genes suspected to be 
associated with variable penetrance had significantly more variable gene expression 
levels in the general population across tissue types.50 Whether this is also true for ABCA4 
remains to be investigated.
In addition to biological processes, also socioeconomic and behavioral factors should be 
considered as potential modifiers. Environmental factors that have been implicated in the 
pathophysiology are accumulation of vitamin A derivatives and phototoxicity, so diet and 
sunlight exposure might be clinically relevant. Coming back to the example of the 
well-studied Leber hereditary optic neuropathy that has incomplete penetrance: A study 
in patients and unaffected carriers found an association between smoking and drinking 
alcohol and the likelihood of penetrance.51 
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Clinical, genomic and transcriptomic studies, (inter)national 
collaboration, and disease modeling
In studies of penetrance and modifiers, ideally, we would examine the statistical 
occurrence of disease in a group of known genotypes, and genetically and clinically 
examine affected and unaffected individuals. Unfortunately, such a study design faces 
financial and ethical challenges. One would need to study ten-thousands of people to 
find a patient, since the disease is rare. This challenge is traditionally overcome by large 
family studies but the ethical aspect is not. As discussed in this thesis, large-scale genomic 
studies of patients and the general population provide a powerful alternative approach to 
study the penetrance of specific genotypes of interest (LOVD, GnomAD).52 Emerging 
datasets with combinations of genomic, transcriptomic, metabolomic and clinical data 
and techniques to assess haplotypes (such as long-read sequencing), could aid the 
modifier search. Furthermore, (inter)national collaboration is essential for future studies 
into modifiers. The sex differences observed in chapter 4 had not previously been 
established despite abundant research into this disease. Local cohorts would certainly be 
underpowered to identify the modifier(s) from the long list of potential genetic factors, 
biological factors and behavioral factors described above. 
Models of STGD1 would facilitate studies into the effect of theoretically plausible modifiers 
on retinal health. The only well-studied animal model is the mouse, which is not ideal to 
evaluate the tremendous phenotypic heterogeneity observed in humans since it lacks 
the macula and has few cones.20,53-55 Also considering the long list of hypothetical 
modifiers, organoid and organ-on-a-chip developments have the obvious potential to 
revolutionize research into pathophysiology of STGD1 in the future. Although no in vitro 
model fully recapitulates the complex 3D architecture of the human retina to date, large 
progress has been made. 3D models of the human retina that originate from human 
induced pluripotent stem cells have been created and already shown useful to evaluate 
drug effects.56 
3.  FINAL REMARKS
The increased diagnostic yield of genetic tests and the acquired knowledge of the role of 
frequent ABCA4 alleles in STGD1 allows to differentiate STGD1 from other macular diseases 
and reach a timely diagnosis. The majority of patients with STGD1 in The Netherlands is 
compound heterozygous for a mild allele. We studied these patients in particular and 
found (1) a functional discordance between patients (and asymptomatic individuals) with 
equal ABCA4 genotypes; (2) incomplete penetrance of common ABCA4 alleles; and (3) a 
female preponderance among patients. Although the exceptional phenotypic diversity in 
this sizeable patient group poses a diagnostic challenge, these patients potentially also 
create the opportunity to fill the gap in our understanding of STGD1 pathophysiology. 
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Understanding the mechanisms underlying incomplete penetrance and variable 
expression would improve counseling and could even pave the way for novel diagnostic 
and treatment approaches. 
Incomplete penetrance and variable expression are expected to be more common 
throughout retinal diseases than currently has been established, due to our focus on 
affected individuals. One major cause is the fact that we have long ignored the genetic 
information that is available in the “healthy” population. This thesis outlined a strategy to 
assess incomplete penetrance that can be applied to other inherited diseases as well. The 
quest to modifiers, suitable clinical endpoints, and a cure faces the challenges created by 
the great genetic and phenotypic heterogeneity in combination with small patient 
numbers. These challenges are most likely to be overcome by large collaborations that 
entail the creation of large uniform datasets, combining basic characteristics (incl. sex), 
genetic (incl. ABCA4 exons and introns but rather even the complete genome, and 
haplotype), transcriptomic, phenotypic, disease progression and environmental (incl. 
comorbidity, medicine, diet) data. Deciphering the conditions that are needed for some 
mild alleles to become pathogenic is likely to be a most interesting and fast moving area 
of study over the coming years. 
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SUMMARY
Stargardt disease (STGD1) is an inherited macular dystrophy that causes progressive vision 
loss. The management of the disease involves visual aids, lifestyle measures that may 
inhibit disease progression, and counseling on prognosis and inheritance. Accurate 
management depends on a correct and timely diagnosis. However, the diagnosis can be 
challenging because of a large variability in phenotypes and disease courses, 
phenotypically overlapping diseases (phenocopies), and inconclusive results from genetic 
tests. These challenges thereby impact current disease management, but also 
experimental, future therapy. Proving efficacy of an experimental therapy requires a 
generally suitable endpoint, one that is clinically meaningful, non-invasive, reliable and 
sensitive. Such an endpoint has been hard to define due to the wide range of phenotypes 
and progression rates – both still incompletely characterized – and the fact that the 
disease is rare. Thus, evaluation of the genetic and phenotypic variation and the natural 
history are still of great importance to eventually be able to assess treatment effect. The 
aim of this thesis was to gain knowledge of the genetic background, the genotype-phe-
notype correlations and the natural progression of STGD1. 
Chapter 1 is a general introduction on the physiology of the human retina and the current 
understanding of the phenotypic characteristics, pathophysiology, genotype and 
management of STGD1. Relatively new in the ABCA4 disease spectrum is late-onset STGD1 
(initial visual complaints ≥45 years). Its diagnosis can be particularly challenging due to its 
phenotypic overlap with the much more common age-related macular degeneration, 
and is further complicated by the unusually high rate of inconclusive genetic tests.
In the first chapters, patients with a phenotype of STGD1 in whom only one ABCA4 allele 
was identified, are studied. Chapter 2 shows that a significant fraction (40%) of these 
genetically unexplained Dutch cases carries the frequent c.5603A>T (p.Asn1868Ile) variant 
as the second allele. The other, previously identified, ABCA4 allele was often known to 
have a severe (deleterious) effect. Patients carrying c.5603A>T manifested initial complaints 
of the disease past childhood, and exceptionally often even past the age of 45 years (42%) 
with characteristic late-onset STGD1 features of sharply demarcated atrophy in a 
foveal-sparing pattern and flecks throughout the posterior pole and midperiphery. 
However, the age-of-onset range was extra-ordinary large (18-72 years) despite genotypes 
of seemingly equal severity: the combination of c.5603A>T and a severe allele. Additionally, 
four asymptomatic relatives carrying a combination of a severe allele and c.5603A>T were 
identified. Based on ABCA4 allele frequency population data, we calculated the penetrance 
of c.5603A>T, when present in trans with a severe variant, to be below 5%. Chapter 3 
describes two additional mild alleles, the deep-intronic variants c.4253+43G>A and 
c.769-784C>T. Variant c.769-784C>T was consistently found on the same allele as c.5603A>T 
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but did affect splicing in photoreceptor progenitor cells: It resulted in a pseudo-exon 
insertion in 15% of the total mRNA of patient-derived photoreceptor progenitor cells, i.e. 
~30% of the c.769-784C>T allele alone. Again, mostly late-onset foveal-sparing STGD1 was 
observed among patients who harbored these variants. Together, these three frequent 
mild ABCA4 alleles explain the missing heritability in late-onset STGD1 (~50% of previously 
unexplained cases), distinguishing STGD1 from age-related macular degeneration. Yet, 
each of these three mild alleles was associated with a large variability in age of onset, 
phenotypes in fundo and visual acuity courses. Both the exceptional differences in disease 
expression and the reduced penetrance suggest that genetic and/or environmental 
modifiers act in STGD1. The identification of these unknown modifiers would improve 
counseling, and may help unravel the pathophysiology of the disease, needed to find a 
therapy.   
Chapter 4 describes functional discordance between STGD1 siblings who carry the same 
disease-causing ABCA4 variants. Substantial differences were observed in the age of onset 
(up to 39 years) and the time to develop severe visual impairment (range, 1 to 29 years). 
These differences were exceptionally large in families carrying a known mild allele. The 
prevalent intersibling functional discordance confirms the existence of environmental 
and/or genetic modifying factors outside the ABCA4 gene. Physicians should be wary of 
sibling-based prognosis, especially when mild alleles are identified.
In chapter 5, the natural history of STGD1 over 3 to 5 years was studied. Retinal pigment 
epithelium atrophy measured using short-wave autofluorescence currently is a major 
endpoint in trials, but this imaging biomarker is of exclusive use for advanced disease, 
while strategies like gene therapy or lipofuscin reduction hold most promise in early 
disease stages. Disease activity in early stages can be captured by autofluorescence 
patterns indicating lipofuscin accumulation. Therefore, the change in retinal sensitivity 
and autofluorescence in multiple macular loci were assessed using microperimetry and 
short-wavelength autofluorescence imaging. Autofluorescence change did not 
adequately reflect the corresponding local change in sensitivity. Retinal sensitivity 
declined most in locations that did not show any change in autofluorescence intensity. 
Natural history studies with more than two time points, quantitively assessed autofluores-
cence, advanced eye tracking and co-registration software and patients in earlier disease 
stages are required to assess the value of autofluorescence as an early clinical endpoint. 
In chapter 6, we studied the association between mild ABCA4 alleles and the patient’s sex 
in STGD1. Two of our previous – though small – studies led to the hypothesis that 
sex-related risk factors for STGD1 might have an impact on only a subgroup of patients (i.e. 
those carrying a low penetrant ABCA4 allele). 1) Among patients carrying the c.5603A>T 
allele in chapter 2, most patients were female (65%) whereas three out of three unaffected 
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(putative nonpenetrant) siblings were male; 2) In the siblings study of chapter 4, five 
families showed an extra-ordinary wide variation in age at onset (13-39 years); in each of 
these families, the patient affected latest was male. In a cross-sectional study of 550 
patients with genetically confirmed STGD1, more women were observed among patients 
who harbored a mild ABCA4 genotype compared with patients who harbored (moderately) 
severe ABCA4 genotypes. The mild ABCA4 genotypes under study concerned the two 
most frequent and incompletely penetrant alleles c.5603A>T, p.(Asn1868Ile) (total No. 125; 
female:male ratio, 1.7:1), and c.5882G>A, p.(Gly1961Glu) (total No. 79; female:male ratio, 
2.1:1). The patient group without mild alleles (total No. 284) had a sex ratio of 1:1. The 
findings suggest that sex plays a role in the diagnosis and/or etiology of STGD1, and urge 
to consider the possibility that STGD1 is a multifactorial disease rather than an autosomal 
recessive disease in a quarter of all patients (i.e. those carrying a combination of a mild 
allele with a severe allele). Moreover, the data remind us of the importance of including 
sex as a basic variable in all fundamental research and clinical trials, also when an inherited 
retinal disease like STGD1 is concerned.
Chapter 7 describes the incidence, prevalence and diagnostic trends of STGD1, for which 
we used a nationwide collaborative registry of inherited retinal diseases. Although STGD1 
is widely regarded as the most common Mendelian inherited eye disorder, the prevalence 
had not been studied. The incidence in this study was 1.67-1.95 per 1,000,000 persons per 
year. The point prevalence approximated 1 in 22,000 to 1 in 19,000, which is far less than 
the genetically estimated prevalence 1 in 6,578 to 1 in 870, based on ABCA4 mutation 
carrier frequencies. This mismatch between genetically calculated prevalence and 
observed disease prevalence is created by the multitude of ABCA4 variants with unknown 
significance, by the fact that many combinations of mutations are too mild to result in 
disease, and by diagnostic advances over time. With the increasing number of clinical 
studies in this rare disease, national disease registries employing clear case definitions may 
become indispensable for a realistic planning of trials, and a time- and cost-efficient 
patient selection. Late-onset STGD1 was more frequently diagnosed in recent years (33% 
of the diagnoses in 2014-2018, compared to 19% in 2004-2008), likely due to higher 
awareness of its phenotype. Diagnostic delay was associated with a higher age of onset. 
Misdiagnosis for age-related macular degeneration (22%) and incidental STGD1 findings 
(14%) were common in patients with late-onset STGD1. In this pre-therapeutic era, mis- 
and underdiagnosis of especially late-onset STGD1 and the role of sex in STGD1 should 
receive special attention.
Chapter 8 integrates the findings from this thesis to provide a strategy for genotype-based 
family counseling. Generalized autosomal recessive risk counseling is hardly applicable 
since mild alleles – which are the most frequent cause of STGD1 – in a homozygous 
configuration do not cause STGD1 (or far less frequently than expected; ABCA4 disease 
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model, explained in General Introduction). The incomplete penetrance of frequent alleles 
further complicates counseling. The presented framework shows the relevance of using a 
genotype-based counseling approach, because the risk at STGD1 in offspring greatly 
depends on the severity of the ABCA4 variants of the patient or carrier that seeks family 
counseling. For instance, the risk that a child develops STGD1 at some point in life is 
estimated at 1 in 35-32 when the patient that seeks counseling carries two severe alleles 
vs 1 in 62-57 when the patient that seeks counseling carries a severe and a mild, completely 
penetrant allele. The genotype-directed counseling approach furthermore allows for 
consideration of large inheritance risk differences of STGD1 in early life versus later in life. 
The inheritance risks for genotypes that generally lead to STGD1 in childhood are 2 to 
4-fold lower than the total STGD1 inheritance risks.
Finally, chapter 9 places the aforementioned results in a broader and future context. The 
knowledge gained aids in facing the diagnostic challenges of late-onset STGD1. We 
learned that mild alleles are responsible for the majority of STGD1 cases in The Netherlands. 
Patients carrying mild alleles show a clinical variability that cannot fully be explained by 
the ABCA4 genotype. This poses challenges for diagnosis and counseling, and for defining 
the natural disease progression, needed for measuring effect of experimental treatments. 
At the same time, incomplete penetrance and variable expression could provide a new 
angle for studying this disease: further studies into the underlying mechanisms may 
eventually deepen our understanding of the disease pathophysiology and potential 
treatment strategies. Since the disease is rare, progressive and heterogeneous, these 
studied require (inter)national collaborations.
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SAMENVATTING
De ziekte van Stargardt (STGD1) is een erfelijke maculadystrofie die progressief verlies van 
het gezichtsvermogen veroorzaakt. De zorg voor deze patiëntengroep omvat visuele 
hulpmiddelen, leefstijladviezen die de ziekteprogressie kunnen remmen en counseling 
ten aanzien van prognose en overerving. Goede zorg is afhankelijk van een juiste en 
tijdige diagnose. De diagnose wordt echter bemoeilijkt door een grote variabiliteit in 
fenotypes en ziekteverloop, fenotypisch overlappende ziekten (‘phenocopies’) en 
niet-eenduidige resultaten van genetische tests. Deze uitdagingen hebben een impact 
op de huidige zorg voor deze patiënten en ook op experimentele, toekomstige therapie. 
Het bewijzen van de werkzaamheid van een experimentele therapie vereist een algemeen 
geschikt eindpunt, een eindpunt dat klinisch zinvol, niet-invasief, betrouwbaar en gevoelig 
is. Een dergelijk eindpunt is moeilijk te definiëren door de variëteit aan fenotypes en pro-
gressiesnelheden – beide nog onvolledig gekarakteriseerd – en het feit dat de ziekte 
zeldzaam is. Evaluatie van de genotypische en fenotypische variatie en het natuurlijk 
beloop zijn dus van groot belang om uiteindelijk het behandeleffect te kunnen 
beoordelen. Het doel van dit proefschrift was om kennis te verwerven over de genetische 
achtergrond, de genotype-fenotype correlaties en de natuurlijke progressie van STGD1.
Hoofdstuk 1 is een algemene inleiding over de fysiologie van het netvlies en de huidige 
kennis van de fenotypische kenmerken, pathofysiologie, genotype en behandeling van 
STGD1. Relatief nieuw in het ABCA4-ziektespectrum is STGD1 met late aanvang (initiële 
visuele klachten ≥45 jaar). De diagnose kan bijzonder uitdagend zijn vanwege de 
fenotypische overlap met de veel vaker voorkomende leeftijdsgebonden maculadegene-
ratie en wordt verder gecompliceerd door het ongewoon hoge aantal niet-eenduidige 
uitslagen van genetische tests.
In de eerste hoofdstukken worden patiënten bestudeerd met het fenotype STGD1 bij wie 
slechts één ABCA4-allel werd geïdentificeerd. Hoofdstuk 2 laat zien dat een significante 
fractie (40%) van deze genetisch onverklaarde Nederlandse patiënten de frequente c.5603A>T 
(p.Asn1868Ile) variant als tweede allel draagt. Van het andere, eerder geïdentificeerde, 
ABCA4-allel was vaak bekend dat het een ernstig schadelijke genetische variant was. 
Patiënten met c.5603A>T vertoonden de eerste klachten van de ziekte pas na de kindertijd, 
en vaak zelfs pas na de leeftijd van 45 jaar (42%) met karakteristieke late STGD1 kenmerken 
van scherp afgebakende atrofie in een fovea-sparend patroon en vlekjes in de gehele 
achterpool en de midperiferie. Het verschil in de aanvangsleeftijd was echter buiten - 
gewoon groot (18-72 jaar) ondanks genotypen van schijnbaar gelijke ernst: de combinatie 
van c.5603A>T en een ernstig allel. Daarnaast werden vier asymptomatische familieleden 
met een combinatie van een ernstig allel en c.5603A>T geïdentificeerd. Op basis van AB-
CA4-allelfrequentiepopulatiegegevens hebben we berekend dat de penetrantie van 
c.5603A>T, indien aanwezig in trans met een ernstige variant, lager is dan 5%. Hoofdstuk 3 
beschrijft twee aanvullende milde allelen, de diep-intronische c.4253+43G>A en c.769-784C>T. 
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Variant c.769-784C>T werd consistent gevonden op hetzelfde allel als c.5603A>T, maar had 
wel invloed op de splicing in fotoreceptor-voorlopercellen: het resulteerde in een pseudo- 
exon-insertie in 15% van het totale mRNA van fotoreceptor progenitorcellen van een 
patiënt, d.w.z. ~30% van het c.769-784C>T-allel alleen. Bovendien werd bij patiënten die 
deze varianten hadden meestal fovea-sparende STGD1 met late aanvang waargenomen. 
Samen verklaren deze drie frequente milde ABCA4-allelen de ontbrekende erfelijkheid in 
STGD1 met late aanvang (~ 50% van de eerder onverklaarde gevallen), waardoor STGD1 
wordt onderscheiden van leeftijdsgebonden maculadegeneratie. Toch was elk van deze 
drie milde allelen geassocieerd met een grote variabiliteit in beginleeftijd, fenotypes in 
fundo en gezichtsscherpte. Zowel de uitzonderlijke verschillen in ziekte-expressie als de 
verminderde penetrantie suggereren dat genetische en/of omgevingsfactoren een rol 
spelen in STGD1. De identificatie van deze onbekende ‘modifiers’ zou de counseling 
verbeteren en kan helpen bij het ontrafelen van de pathofysiologie van de ziekte en 
daarbij mogelijk het vinden van een  therapie.
Hoofdstuk 4 beschrijft functionele discordantie tussen broers en zussen met STGD1 die 
dezelfde ziekteveroorzakende ABCA4-varianten dragen. Aanzienlijke verschillen werden 
waargenomen in de leeftijd waarop de ziekte begon (verschillen tot zelfs 39 jaar) en de tijd 
tot het ontwikkelen van een ernstige visuele beperking (1 tot 29 jaar). Deze verschillen 
waren uitzonderlijk groot in families met een bekend mild allel. De veelvoorkomende 
functionele discordantie tussen broers en zussen sterkt de hypothese van het bestaan  van 
omgevings- en/of genetische ‘modifiers’ buiten het ABCA4-gen. Artsen moeten voorzichtig 
zijn met uitspraken over de prognose op basis van het ziekteverloop bij broers en zussen, 
vooral wanneer milde ABCA4 allelen zijn geïdentificeerd.
In hoofdstuk 5 werd het natuurlijke beloop van STGD1 gedurende 3 tot 5 jaar bestudeerd. 
Retinale pigmentepitheelatrofie gemeten met behulp van short-wave autofluorescentie 
is momenteel een belangrijk eindpunt in studies, maar deze beeldvormende biomarker is 
exclusief bruikbaar voor gevorderde ziekte, terwijl strategieën zoals gentherapie of lipo-
fuscinereductie het meest veelbelovend zijn in vroege ziektestadia. Ziekteactiviteit in 
vroege stadia kan worden vastgelegd door autofluorescentiepatronen die op accumulatie 
van lipofuscine wijzen. Daarom werden de verandering in retinale gevoeligheid en auto-
fluorescentie in meerdere maculaire loci beoordeeld met behulp van microperimetrie en 
autofluorescentiebeeldvorming met korte golflengte. Autofluorescentieverandering 
weer spiegelde niet adequaat de lokale verandering in gevoeligheid van het netvlies. 
De gevoeligheid van het netvlies nam het meest af op locaties die geen verandering in de 
autofluorescentie-intensiteit vertoonden. Natuurlijk beloop studies met meer dan twee 
tijdstippen, kwantitatief beoordeelde autofluorescentie, geavanceerde eye-tracking en 
co-registratiesoftware en patiënten in eerdere ziektestadia zijn nodig om de waarde van 
autofluorescentie als een vroeg klinisch eindpunt te beoordelen.
In hoofdstuk 6 bestudeerden we de associatie tussen milde ABCA4-allelen en het 
geslacht van de patiënt in STGD1. Twee van onze eerdere – hoewel kleine – onderzoeken 
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leidden tot de hypothese dat geslachtsgerelateerde risicofactoren voor STGD1 een rol 
zouden kunnen spelen in een subgroep van patiënten, degenen met een laag penetrant 
ABCA4-allel: 1) Van de patiënten met het c.5603A>T allel in hoofdstuk 2 waren de meeste 
patiënten vrouw (65%), terwijl drie van de drie niet-aangedane (vermoedelijk niet-pene-
trante) broers en zussen mannelijk waren; 2) In het onderzoek naar broers en zussen van 
hoofdstuk 4 vertoonden vijf gezinnen een buitengewoon grote variatie in leeftijd bij 
aanvang (13-39 jaar); in elk van deze families was de laatst getroffen patiënt een man. In 
een cross-sectionele studie van 550 patiënten met genetisch bevestigde STGD1 werden 
meer vrouwen dan mannen waargenomen onder patiënten met een mild ABCA4-
genotype. De milde ABCA4-genotypen die werden onderzocht hadden betrekking op de 
twee meest voorkomende en onvolledig penetrante allelen c.5603A>T, p.(Asn1868Ile) 
(totaal nr. 125; verhouding vrouw:man, 1,7:1), en c.5882G>A, p.(Gly1961Glu) (totaal nr. 79; 
verhouding vrouw:man, 2,1:1). De patiëntengroep zonder milde allelen (n=284) had een 
geslachtsverhouding van 1:1. De bevindingen suggereren dat geslacht een rol speelt bij 
de diagnose en/of etiologie van STGD1 en, daarmee, dat STGD1 potentieel een multi-
factoriële achtergrond heeft in plaats van puur autosomaal recessief bij minstens een 
kwart van alle patiënten (d.w.z. degenen die drager zijn van een combinatie van één van 
deze milde allelen met een ernstig allel). Bovendien herinneren de data ons aan het 
belang van het opnemen van geslacht als basisvariabele in fundamentele onderzoeken 
en klinische onderzoeken, ook als het een mono-allelische aandoening betreft.
Hoofdstuk 7 beschrijft de incidentie, prevalentie en diagnostische trends in STGD1, 
waarvoor we een landelijke, collaboratieve registratie van erfelijke netvliesaandoeningen 
gebruikten. Hoewel STGD1 algemeen wordt beschouwd als de meest voorkomende 
Mendeliaans overervende oogaandoening, was de prevalentie niet onderzocht. De 
incidentie in deze studie was 1,67-1,95 per 1.000.000 personen per jaar. De puntprevalentie 
bedroeg ongeveer 1 op 22.000 tot 1 op 19.000, wat veel minder is dan de genetisch 
geschatte prevalentie van 1 op 6.578 tot 1 op 870, gebaseerd op ABCA4-mutatiedrager-
frequenties. Deze mismatch tussen genetisch berekende prevalentie en waargenomen ziekte-
prevalentie wordt gecreëerd door de veelheid aan ABCA4-varianten met onbekende 
betekenis, door het feit dat veel combinaties van varianten te mild zijn om tot ziekte te 
leiden, en door diagnostische vooruitgang in de tijd. Met het toenemende aantal klinische 
studies naar deze zeldzame ziekte zijn nationale ziekteregisters, die duidelijke casusdefinities 
gebruiken, onmisbaar geworden voor een realistische planning van onderzoeken en een 
tijd- en kostenefficiënte selectie van patiënten. Late-onset STGD1 werd de afgelopen jaren 
vaker gediagnosticeerd (33% van de diagnoses in 2014-2018, vergeleken met 19% in 
2004-2008), waarschijnlijk vanwege betere herkenning van het fenotype. Diagnostische 
vertraging was geassocieerd met een hogere beginleeftijd. Misdiagnose als leeftijdsgebonden 
maculadegeneratie (22%) en STGD1 als toevalsbevinding (14%) kwamen vaak voor bij 
patiënten met late-onset STGD1. In dit pre-therapeutische tijdperk verdient mis- en onder -
diagnose van met name late-onset STGD1 en de rol van geslacht in STGD1 speciale aandacht.
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Hoofdstuk 8 integreert de bevindingen uit dit proefschrift om een  strategie te bieden 
voor genotype-gerichte family counseling. Genetische counseling op basis van algemene 
autosomaal recessieve overerving is niet accuraat omdat milde allelen – die de meest 
voorkomende oorzaak van STGD1 zijn – in een homozygote configuratie geen STGD1 
veroorzaken (of veel minder vaak dan verwacht; ABCA4-ziektemodel, uitgelegd in ‘General 
introduction’). De onvolledige penetrantie van frequente allelen bemoeilijkt de counseling 
verder. De gepresenteerde benadering voor de inschatting van overervingsrisico’s toont 
de relevantie van het toespitsen op specifieke genotypes, omdat het risico op STGD1 
bij nakomelingen sterk afhangt van de ernst van de ABCA4-varianten van de patiënt of 
drager die counseling zoekt. Het risico dat een nakomeling STGD1 ontwikkelt op enig 
moment in het leven wordt bijvoorbeeld geschat op 1 op 35-32 wanneer de patiënt die 
counseling zoekt twee ernstige allelen draagt versus 1 op 62-57 wanneer de patiënt die 
counseling zoekt een ernstig en een mild, volledig penetrant allel draagt. De genotype- 
gerichte counselingbenadering maakt het bovendien mogelijk om de grote verschillen in 
overervingsrisico van STGD1 met een waarschijnlijk begin in de kinderjaren versus een 
begin later in het leven in overweging te nemen. De overervingsrisico’s voor genotypen 
die over het algemeen leiden tot STGD1 in de kindertijd zijn 2 tot 4 keer lager dan de totale 
STGD1 overervingsrisico’s.
Tot slot plaatst hoofdstuk 9 de bovengenoemde resultaten in een bredere en toekomstige 
context. De opgedane kennis helpt bij het aangaan van de diagnostische uitdagingen van 
late-onset STGD1. We hebben geleerd dat milde allelen verantwoordelijk zijn voor de 
meeste STGD1 gevallen. Patiënten met milde allelen vertonen een klinische variabiliteit 
die niet volledig kan worden verklaard door het ABCA4-genotype. Dit stelt uitdagingen 
voor diagnose en counseling, en voor het definiëren van de natuurlijke ziekteprogressie 
wat nodig is om het effect van experimentele behandelingen te meten. Tegelijkertijd 
bieden onvolledige penetrantie en variabele expressie een nieuwe invalshoek voor het 
bestuderen van deze ziekte: verder onderzoek naar de onderliggende mechanismen kan 
uiteindelijk ons  begrip van de pathofysiologie van de ziekte verbeteren en behandeling 
mogelijk maken. Aangezien de ziekte zeldzaam, progressief en heterogeen is, vereisen 
deze studies (inter)nationale samenwerkingen.
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DATA MANAGEMENT









Yes Study ID number has 
been assigned to 
each individual.
Written informed consents of participants are 
stored in a locked archive at the Department 
of Ophthalmology, Radboudumc, Nijmegen, 
The Netherlands. The key file can be found on 
the H-drive and is only accessible by clinicians 
at the study site and the database manager. 





Yes NA Data are stored in an online-protected 
secured database and is only accessible by 




Yes Data are stored by 
study ID number
Data can be found in an online-protected 
secured database and is only accessible by 




Yes A DNA number is 
assigned to each 
individual by the 
cell culture facility of 
the Department of 
Human Genetics.
The key is stored in the MCCD database and 
is only accessible by clinicians and employees 
of the cell culture facility. DNA samples are 
stored at the Department of Human Genetics, 
Radboudumc, Nijmegen, The Netherlands. 
Contact person is Saskia van der Velde-Visser; 
saskia.vandervelde-visser@radboudumc.nl.
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Donders Institute for Brain, Cognition and Behaviour
PhD period: 15-5-2017 to 15-8-2020
Promotors: Prof. dr. C.B. Hoyng &
Prof. dr. F.P.M. Cremers
Year(s)
COURSES & WORKSHOPS
Course on Regulation and Organization for clinical researchers (BROK) 2017
Principles of Research in Medicine & Epidemiology 2017
Principles of Genetic Epidemiology 2017
Biometrics 2017, 2018




Donders Graduate School Day (n=3) 2017-2019
Refereeravonden Oogheelkunde (n=3)^ 2017-2019
Radboud Research Round Sensory Disorders (n=6)^ 2017-2020
PhD defenses (n=10) 2017-2020
Radboudumc lectures, international speakers (RL Allikmets, CA Curcio, RS Molday) (n=3) 2018
SYMPOSIA & CONFERENCES
European Course on Genetics in Hereditary Retinal Disease 2017
OOG/ZOG (n=2) 2017, 2019
Medische retina symposium (n=3) 2017-2019
JMD symposium (n=1)^ 2018
Dutch Ophthalmology PhD Students (DOPS) Conference (n=3)^ 2018-2020
Euretina, Vienna, Austria^ 2018
ARVO Annual Meeting, Vancouver, Canada^ 2019
OTHER
RD5000 consortium meetings / werkgroep ophthalmogenetica (n=5) 2017-2019
PPA progress meetings n=6^ 2017-2020
PPA annual meetings n=2^ 2018, 2019
RUSH2a progress meetings n=20 2017-2019
CRUSH progress meetings n=5 2018-2019
Teaching Bachelor students Biomedical Sciences or Medicine (n=1) 2019
Supervision research internship Master students Medicine (n=2) 2018, 2019
Open Dag Radboudumc^ 2019
^indicates oral or poster presentation
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